[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fieCCqgTX-n5YoolY1I6AKazu44JQmShIfYNzRB_bcqA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":53,"rows":60},"Alcon Research",[4],622,false,17,108,121938,7,363,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Ocular Hypertension",98,{"name":18,"count":19},"Cataract",72,{"name":21,"count":22},"Myopia",61,{"name":24,"count":25},"Dry Eye",50,{"name":27,"count":28},"Refractive Errors",46,{"name":30,"count":31},"Refractive Error",44,{"name":33,"count":34},"Glaucoma",38,{"name":36,"count":37},"Astigmatism",35,[39,44,48],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07531043","An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness","2027-02","Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT07578363","An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults","2027-03",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05769153","Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","2027-05","AR-14034 SR implant lower dose",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,231,253,292,310,328,346,364,455,524,595,654,688,756,804,853,897,940,973,1009,1045,1073,1106,1133,1163,1192,1214,1244,1278,1313,1345,1368,1390,1414,1432,1457,1481,1499,1523,1545,1568,1590,1608,1633,1651,1669,1687,1710,1733,1751,1774,1792,1816,1839,1862,1880,1901,1926,1944,1966,1987,2011,2033,2051,2073,2091,2115,2133,2155,2178,2200,2223,2246,2264,2287,2305,2323,2344,2362,2380,2398,2416,2438,2456,2477,2501,2525,2543,2565,2589,2607,2630,2648,2670,2688,2710,2728,2750,2771,2845,2908,2948,3010,3066,3116,3154,3192,3222,3252,3282,3316,3359,3399,3441,3481,3507,3538,3571,3597,3619,3644,3674,3696,3722,3744,3766,3788,3821,3843,3865,3891,3921,3949,3982,4008,4046,4068,4101,4130,4154,4172,4194,4218,4236,4254,4277,4295,4313,4337,4360,4378,4400,4422,4440,4458,4476,4494,4517,4535,4553,4571,4592,4615,4633,4655,4673,4691,4709,4727,4752,4770,4793,4811,4829,4850,4873,4891,4913,4931,4949,4967,4985,5003,5027,5045,5068,5086,5107,5125,5143,5161,5179,5197,5215,5233,5251,5269,5290,5312,5330,5353,5371,5389,5407,5431,5449,5467,5489,5511,5534,5552,5570,5588,5606,5641,5667,5693,5719,5741,5763,5792,5829,5847,5868,5890,5908,5926,5944,5966,5984,6007,6025,6049,6067,6085,6103,6121,6139,6163,6181,6205,6223,6245,6263,6286,6304,6329,6347,6365,6388,6406,6424,6446,6464,6482,6500,6524,6542,6560,6587,6605,6623,6647,6665,6683,6707,6725,6743,6771,6789,6807,6825,6843,6861,6879,6897,6915,6933,6951,6969,6990,7008,7031,7049,7067,7085,7108,7129,7150,7168,7186,7204,7222,7240,7258,7276,7294,7312,7330,7348,7371,7389,7407,7425,7443,7467,7485,7503,7526,7544,7562,7580,7603,7625,7643,7661,7701,7728,7750,7774,7792,7815,7833,7855,7878,7900],{"intervention":62,"totalTrials":63,"cells":64},"Vehicle",14,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":120,"PHASE4":196,"NA":229},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[72,85,95,108],{"nctId":73,"briefTitle":74,"status":75,"phases":76,"primaryCompletion":77,"start":78,"enrollment":67,"conditions":79,"interventions":81},"NCT01238783","Safety and Efficacy of AL-15469A 0.5% \u002F AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis","WITHDRAWN",[56],"2011-12","2011-01",[80],"Bacterial Conjunctivitis",[82,83,84,62],"AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension","AL-15469A 0.5%","AL-6515 0.3%",{"nctId":86,"briefTitle":87,"status":75,"phases":88,"primaryCompletion":89,"completion":89,"start":89,"enrollment":67,"conditions":90,"interventions":92},"NCT00881673","To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge",[56],"2009-05",[91],"Allergic Conjunctivitis",[93,94,62],"AL38583 Ophthalmic Solution","Maxidex",{"nctId":96,"briefTitle":97,"status":98,"phases":99,"primaryCompletion":100,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":105},"NCT00761709","Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension","COMPLETED",[56],"2009-10","2009-07",104,[104,15],"Open-Angle Glaucoma",[106,107,62],"AL-39256 Ophthalmic Suspension, 1%","Latanoprost Ophthalmic Solution, 0.005%",{"nctId":109,"briefTitle":110,"status":98,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT00670033","Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension",[56],"2008-09","2008-04",158,[15,116],"Open-angle Glaucoma",[118,119,62],"Travoprost ophthalmic solution","Travoprost ophthalmic solution, 0.004%",{"trials":121,"activeCount":195,"soonestReadout":42},[122,134,142,148,161,173,184],{"nctId":123,"briefTitle":124,"status":98,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT02339584","Efficacy and Safety of Brinzolamide\u002FBrimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)",[57],"2016-11-01","2015-04-14",493,[104,15],[131,132,133,62],"Brinzolamide 10 mg\u002FmL \u002F Brimonidine 2 mg\u002FmL fixed combination eye drops, suspension","Brinzolamide 10 mg\u002FmL eye drops, suspension","Brimonidine 2 mg\u002FmL eye drops, solution",{"nctId":40,"briefTitle":41,"status":135,"phases":136,"primaryCompletion":42,"completion":42,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NOT_YET_RECRUITING",[57],"2026-10",240,[140],"Ocular Hyperemia",[43,62],{"nctId":45,"briefTitle":46,"status":135,"phases":143,"primaryCompletion":47,"completion":47,"start":144,"enrollment":145,"conditions":146,"interventions":147},[57],"2026-09",178,[140],[43,62],{"nctId":149,"briefTitle":150,"status":98,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},"NCT06538662","An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations",[57],"2025-01-27","2025-04-03","2024-10-07",283,[157,158],"Ocular Redness","Eye Irritation",[160,62],"FID 123320 Ophthalmic Solution",{"nctId":162,"briefTitle":163,"status":98,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT01309204","Brinzolamide\u002FBrimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension",[57],"2013-01","2011-05",1184,[104,15],[170,62,171,172],"Brinzolamide 1%\u002Fbrimonidine tartrate 0.2% fixed combination ophthalmic suspension","Brinzolamide 1% ophthalmic suspension","Brimonidine tartrate 0.2% ophthalmic solution",{"nctId":174,"briefTitle":175,"status":98,"phases":176,"primaryCompletion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT00578929","Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients",[57],"2008-11","2007-09",2388,[181],"Seasonal Allergic Rhinitis",[183,62],"Olopatadine Hydrochloride Nasal Spray 0.6%",{"nctId":185,"briefTitle":186,"status":98,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":193},"NCT06444529","A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness",[57],"2024-11-14","2025-01-08","2024-08-21",159,[157],[194,62],"Apraclonidine Hydrochloride Ophthalmic Solution",2,{"trials":197,"activeCount":67},[198,210,220],{"nctId":199,"briefTitle":200,"status":98,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT01937312","Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue",[58],"2014-05","2013-10",282,[15,206],"Open Angle Glaucoma",[208,62,209],"Brinzolamide 1%\u002Fbrimonidine 0.2% ophthalmic suspension","Prostaglandin analogue",{"nctId":211,"briefTitle":212,"status":98,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT02770248","24-hr Intraocular Pressure Control With SIMBRINZA ®",[58],"2017-01-14","2016-05-23",162,[33],[219,62],"Brinzolamide 1%\u002Fbrimonidine 0.2% tartrate ophthalmic suspension",{"nctId":221,"briefTitle":222,"status":98,"phases":223,"primaryCompletion":224,"completion":224,"start":203,"enrollment":225,"conditions":226,"interventions":227},"NCT01937299","Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®",[58],"2014-04",307,[15,206],[208,62,228],"Travoprost 0.004% ophthalmic solution",{"trials":230,"activeCount":67},[],{"intervention":43,"totalTrials":195,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":249,"NA":251},{"trials":234,"activeCount":67},[],{"trials":236,"activeCount":67},[],{"trials":238,"activeCount":67},[],{"trials":240,"activeCount":195,"soonestReadout":42},[241,245],{"nctId":40,"briefTitle":41,"status":135,"phases":242,"primaryCompletion":42,"completion":42,"start":137,"enrollment":138,"conditions":243,"interventions":244},[57],[140],[43,62],{"nctId":45,"briefTitle":46,"status":135,"phases":246,"primaryCompletion":47,"completion":47,"start":144,"enrollment":145,"conditions":247,"interventions":248},[57],[140],[43,62],{"trials":250,"activeCount":67},[],{"trials":252,"activeCount":67},[],{"intervention":254,"totalTrials":195,"cells":255},"Aflibercept",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":286,"PHASE4":288,"NA":290},{"trials":257,"activeCount":67},[],{"trials":259,"activeCount":67},[],{"trials":261,"activeCount":285,"soonestReadout":51},[262,273],{"nctId":263,"briefTitle":264,"status":98,"phases":265,"primaryCompletion":203,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT01796964","Efficacy and Safety Study of ESBA1008 Versus EYLEA®",[56],"2014-08","2013-03",173,[270],"Exudative Age-Related Macular Degeneration",[272,254],"ESBA1008 solution",{"nctId":49,"briefTitle":50,"status":274,"phases":275,"primaryCompletion":51,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":281},"ACTIVE_NOT_RECRUITING",[55,56],"2027-10","2023-12-06",139,[280],"Neovascular Age-related Macular Degeneration (nAMD)",[52,282,283,254,284],"AR-14034 SR implant higher dose","AR-14034 SR implant","Sham procedure",1,{"trials":287,"activeCount":67},[],{"trials":289,"activeCount":67},[],{"trials":291,"activeCount":67},[],{"intervention":52,"totalTrials":285,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":295,"activeCount":67},[],{"trials":297,"activeCount":67},[],{"trials":299,"activeCount":285,"soonestReadout":51},[300],{"nctId":49,"briefTitle":50,"status":274,"phases":301,"primaryCompletion":51,"completion":276,"start":277,"enrollment":278,"conditions":302,"interventions":303},[55,56],[280],[52,282,283,254,284],{"trials":305,"activeCount":67},[],{"trials":307,"activeCount":67},[],{"trials":309,"activeCount":67},[],{"intervention":282,"totalTrials":285,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":313,"activeCount":67},[],{"trials":315,"activeCount":67},[],{"trials":317,"activeCount":285,"soonestReadout":51},[318],{"nctId":49,"briefTitle":50,"status":274,"phases":319,"primaryCompletion":51,"completion":276,"start":277,"enrollment":278,"conditions":320,"interventions":321},[55,56],[280],[52,282,283,254,284],{"trials":323,"activeCount":67},[],{"trials":325,"activeCount":67},[],{"trials":327,"activeCount":67},[],{"intervention":283,"totalTrials":285,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":331,"activeCount":67},[],{"trials":333,"activeCount":67},[],{"trials":335,"activeCount":285,"soonestReadout":51},[336],{"nctId":49,"briefTitle":50,"status":274,"phases":337,"primaryCompletion":51,"completion":276,"start":277,"enrollment":278,"conditions":338,"interventions":339},[55,56],[280],[52,282,283,254,284],{"trials":341,"activeCount":67},[],{"trials":343,"activeCount":67},[],{"trials":345,"activeCount":67},[],{"intervention":284,"totalTrials":285,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":349,"activeCount":67},[],{"trials":351,"activeCount":67},[],{"trials":353,"activeCount":285,"soonestReadout":51},[354],{"nctId":49,"briefTitle":50,"status":274,"phases":355,"primaryCompletion":51,"completion":276,"start":277,"enrollment":278,"conditions":356,"interventions":357},[55,56],[280],[52,282,283,254,284],{"trials":359,"activeCount":67},[],{"trials":361,"activeCount":67},[],{"trials":363,"activeCount":67},[],{"intervention":365,"totalTrials":366,"cells":367},"Olopatadine hydrochloride ophthalmic solution, 0.2%",8,{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":428,"NA":453},{"trials":369,"activeCount":67},[],{"trials":371,"activeCount":67},[],{"trials":373,"activeCount":67},[],{"trials":375,"activeCount":67},[376,388,399,408,418],{"nctId":377,"briefTitle":378,"status":98,"phases":379,"primaryCompletion":380,"completion":380,"start":100,"enrollment":381,"conditions":382,"interventions":383},"NCT00987272","Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects",[57],"2009-11",267,[91],[384,385,386,387],"Olopatadine Hydrochloride Ophthalmic Solution, 0.2%","Olopatadine Hydrochloride Ophthalmic Solution, 0.1%","Olopatadine 0.2% Vehicle","Olopatadine 0.1% Vehicle",{"nctId":389,"briefTitle":390,"status":98,"phases":391,"primaryCompletion":392,"completion":392,"start":165,"enrollment":393,"conditions":394,"interventions":395},"NCT01743027","Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis",[57],"2013-07",902,[91],[396,365,397,398],"AL-4943A ophthalmic solution","Olopatadine hydrochloride ophthalmic solution, 0.1%","AL-4943A ophthalmic solution vehicle",{"nctId":400,"briefTitle":401,"status":98,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":407},"NCT01037179","An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis",[57],"2010-05","2010-02",110,[91],[384],{"nctId":409,"briefTitle":410,"status":98,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":416},"NCT01479374","Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model",[57],"2012-03","2012-01",397,[91],[396,417,365],"AL-4943A vehicle",{"nctId":419,"briefTitle":420,"status":98,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":426},"NCT00331500","Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis",[57],"2006-07-27","2006-04-18",287,[91],[384,427],"Olopatadine Hydrochloride Ophthalmic Solution Vehicle",{"trials":429,"activeCount":67},[430,439,446],{"nctId":431,"briefTitle":432,"status":98,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":438},"NCT01159769","Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis",[58],"2010-08","2010-06",215,[91],[365],{"nctId":440,"briefTitle":441,"status":98,"phases":442,"primaryCompletion":77,"completion":77,"start":166,"enrollment":443,"conditions":444,"interventions":445},"NCT01272089","A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis",[58],300,[91],[384],{"nctId":447,"briefTitle":448,"status":98,"phases":449,"primaryCompletion":392,"completion":392,"start":450,"enrollment":8,"conditions":451,"interventions":452},"NCT01697969","Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients",[58],"2012-09",[91],[365],{"trials":454,"activeCount":67},[],{"intervention":456,"totalTrials":457,"cells":458},"Brinzolamide 1%\u002Fbrimonidine tartrate 0.2% ophthalmic suspension",6,{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":484,"PHASE4":510,"NA":522},{"trials":460,"activeCount":67},[],{"trials":462,"activeCount":67},[],{"trials":464,"activeCount":67},[465,476],{"nctId":466,"briefTitle":467,"status":98,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT01426867","A Comfort Study of Brinzolamide 1% \u002F Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%",[56],"2011-11","2011-09",103,[104,15],[456,474,475],"Brinzolamide ophthalmic suspension, 1%","Brimonidine tartrate ophthalmic solution, 0.2%",{"nctId":477,"briefTitle":478,"status":479,"phases":480,"primaryCompletion":404,"completion":404,"start":100,"enrollment":481,"conditions":482,"interventions":483},"NCT00961649","Safety and Efficacy of Brinzolamide\u002FBrimonidine Fixed Combination","TERMINATED",[56],195,[104,15],[456,474,475],{"trials":485,"activeCount":67},[486,493,502],{"nctId":487,"briefTitle":488,"status":98,"phases":489,"primaryCompletion":165,"completion":165,"start":166,"enrollment":490,"conditions":491,"interventions":492},"NCT01310777","Brinzolamide\u002FBrimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension",[57],771,[104,15],[456,171,172],{"nctId":494,"briefTitle":495,"status":98,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":501},"NCT01297920","Three Month Efficacy\u002FSafety Study With a 3-Month Safety Extension of Brinzolamide 1%\u002FBrimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%",[57],"2012-06","2011-03",1062,[104,15],[456,474,475],{"nctId":503,"briefTitle":504,"status":98,"phases":505,"primaryCompletion":412,"completion":412,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT01297517","Efficacy and Safety Study of Brinzolamide 1%\u002FBrimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%",[57],"2011-02",1001,[104,15],[456,474,475],{"trials":511,"activeCount":67},[512],{"nctId":513,"briefTitle":514,"status":479,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":268,"conditions":518,"interventions":519},"NCT02730871","Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®",[58],"2018-07-13","2016-06-24",[116,15],[456,520,521],"Brinzolamide\u002Fbrimonidine vehicle","Travoprost 0.004%\u002Ftimolol 0.5% solution",{"trials":523,"activeCount":67},[],{"intervention":525,"totalTrials":457,"cells":526},"Travoprost",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":544,"PHASE4":583,"NA":593},{"trials":528,"activeCount":67},[],{"trials":530,"activeCount":67},[],{"trials":532,"activeCount":67},[533],{"nctId":534,"briefTitle":535,"status":98,"phases":536,"primaryCompletion":403,"start":537,"enrollment":538,"conditions":539,"interventions":541},"NCT01114893","Travoprost Five Day Posology Study",[56],"2010-04",60,[540,15],"Open-angle Glaucoma (OAG)",[542,543,525],"Travoprost 0.004%","Travoprost Vehicle",{"trials":545,"activeCount":67},[546,556,566,575],{"nctId":547,"briefTitle":548,"status":98,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":554},"NCT00293761","A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension",[57],"2006-05","2006-01",109,[116,15],[555,525],"Travoprost, Investigational",{"nctId":557,"briefTitle":558,"status":98,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"conditions":562,"interventions":564},"NCT00051181","A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma",[57],"2003-06","2000-01",[563,15],"Glaucoma, Angle-Closure",[525,565],"Latanoprost",{"nctId":567,"briefTitle":568,"status":98,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"conditions":572,"interventions":574},"NCT00051155","A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)",[57],"2004-07","2001-01",[573,15],"Glaucoma, Open-Angle",[525,565],{"nctId":576,"briefTitle":577,"status":98,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"conditions":581,"interventions":582},"NCT00051142","A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)",[57],"2004-06","2001-02",[573,15],[525,565],{"trials":584,"activeCount":67},[585],{"nctId":586,"briefTitle":587,"status":98,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"conditions":591,"interventions":592},"NCT00061503","Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension",[58],"2004-03","2003-04",[33,15],[525],{"trials":594,"activeCount":67},[],{"intervention":596,"totalTrials":597,"cells":598},"Travoprost ophthalmic solution 0.004% with SofZia® preservative system",5,{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":625,"NA":652},{"trials":600,"activeCount":67},[],{"trials":602,"activeCount":67},[],{"trials":604,"activeCount":67},[],{"trials":606,"activeCount":67},[607,617],{"nctId":608,"briefTitle":609,"status":98,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT00761319","Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health",[57],"2009-09","2008-10",705,[116,15],[596,616],"Latanoprost ophthalmic solution 0.005%",{"nctId":618,"briefTitle":619,"status":98,"phases":620,"primaryCompletion":89,"completion":89,"start":621,"enrollment":622,"conditions":623,"interventions":624},"NCT00690794","Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],"2008-07",726,[116,15],[596,616],{"trials":626,"activeCount":67},[627,636,644],{"nctId":628,"briefTitle":629,"status":98,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":635},"NCT00527592","A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",[58],"2008-08","2007-05",54,[104,15],[596,616],{"nctId":637,"briefTitle":638,"status":98,"phases":639,"primaryCompletion":640,"completion":640,"start":621,"enrollment":641,"conditions":642,"interventions":643},"NCT00708422","Effects of Travatan Z and Xalatan on Ocular Surface Health",[58],"2009-08",231,[33,15],[596,616],{"nctId":645,"briefTitle":646,"status":98,"phases":647,"primaryCompletion":89,"completion":89,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT00798759","Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN",[58],"2008-12",236,[116,15],[596,616],{"trials":653,"activeCount":67},[],{"intervention":616,"totalTrials":597,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":672,"NA":686},{"trials":657,"activeCount":67},[],{"trials":659,"activeCount":67},[],{"trials":661,"activeCount":67},[],{"trials":663,"activeCount":67},[664,668],{"nctId":608,"briefTitle":609,"status":98,"phases":665,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":666,"interventions":667},[57],[116,15],[596,616],{"nctId":618,"briefTitle":619,"status":98,"phases":669,"primaryCompletion":89,"completion":89,"start":621,"enrollment":622,"conditions":670,"interventions":671},[57],[116,15],[596,616],{"trials":673,"activeCount":67},[674,678,682],{"nctId":628,"briefTitle":629,"status":98,"phases":675,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":676,"interventions":677},[58],[104,15],[596,616],{"nctId":637,"briefTitle":638,"status":98,"phases":679,"primaryCompletion":640,"completion":640,"start":621,"enrollment":641,"conditions":680,"interventions":681},[58],[33,15],[596,616],{"nctId":645,"briefTitle":646,"status":98,"phases":683,"primaryCompletion":89,"completion":89,"start":648,"enrollment":649,"conditions":684,"interventions":685},[58],[116,15],[596,616],{"trials":687,"activeCount":67},[],{"intervention":689,"totalTrials":597,"cells":690},"Latanoprost 0.005% Ophthalmic Solution",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":723,"PHASE4":742,"NA":754},{"trials":692,"activeCount":67},[],{"trials":694,"activeCount":67},[],{"trials":696,"activeCount":67},[697,709],{"nctId":698,"briefTitle":699,"status":98,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT00069706","Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients",[56],"2003-10","2003-07",118,[116,15],[706,689,707,708],"AL-12182 0.003% Ophthalmic Solution","AL-12182 0.01% Ophthalmic Solution","AL-12182 0.03% Ophthalmic Solution",{"nctId":710,"briefTitle":711,"status":98,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT06441643","Next Generation Rocklatan",[56],"2025-11-14","2024-09-04",426,[206,15],[718,719,689,720,721,722],"AR-17043 Ophthalmic Solution","PG043 Ophthalmic Solution","Netarsudil 0.02% Ophthalmic Solution","Netarsudil 0.02%\u002FLatanoprost 0.005% Ophthalmic Solution","AR-17043 Vehicle",{"trials":724,"activeCount":67},[725,734],{"nctId":726,"briefTitle":548,"status":98,"phases":727,"primaryCompletion":728,"completion":728,"start":579,"enrollment":729,"conditions":730,"interventions":731},"NCT00293787",[57],"2005-08",156,[116,15],[732,689,733],"Travoprost 0.004% \u002F Timolol 0.5% Ophthalmic Solution","Timolol Maleate Ophthalmic Solution 0.5%",{"nctId":735,"briefTitle":548,"status":98,"phases":736,"primaryCompletion":737,"completion":737,"start":570,"enrollment":268,"conditions":738,"interventions":739},"NCT00293800",[57],"2005-12",[104,15],[740,689,741],"Travoprost 0.004%\u002FTimolol 0.5% Ophthalmic Solution","Timolol 0.5% Ophthalmic Solution",{"trials":743,"activeCount":67},[744],{"nctId":745,"briefTitle":746,"status":98,"phases":747,"primaryCompletion":101,"completion":101,"start":748,"enrollment":749,"conditions":750,"interventions":751},"NCT00759941","A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin",[58],"2007-10",86,[33],[752,753],"Brinzolamide 1% ophthalmic solution","Latanoprost 0.005% ophthalmic solution",{"trials":755,"activeCount":67},[],{"intervention":757,"totalTrials":758,"cells":759},"Brinzolamide\u002Ftimolol maleate fixed combination",4,{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":802},{"trials":761,"activeCount":67},[],{"trials":763,"activeCount":67},[],{"trials":765,"activeCount":67},[],{"trials":767,"activeCount":67},[],{"trials":769,"activeCount":67},[770,778,788,795],{"nctId":771,"briefTitle":772,"status":479,"phases":773,"primaryCompletion":774,"completion":774,"start":412,"enrollment":775,"conditions":776,"interventions":777},"NCT01514734","Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%\u002FTimolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%\u002FTimolol 0.5% Fixed Combination) Therapy in Brazil",[58],"2012-08",9,[33],[757],{"nctId":779,"briefTitle":780,"status":98,"phases":781,"primaryCompletion":166,"completion":166,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT01471158","Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma",[58],"2010-09",120,[33],[786,787],"Brinzolamide\u002FTimolol Maleate Fixed Combination","Dorzolamide\u002Ftimolol Maleate Fixed Combination",{"nctId":789,"briefTitle":790,"status":98,"phases":791,"primaryCompletion":434,"completion":434,"start":101,"enrollment":792,"conditions":793,"interventions":794},"NCT00966576","Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy",[58],47,[33],[786],{"nctId":796,"briefTitle":797,"status":98,"phases":798,"primaryCompletion":799,"completion":799,"start":77,"enrollment":25,"conditions":800,"interventions":801},"NCT01518244","Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%\u002FTimolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%\u002FTimolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America",[58],"2013-02",[33],[757],{"trials":803,"activeCount":67},[],{"intervention":805,"totalTrials":758,"cells":806},"Cosopt",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":823,"NA":851},{"trials":808,"activeCount":67},[],{"trials":810,"activeCount":67},[],{"trials":812,"activeCount":67},[],{"trials":814,"activeCount":67},[815],{"nctId":816,"briefTitle":817,"status":479,"phases":818,"primaryCompletion":819,"completion":819,"start":612,"enrollment":457,"conditions":820,"interventions":821},"NCT00767481","1 Year Study Trav\u002FBrinz QD Fixed Combination Versus COSOPT",[57],"2009-02",[33,15],[822,805],"Travoprost\u002FBrinzolamide",{"trials":824,"activeCount":67},[825,834,843],{"nctId":826,"briefTitle":827,"status":98,"phases":828,"primaryCompletion":829,"completion":829,"start":819,"enrollment":830,"conditions":831,"interventions":832},"NCT00761995","Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension",[58],"2010-07",200,[33,15],[833,805],"Azopt",{"nctId":835,"briefTitle":836,"status":98,"phases":837,"primaryCompletion":838,"completion":838,"start":537,"enrollment":839,"conditions":840,"interventions":841},"NCT01111890","Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension",[58],"2011-07",70,[33,15],[842,805],"Azarga",{"nctId":844,"briefTitle":845,"status":479,"phases":846,"primaryCompletion":631,"start":847,"enrollment":28,"conditions":848,"interventions":849},"NCT00471068","Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension",[58],"2007-03",[116,15],[850,805],"Travatan",{"trials":852,"activeCount":67},[],{"intervention":833,"totalTrials":758,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":881,"NA":895},{"trials":856,"activeCount":67},[],{"trials":858,"activeCount":67},[],{"trials":860,"activeCount":67},[],{"trials":862,"activeCount":67},[863,870],{"nctId":864,"briefTitle":865,"status":479,"phases":866,"primaryCompletion":819,"completion":819,"start":612,"enrollment":8,"conditions":867,"interventions":868},"NCT00767494","Travoprost\u002FBrinzolamide Fixed Combination Versus Travatan and Versus AZOPT",[57],[33,15],[869,833,850],"Travoprost\u002FBrinzolamide fixed combination",{"nctId":871,"briefTitle":872,"status":98,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":878},"NCT00061516","Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension",[57],"2006-02","2003-01",78,[33,15],[879,880],"BETAXON","AZOPT",{"trials":882,"activeCount":67},[883,887],{"nctId":826,"briefTitle":827,"status":98,"phases":884,"primaryCompletion":829,"completion":829,"start":819,"enrollment":830,"conditions":885,"interventions":886},[58],[33,15],[833,805],{"nctId":888,"briefTitle":889,"status":98,"phases":890,"primaryCompletion":891,"completion":891,"start":892,"enrollment":481,"conditions":893,"interventions":894},"NCT00382226","IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%\u002FTimolol 0.5% Fixed Combination as Adjunctive Therapy",[58],"2007-08","2006-09",[33],[833],{"trials":896,"activeCount":67},[],{"intervention":850,"totalTrials":758,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":917,"PHASE4":932,"NA":938},{"trials":900,"activeCount":67},[],{"trials":902,"activeCount":67},[],{"trials":904,"activeCount":67},[905],{"nctId":906,"briefTitle":907,"status":98,"phases":908,"primaryCompletion":909,"start":748,"enrollment":910,"conditions":911,"interventions":912},"NCT00637130","Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost",[56],"2008-01",138,[116,15],[913,914,915,916],"Travoprost ophthalmic solution, 0.0008%","Travoprost ophthalmic solution, 0.001%","Travoprost ophthalmic solution, 0.0012%","TRAVATAN",{"trials":918,"activeCount":67},[919,923],{"nctId":864,"briefTitle":865,"status":479,"phases":920,"primaryCompletion":819,"completion":819,"start":612,"enrollment":8,"conditions":921,"interventions":922},[57],[33,15],[869,833,850],{"nctId":924,"briefTitle":925,"status":98,"phases":926,"primaryCompletion":927,"start":551,"enrollment":928,"conditions":929,"interventions":931},"NCT00051168","A Long-term Safety Study of Once-daily Travatan",[57],"2009-03",502,[930,15],"Glaucoma, Open-angle",[850],{"trials":933,"activeCount":67},[934],{"nctId":844,"briefTitle":845,"status":479,"phases":935,"primaryCompletion":631,"start":847,"enrollment":28,"conditions":936,"interventions":937},[58],[116,15],[850,805],{"trials":939,"activeCount":67},[],{"intervention":208,"totalTrials":941,"cells":942},3,{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":971},{"trials":944,"activeCount":67},[],{"trials":946,"activeCount":67},[],{"trials":948,"activeCount":67},[],{"trials":950,"activeCount":67},[],{"trials":952,"activeCount":67},[953,957,967],{"nctId":199,"briefTitle":200,"status":98,"phases":954,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":955,"interventions":956},[58],[15,206],[208,62,209],{"nctId":958,"briefTitle":959,"status":98,"phases":960,"primaryCompletion":961,"completion":961,"start":203,"enrollment":962,"conditions":963,"interventions":964},"NCT01978600","Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension",[58],"2014-03",89,[104,15],[965,966],"Brinzolamide 1%\u002FBrimonidine 0.2% ophthalmic suspension","Timolol Maleate 0.5%",{"nctId":221,"briefTitle":222,"status":98,"phases":968,"primaryCompletion":224,"completion":224,"start":203,"enrollment":225,"conditions":969,"interventions":970},[58],[15,206],[208,62,228],{"trials":972,"activeCount":67},[],{"intervention":542,"totalTrials":941,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":985,"PHASE4":987,"NA":1007},{"trials":976,"activeCount":67},[],{"trials":978,"activeCount":67},[],{"trials":980,"activeCount":67},[981],{"nctId":534,"briefTitle":535,"status":98,"phases":982,"primaryCompletion":403,"start":537,"enrollment":538,"conditions":983,"interventions":984},[56],[540,15],[542,543,525],{"trials":986,"activeCount":67},[],{"trials":988,"activeCount":67},[989,1000],{"nctId":990,"briefTitle":991,"status":98,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT00762645","Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)",[58],"2008-05","2007-02",30,[997],"Angle-closure Glaucoma",[542,999],"Pilocarpine 1%",{"nctId":1001,"briefTitle":1002,"status":98,"phases":1003,"primaryCompletion":799,"completion":799,"start":77,"enrollment":1004,"conditions":1005,"interventions":1006},"NCT01493427","Efficacy of Changing to TRAVATAN® From Prior Therapy",[58],202,[104,15],[542],{"trials":1008,"activeCount":67},[],{"intervention":741,"totalTrials":941,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1033,"NA":1043},{"trials":1012,"activeCount":67},[],{"trials":1014,"activeCount":67},[],{"trials":1016,"activeCount":67},[],{"trials":1018,"activeCount":67},[1019,1029],{"nctId":1020,"briefTitle":1021,"status":98,"phases":1022,"primaryCompletion":165,"completion":165,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1026},"NCT01357616","Fixed Combination Brinzolamide 1%\u002FTimolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension",[57],"2010-11",328,[104,15],[1027,171,1028],"Brinzolamide 1% \u002F Timolol 0.5% fixed combination ophthalmic suspension","Timolol 0.5% ophthalmic solution",{"nctId":735,"briefTitle":548,"status":98,"phases":1030,"primaryCompletion":737,"completion":737,"start":570,"enrollment":268,"conditions":1031,"interventions":1032},[57],[104,15],[740,689,741],{"trials":1034,"activeCount":67},[1035],{"nctId":1036,"briefTitle":1037,"status":98,"phases":1038,"primaryCompletion":113,"completion":113,"start":550,"enrollment":1039,"conditions":1040,"interventions":1041},"NCT00763061","Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension",[58],111,[33],[1042,741],"Travoprost 0.004% Ophthalmic Solution",{"trials":1044,"activeCount":67},[],{"intervention":209,"totalTrials":195,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1071},{"trials":1048,"activeCount":67},[],{"trials":1050,"activeCount":67},[],{"trials":1052,"activeCount":67},[],{"trials":1054,"activeCount":67},[],{"trials":1056,"activeCount":67},[1057,1061],{"nctId":199,"briefTitle":200,"status":98,"phases":1058,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":1059,"interventions":1060},[58],[15,206],[208,62,209],{"nctId":1062,"briefTitle":1063,"status":98,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT02419508","SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)",[58],"2018-02-27","2015-08-07",290,[104,15],[219,1070,209],"Brinz\u002Fbrim vehicle",{"trials":1072,"activeCount":67},[],{"intervention":1074,"totalTrials":195,"cells":1075},"Nepafenac 0.1%",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1104},{"trials":1077,"activeCount":67},[],{"trials":1079,"activeCount":67},[],{"trials":1081,"activeCount":67},[],{"trials":1083,"activeCount":67},[],{"trials":1085,"activeCount":67},[1086,1095],{"nctId":1087,"briefTitle":1088,"status":98,"phases":1089,"primaryCompletion":435,"completion":435,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT00818844","Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery",[58],"2009-01",40,[1093],"Epiretinal Membrane",[1074],{"nctId":1096,"briefTitle":1097,"status":98,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":874,"enrollment":1091,"conditions":1100,"interventions":1102},"NCT00330798","A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief",[58],"2006-06",[1101],"Photorefractive Keratectomy",[1103],"nepafenac 0.1%",{"trials":1105,"activeCount":67},[],{"intervention":94,"totalTrials":195,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1118,"PHASE4":1120,"NA":1131},{"trials":1109,"activeCount":67},[],{"trials":1111,"activeCount":67},[],{"trials":1113,"activeCount":67},[1114],{"nctId":86,"briefTitle":87,"status":75,"phases":1115,"primaryCompletion":89,"completion":89,"start":89,"enrollment":67,"conditions":1116,"interventions":1117},[56],[91],[93,94,62],{"trials":1119,"activeCount":67},[],{"trials":1121,"activeCount":67},[1122],{"nctId":1123,"briefTitle":1124,"status":98,"phases":1125,"primaryCompletion":819,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1130},"NCT00631358","Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention",[58],"2008-02",97,[1129],"Sjogren's Syndrome",[94],{"trials":1132,"activeCount":67},[],{"intervention":1134,"totalTrials":195,"cells":1135},"IOP Lowering Medications",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1150,"NA":1161},{"trials":1137,"activeCount":67},[],{"trials":1139,"activeCount":67},[],{"trials":1141,"activeCount":67},[],{"trials":1143,"activeCount":67},[1144],{"nctId":1145,"briefTitle":1146,"status":98,"phases":1147,"primaryCompletion":570,"completion":570,"start":561,"conditions":1148,"interventions":1149},"NCT00047593","Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98",[57],[104,15],[1134],{"trials":1151,"activeCount":67},[1152],{"nctId":1153,"briefTitle":1154,"status":479,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT00047606","Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32",[58],"2003-11","2002-08",84,[116,15],[1134],{"trials":1162,"activeCount":67},[],{"intervention":1164,"totalTrials":195,"cells":1165},"Bimatoprost 0.01% ophthalmic solution",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1190},{"trials":1167,"activeCount":67},[],{"trials":1169,"activeCount":67},[],{"trials":1171,"activeCount":67},[],{"trials":1173,"activeCount":67},[],{"trials":1175,"activeCount":67},[1176,1183],{"nctId":1177,"briefTitle":1178,"status":98,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":450,"enrollment":102,"conditions":1181,"interventions":1182},"NCT01664039","An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®",[58],"2014-06",[33,15],[228,1164],{"nctId":1184,"briefTitle":1185,"status":98,"phases":1186,"primaryCompletion":497,"completion":497,"start":1187,"enrollment":1158,"conditions":1188,"interventions":1189},"NCT01464424","Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)",[58],"2011-10",[33,15,104],[228,1164],{"trials":1191,"activeCount":67},[],{"intervention":219,"totalTrials":195,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1202,"NA":1212},{"trials":1195,"activeCount":67},[],{"trials":1197,"activeCount":67},[],{"trials":1199,"activeCount":67},[],{"trials":1201,"activeCount":67},[],{"trials":1203,"activeCount":67},[1204,1208],{"nctId":211,"briefTitle":212,"status":98,"phases":1205,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":1206,"interventions":1207},[58],[33],[219,62],{"nctId":1062,"briefTitle":1063,"status":98,"phases":1209,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1210,"interventions":1211},[58],[104,15],[219,1070,209],{"trials":1213,"activeCount":67},[],{"intervention":1215,"totalTrials":195,"cells":1216},"DuoTrav",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1233,"NA":1242},{"trials":1218,"activeCount":67},[],{"trials":1220,"activeCount":67},[],{"trials":1222,"activeCount":67},[],{"trials":1224,"activeCount":67},[1225],{"nctId":1226,"briefTitle":1227,"status":75,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":927,"enrollment":67,"conditions":1230,"interventions":1231},"NCT00862472","Safety and Efficacy Study of DuoTrav APS Versus DuoTrav",[57],"2009-06",[116,15],[1232,1215],"DuoTrav APS",{"trials":1234,"activeCount":67},[1235],{"nctId":1236,"briefTitle":1237,"status":98,"phases":1238,"primaryCompletion":380,"start":819,"enrollment":1239,"conditions":1240,"interventions":1241},"NCT00828906","DuoTrav® Eye Drops As Replacement Therapy Program",[58],128,[116,15],[1215],{"trials":1243,"activeCount":67},[],{"intervention":1245,"totalTrials":195,"cells":1246},"Olopatadine Hydrochloride Ophthalmic Solution 0.1%",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1265,"NA":1276},{"trials":1248,"activeCount":67},[],{"trials":1250,"activeCount":67},[],{"trials":1252,"activeCount":67},[],{"trials":1254,"activeCount":67},[1255],{"nctId":1256,"briefTitle":1257,"status":98,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1263},"NCT02322216","Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects",[57],"2015-10","2014-12",383,[91],[1264,1245,386],"Olopatadine Hydrochloride Ophthalmic Solution 0.2%",{"trials":1266,"activeCount":67},[1267],{"nctId":1268,"briefTitle":1269,"status":98,"phases":1270,"primaryCompletion":838,"completion":838,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT01109485","Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients",[58],"2010-03",42,[91],[1275],"Olopatadine hydrochloride ophthalmic solution 0.1%",{"trials":1277,"activeCount":67},[],{"intervention":1279,"totalTrials":195,"cells":1280},"Ocriplasmin",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1299,"NA":1311},{"trials":1282,"activeCount":67},[],{"trials":1284,"activeCount":67},[],{"trials":1286,"activeCount":67},[],{"trials":1288,"activeCount":67},[1289],{"nctId":1290,"briefTitle":1291,"status":98,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":392,"enrollment":1294,"conditions":1295,"interventions":1297},"NCT01889251","A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion",[57],"2014-09",251,[1296],"Symptomatic Vitreomacular Adhesion",[1279,1298],"Sham",{"trials":1300,"activeCount":67},[1301],{"nctId":1302,"briefTitle":1303,"status":98,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":224,"enrollment":1306,"conditions":1307,"interventions":1310},"NCT02035748","Assessment of Patients Treated With JETREA® for Vitreomacular Traction",[58],"2015-09",628,[1308,1309],"Vitreomacular Traction","Vitreomacular Adhesion",[1279],{"trials":1312,"activeCount":67},[],{"intervention":1314,"totalTrials":195,"cells":1315},"Olopatadine HCl Nasal Spray, 0.6%",{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1343},{"trials":1317,"activeCount":67},[],{"trials":1319,"activeCount":67},[],{"trials":1321,"activeCount":67},[],{"trials":1323,"activeCount":67},[],{"trials":1325,"activeCount":67},[1326,1334],{"nctId":1327,"briefTitle":1328,"status":98,"phases":1329,"primaryCompletion":89,"start":927,"enrollment":1330,"conditions":1331,"interventions":1332},"NCT00845195","Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid",[58],150,[181],[1314,1333],"Azelastine HCl Nasal Spray, 0.1%",{"nctId":1335,"briefTitle":1336,"status":98,"phases":1337,"primaryCompletion":1090,"start":993,"enrollment":1338,"conditions":1339,"interventions":1340},"NCT00691665","Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial",[58],130,[181],[1341,1342],"Olopatadine HCL Nasal Spray, 0.6%","Fluticasone Propionate Nasal Spray, 50 mcg",{"trials":1344,"activeCount":67},[],{"intervention":1346,"totalTrials":285,"cells":1347},"Olopatadine hydrochloride, 0.1% ophthalmic solution",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1354,"PHASE4":1356,"NA":1366},{"trials":1349,"activeCount":67},[],{"trials":1351,"activeCount":67},[],{"trials":1353,"activeCount":67},[],{"trials":1355,"activeCount":67},[],{"trials":1357,"activeCount":67},[1358],{"nctId":1359,"briefTitle":1360,"status":98,"phases":1361,"primaryCompletion":498,"completion":498,"start":1362,"enrollment":1363,"conditions":1364,"interventions":1365},"NCT01282138","Assessment of Alcon's Ocular Image Quantification System",[58],"2010-12",13,[91],[1346],{"trials":1367,"activeCount":67},[],{"intervention":1369,"totalTrials":285,"cells":1370},"brinzolamide 1.0%",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1388},{"trials":1372,"activeCount":67},[],{"trials":1374,"activeCount":67},[],{"trials":1376,"activeCount":67},[],{"trials":1378,"activeCount":67},[],{"trials":1380,"activeCount":67},[1381],{"nctId":1382,"briefTitle":1383,"status":98,"phases":1384,"primaryCompletion":178,"completion":178,"start":892,"enrollment":995,"conditions":1385,"interventions":1387},"NCT00300079","Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension",[58],[1386,15],"Primary Open Angle Glaucoma",[1369],{"trials":1389,"activeCount":67},[],{"intervention":1391,"totalTrials":285,"cells":1392},"Olopatadine HCl ophthalmic solution, 0.1%",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1412},{"trials":1394,"activeCount":67},[],{"trials":1396,"activeCount":67},[],{"trials":1398,"activeCount":67},[],{"trials":1400,"activeCount":67},[],{"trials":1402,"activeCount":67},[1403],{"nctId":1404,"briefTitle":1405,"status":98,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":25,"conditions":1409,"interventions":1410},"NCT02251613","Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan",[58],"2014-01","2013-12",[91],[1391,1411],"Epinastine HCl ophthalmic solution, 0.05%",{"trials":1413,"activeCount":67},[],{"intervention":1411,"totalTrials":285,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1424,"NA":1430},{"trials":1417,"activeCount":67},[],{"trials":1419,"activeCount":67},[],{"trials":1421,"activeCount":67},[],{"trials":1423,"activeCount":67},[],{"trials":1425,"activeCount":67},[1426],{"nctId":1404,"briefTitle":1405,"status":98,"phases":1427,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":25,"conditions":1428,"interventions":1429},[58],[91],[1391,1411],{"trials":1431,"activeCount":67},[],{"intervention":1433,"totalTrials":285,"cells":1434},"Ocriplasmin 0.125 mg in a 0.1 mL volume",{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1455},{"trials":1436,"activeCount":67},[],{"trials":1438,"activeCount":67},[],{"trials":1440,"activeCount":67},[],{"trials":1442,"activeCount":67},[],{"trials":1444,"activeCount":67},[1445],{"nctId":1446,"briefTitle":1447,"status":98,"phases":1448,"primaryCompletion":1449,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT02322229","Ocriplasmin for Vitreomacular Traction\u002FSymptomatic Vitreomacular Adhesion",[58],"2015-12-11","2016-05-09","2015-05-26",62,[1308,1309],[1433],{"trials":1456,"activeCount":67},[],{"intervention":1458,"totalTrials":285,"cells":1459},"Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1479},{"trials":1461,"activeCount":67},[],{"trials":1463,"activeCount":67},[],{"trials":1465,"activeCount":67},[],{"trials":1467,"activeCount":67},[],{"trials":1469,"activeCount":67},[1470],{"nctId":1471,"briefTitle":1472,"status":98,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":470,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT01340014","Patient Preference Comparison of AZARGA Versus COSOPT",[58],"2012-10",112,[104,15],[1458,1478],"Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution",{"trials":1480,"activeCount":67},[],{"intervention":1478,"totalTrials":285,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1497},{"trials":1484,"activeCount":67},[],{"trials":1486,"activeCount":67},[],{"trials":1488,"activeCount":67},[],{"trials":1490,"activeCount":67},[],{"trials":1492,"activeCount":67},[1493],{"nctId":1471,"briefTitle":1472,"status":98,"phases":1494,"primaryCompletion":1474,"completion":1474,"start":470,"enrollment":1475,"conditions":1495,"interventions":1496},[58],[104,15],[1458,1478],{"trials":1498,"activeCount":67},[],{"intervention":1500,"totalTrials":285,"cells":1501},"Travoprost Ophthalmic Solution 0.004%",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1521},{"trials":1503,"activeCount":67},[],{"trials":1505,"activeCount":67},[],{"trials":1507,"activeCount":67},[],{"trials":1509,"activeCount":67},[],{"trials":1511,"activeCount":67},[1512],{"nctId":1513,"briefTitle":1514,"status":98,"phases":1515,"primaryCompletion":1180,"completion":1180,"start":1516,"enrollment":1517,"conditions":1518,"interventions":1520},"NCT01995136","Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma",[58],"2013-09",32,[1519,15],"Normal Tension Glaucoma",[1500],{"trials":1522,"activeCount":67},[],{"intervention":1524,"totalTrials":285,"cells":1525},"Travatan-Z",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1543},{"trials":1527,"activeCount":67},[],{"trials":1529,"activeCount":67},[],{"trials":1531,"activeCount":67},[],{"trials":1533,"activeCount":67},[],{"trials":1535,"activeCount":67},[1536],{"nctId":1537,"briefTitle":1538,"status":98,"phases":1539,"primaryCompletion":891,"completion":891,"start":632,"enrollment":1540,"conditions":1541,"interventions":1542},"NCT00444665","Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy",[58],750,[33],[1524],{"trials":1544,"activeCount":67},[],{"intervention":1546,"totalTrials":285,"cells":1547},"Moxifloxacin 0.5%\u002FDexamethasone 0.1% ophthalmic solution",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1566},{"trials":1549,"activeCount":67},[],{"trials":1551,"activeCount":67},[],{"trials":1553,"activeCount":67},[],{"trials":1555,"activeCount":67},[],{"trials":1557,"activeCount":67},[1558],{"nctId":1559,"briefTitle":1560,"status":98,"phases":1561,"primaryCompletion":774,"completion":774,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1565},"NCT01859702","Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic\u002FSteroid Dosing in Cataract Surgery Patients",[58],"2012-04",36,[18],[1546],{"trials":1567,"activeCount":67},[],{"intervention":1569,"totalTrials":285,"cells":1570},"Travoprost 0.004%\u002Ftimolol maleate 0.5% fixed combination ophthalmic solution",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1588},{"trials":1572,"activeCount":67},[],{"trials":1574,"activeCount":67},[],{"trials":1576,"activeCount":67},[],{"trials":1578,"activeCount":67},[],{"trials":1580,"activeCount":67},[1581],{"nctId":1582,"briefTitle":1583,"status":98,"phases":1584,"primaryCompletion":648,"completion":648,"start":891,"enrollment":1585,"conditions":1586,"interventions":1587},"NCT00519753","Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav",[58],522,[33],[1569],{"trials":1589,"activeCount":67},[],{"intervention":752,"totalTrials":285,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1600,"NA":1606},{"trials":1593,"activeCount":67},[],{"trials":1595,"activeCount":67},[],{"trials":1597,"activeCount":67},[],{"trials":1599,"activeCount":67},[],{"trials":1601,"activeCount":67},[1602],{"nctId":745,"briefTitle":746,"status":98,"phases":1603,"primaryCompletion":101,"completion":101,"start":748,"enrollment":749,"conditions":1604,"interventions":1605},[58],[33],[752,753],{"trials":1607,"activeCount":67},[],{"intervention":1609,"totalTrials":285,"cells":1610},"Travoprost 0.004%\u002Ftimolol 0.5% fixed combination eye drops",{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1631},{"trials":1612,"activeCount":67},[],{"trials":1614,"activeCount":67},[],{"trials":1616,"activeCount":67},[],{"trials":1618,"activeCount":67},[],{"trials":1620,"activeCount":67},[1621],{"nctId":1622,"briefTitle":1623,"status":98,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":748,"enrollment":1626,"conditions":1627,"interventions":1628},"NCT00508469","Adherence Assessment With Travalert Dosing Aid",[58],"2010-01",102,[116,15],[1609,1629,1630],"Travoprost 0.004% eye drops","Timolol 0.05% eye drops",{"trials":1632,"activeCount":67},[],{"intervention":1629,"totalTrials":285,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1649},{"trials":1636,"activeCount":67},[],{"trials":1638,"activeCount":67},[],{"trials":1640,"activeCount":67},[],{"trials":1642,"activeCount":67},[],{"trials":1644,"activeCount":67},[1645],{"nctId":1622,"briefTitle":1623,"status":98,"phases":1646,"primaryCompletion":1625,"completion":1625,"start":748,"enrollment":1626,"conditions":1647,"interventions":1648},[58],[116,15],[1609,1629,1630],{"trials":1650,"activeCount":67},[],{"intervention":1630,"totalTrials":285,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1661,"NA":1667},{"trials":1654,"activeCount":67},[],{"trials":1656,"activeCount":67},[],{"trials":1658,"activeCount":67},[],{"trials":1660,"activeCount":67},[],{"trials":1662,"activeCount":67},[1663],{"nctId":1622,"briefTitle":1623,"status":98,"phases":1664,"primaryCompletion":1625,"completion":1625,"start":748,"enrollment":1626,"conditions":1665,"interventions":1666},[58],[116,15],[1609,1629,1630],{"trials":1668,"activeCount":67},[],{"intervention":999,"totalTrials":285,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1679,"NA":1685},{"trials":1672,"activeCount":67},[],{"trials":1674,"activeCount":67},[],{"trials":1676,"activeCount":67},[],{"trials":1678,"activeCount":67},[],{"trials":1680,"activeCount":67},[1681],{"nctId":990,"briefTitle":991,"status":98,"phases":1682,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":1683,"interventions":1684},[58],[997],[542,999],{"trials":1686,"activeCount":67},[],{"intervention":1688,"totalTrials":285,"cells":1689},"Travacom",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1708},{"trials":1691,"activeCount":67},[],{"trials":1693,"activeCount":67},[],{"trials":1695,"activeCount":67},[],{"trials":1697,"activeCount":67},[],{"trials":1699,"activeCount":67},[1700],{"nctId":1701,"briefTitle":1702,"status":98,"phases":1703,"primaryCompletion":469,"completion":469,"start":829,"enrollment":1704,"conditions":1705,"interventions":1707},"NCT01159756","To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure",[58],468,[1706],"Uncontrolled Intraocular Pressure",[1688],{"trials":1709,"activeCount":67},[],{"intervention":1711,"totalTrials":285,"cells":1712},"Travoprost 0.004% BAK-free",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1731},{"trials":1714,"activeCount":67},[],{"trials":1716,"activeCount":67},[],{"trials":1718,"activeCount":67},[],{"trials":1720,"activeCount":67},[],{"trials":1722,"activeCount":67},[1723],{"nctId":1724,"briefTitle":1002,"status":98,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1730},"NCT01510145",[58],"2013-05","2012-02",191,[116,15],[1711],{"trials":1732,"activeCount":67},[],{"intervention":787,"totalTrials":285,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1749},{"trials":1736,"activeCount":67},[],{"trials":1738,"activeCount":67},[],{"trials":1740,"activeCount":67},[],{"trials":1742,"activeCount":67},[],{"trials":1744,"activeCount":67},[1745],{"nctId":779,"briefTitle":780,"status":98,"phases":1746,"primaryCompletion":166,"completion":166,"start":782,"enrollment":783,"conditions":1747,"interventions":1748},[58],[33],[786,787],{"trials":1750,"activeCount":67},[],{"intervention":1752,"totalTrials":285,"cells":1753},"VIGAMOX",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1772},{"trials":1755,"activeCount":67},[],{"trials":1757,"activeCount":67},[],{"trials":1759,"activeCount":67},[],{"trials":1761,"activeCount":67},[],{"trials":1763,"activeCount":67},[1764],{"nctId":1765,"briefTitle":1766,"status":98,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1099,"enrollment":1769,"conditions":1770,"interventions":1771},"NCT00312338","Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora",[58],"2007-06",137,[80],[1752],{"trials":1773,"activeCount":67},[],{"intervention":842,"totalTrials":285,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1784,"NA":1790},{"trials":1777,"activeCount":67},[],{"trials":1779,"activeCount":67},[],{"trials":1781,"activeCount":67},[],{"trials":1783,"activeCount":67},[],{"trials":1785,"activeCount":67},[1786],{"nctId":835,"briefTitle":836,"status":98,"phases":1787,"primaryCompletion":838,"completion":838,"start":537,"enrollment":839,"conditions":1788,"interventions":1789},[58],[33,15],[842,805],{"trials":1791,"activeCount":67},[],{"intervention":1793,"totalTrials":285,"cells":1794},"Travoprost 0.004%+Timolol 0.5% ophthalmic solution",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1803,"NA":1814},{"trials":1796,"activeCount":67},[],{"trials":1798,"activeCount":67},[],{"trials":1800,"activeCount":67},[],{"trials":1802,"activeCount":67},[],{"trials":1804,"activeCount":67},[1805],{"nctId":1806,"briefTitle":1807,"status":98,"phases":1808,"primaryCompletion":1809,"completion":1809,"start":1810,"enrollment":538,"conditions":1811,"interventions":1813},"NCT01327599","Efficacy of Changing to DUOTRAV® From Prior Therapy",[58],"2012-11","2011-08",[104,15,1812],"Pigment Dispersion Glaucoma",[1793],{"trials":1815,"activeCount":67},[],{"intervention":1817,"totalTrials":285,"cells":1818},"Travoprost 0.004%\u002FTimolol 0.5% Fixed Combination eye drops solution",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1837},{"trials":1820,"activeCount":67},[],{"trials":1822,"activeCount":67},[],{"trials":1824,"activeCount":67},[],{"trials":1826,"activeCount":67},[],{"trials":1828,"activeCount":67},[1829],{"nctId":1830,"briefTitle":1831,"status":98,"phases":1832,"primaryCompletion":506,"completion":506,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1836},"NCT01230736","Safety and Efficacy of Changing to DuoTrav From Prior Therapy",[58],"2010-10",105,[33],[1817],{"trials":1838,"activeCount":67},[],{"intervention":1840,"totalTrials":285,"cells":1841},"Brinzolamide 1% \u002F timolol 0.5% Fixed Combination",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1860},{"trials":1843,"activeCount":67},[],{"trials":1845,"activeCount":67},[],{"trials":1847,"activeCount":67},[],{"trials":1849,"activeCount":67},[],{"trials":1851,"activeCount":67},[1852],{"nctId":1853,"briefTitle":1854,"status":98,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":498,"enrollment":792,"conditions":1857,"interventions":1858},"NCT01263444","Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy",[58],"2013-04",[33,15],[1840,1859],"Habitual prostaglandin monotherapy",{"trials":1861,"activeCount":67},[],{"intervention":1859,"totalTrials":285,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1878},{"trials":1865,"activeCount":67},[],{"trials":1867,"activeCount":67},[],{"trials":1869,"activeCount":67},[],{"trials":1871,"activeCount":67},[],{"trials":1873,"activeCount":67},[1874],{"nctId":1853,"briefTitle":1854,"status":98,"phases":1875,"primaryCompletion":1856,"completion":1856,"start":498,"enrollment":792,"conditions":1876,"interventions":1877},[58],[33,15],[1840,1859],{"trials":1879,"activeCount":67},[],{"intervention":1881,"totalTrials":285,"cells":1882},"Travoprost 0.004%\u002Ftimolol maleate 0.5% fixed combination",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1889,"PHASE4":1891,"NA":1899},{"trials":1884,"activeCount":67},[],{"trials":1886,"activeCount":67},[],{"trials":1888,"activeCount":67},[],{"trials":1890,"activeCount":67},[],{"trials":1892,"activeCount":67},[1893],{"nctId":1894,"briefTitle":1895,"status":98,"phases":1896,"primaryCompletion":412,"completion":412,"start":506,"enrollment":25,"conditions":1897,"interventions":1898},"NCT01336569","Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol",[58],[33],[1881],{"trials":1900,"activeCount":67},[],{"intervention":1902,"totalTrials":285,"cells":1903},"Travoprost 0.004% + Brinzolamide 1.0%",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1924},{"trials":1905,"activeCount":67},[],{"trials":1907,"activeCount":67},[],{"trials":1909,"activeCount":67},[],{"trials":1911,"activeCount":67},[],{"trials":1913,"activeCount":67},[1914],{"nctId":1915,"briefTitle":1916,"status":479,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":550,"enrollment":1919,"conditions":1920,"interventions":1922},"NCT00758342","Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)",[58],"2008-03",37,[1921],"Intraocular Pressure",[1902,1923],"Travoprost 0.004% + Tears Natural",{"trials":1925,"activeCount":67},[],{"intervention":1923,"totalTrials":285,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1936,"NA":1942},{"trials":1929,"activeCount":67},[],{"trials":1931,"activeCount":67},[],{"trials":1933,"activeCount":67},[],{"trials":1935,"activeCount":67},[],{"trials":1937,"activeCount":67},[1938],{"nctId":1915,"briefTitle":1916,"status":479,"phases":1939,"primaryCompletion":1918,"completion":1918,"start":550,"enrollment":1919,"conditions":1940,"interventions":1941},[58],[1921],[1902,1923],{"trials":1943,"activeCount":67},[],{"intervention":1945,"totalTrials":285,"cells":1946},"Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1964},{"trials":1948,"activeCount":67},[],{"trials":1950,"activeCount":67},[],{"trials":1952,"activeCount":67},[],{"trials":1954,"activeCount":67},[],{"trials":1956,"activeCount":67},[1957],{"nctId":1958,"briefTitle":1959,"status":98,"phases":1960,"primaryCompletion":819,"start":112,"enrollment":1961,"conditions":1962,"interventions":1963},"NCT00870103","Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery",[58],64,[18],[1945],{"trials":1965,"activeCount":67},[],{"intervention":1967,"totalTrials":285,"cells":1968},"Travoprost 0.004% \u002F Timolol maleate 0.5%",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1977,"NA":1985},{"trials":1970,"activeCount":67},[],{"trials":1972,"activeCount":67},[],{"trials":1974,"activeCount":67},[],{"trials":1976,"activeCount":67},[],{"trials":1978,"activeCount":67},[1979],{"nctId":1980,"briefTitle":1981,"status":98,"phases":1982,"primaryCompletion":78,"completion":78,"start":112,"enrollment":1563,"conditions":1983,"interventions":1984},"NCT00759239","Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% \u002F Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension",[58],[116,15],[1967,1967],{"trials":1986,"activeCount":67},[],{"intervention":1988,"totalTrials":285,"cells":1989},"Olopatadine",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2009},{"trials":1991,"activeCount":67},[],{"trials":1993,"activeCount":67},[],{"trials":1995,"activeCount":67},[],{"trials":1997,"activeCount":67},[],{"trials":1999,"activeCount":67},[2000],{"nctId":2001,"briefTitle":2002,"status":98,"phases":2003,"primaryCompletion":2004,"start":2005,"enrollment":2006,"conditions":2007,"interventions":2008},"NCT00389025","Mast-Cell Stabilizing Effects of Olopatadine",[58],"2007-04","2006-10",24,[91],[1988],{"trials":2010,"activeCount":67},[],{"intervention":2012,"totalTrials":285,"cells":2013},"Olopatadine 0.1%",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2031},{"trials":2015,"activeCount":67},[],{"trials":2017,"activeCount":67},[],{"trials":2019,"activeCount":67},[],{"trials":2021,"activeCount":67},[],{"trials":2023,"activeCount":67},[2024],{"nctId":2025,"briefTitle":2026,"status":98,"phases":2027,"primaryCompletion":621,"start":621,"enrollment":25,"conditions":2028,"interventions":2029},"NCT00818805","Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)",[58],[91],[2012,2030],"Tranilast 0.5%",{"trials":2032,"activeCount":67},[],{"intervention":2030,"totalTrials":285,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2041,"PHASE4":2043,"NA":2049},{"trials":2036,"activeCount":67},[],{"trials":2038,"activeCount":67},[],{"trials":2040,"activeCount":67},[],{"trials":2042,"activeCount":67},[],{"trials":2044,"activeCount":67},[2045],{"nctId":2025,"briefTitle":2026,"status":98,"phases":2046,"primaryCompletion":621,"start":621,"enrollment":25,"conditions":2047,"interventions":2048},[58],[91],[2012,2030],{"trials":2050,"activeCount":67},[],{"intervention":2052,"totalTrials":285,"cells":2053},"Brinzolamide 10 mg\u002Fml\u002FTimolol 5 mg\u002Fml eye drops suspension",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2062,"NA":2071},{"trials":2055,"activeCount":67},[],{"trials":2057,"activeCount":67},[],{"trials":2059,"activeCount":67},[],{"trials":2061,"activeCount":67},[],{"trials":2063,"activeCount":67},[2064],{"nctId":2065,"briefTitle":2066,"status":98,"phases":2067,"primaryCompletion":413,"completion":413,"start":819,"enrollment":37,"conditions":2068,"interventions":2069},"NCT00800540","Circadian Ocular Perfusion Pressure and Ocular Blood Flow",[58],[33],[2052,2070],"Brimonidine 20 mg\u002Fml\u002FTimolol 5 mg\u002Fml eye drops solution",{"trials":2072,"activeCount":67},[],{"intervention":2070,"totalTrials":285,"cells":2074},{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2089},{"trials":2076,"activeCount":67},[],{"trials":2078,"activeCount":67},[],{"trials":2080,"activeCount":67},[],{"trials":2082,"activeCount":67},[],{"trials":2084,"activeCount":67},[2085],{"nctId":2065,"briefTitle":2066,"status":98,"phases":2086,"primaryCompletion":413,"completion":413,"start":819,"enrollment":37,"conditions":2087,"interventions":2088},[58],[33],[2052,2070],{"trials":2090,"activeCount":67},[],{"intervention":2092,"totalTrials":285,"cells":2093},"Beta-blocker monotherapy",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2113},{"trials":2095,"activeCount":67},[],{"trials":2097,"activeCount":67},[],{"trials":2099,"activeCount":67},[],{"trials":2101,"activeCount":67},[],{"trials":2103,"activeCount":67},[2104],{"nctId":2105,"briefTitle":2106,"status":98,"phases":2107,"primaryCompletion":2108,"completion":2108,"start":1408,"enrollment":2109,"conditions":2110,"interventions":2111},"NCT02003391","Efficacy of Travoprost\u002FTimolol for Uncontrolled Intraocular Pressure",[58],"2015-05",157,[206,15],[2092,2112],"Travoprost 0.004% \u002F timolol 0.5% fixed combination ophthalmic solution",{"trials":2114,"activeCount":67},[],{"intervention":2112,"totalTrials":285,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2125,"NA":2131},{"trials":2118,"activeCount":67},[],{"trials":2120,"activeCount":67},[],{"trials":2122,"activeCount":67},[],{"trials":2124,"activeCount":67},[],{"trials":2126,"activeCount":67},[2127],{"nctId":2105,"briefTitle":2106,"status":98,"phases":2128,"primaryCompletion":2108,"completion":2108,"start":1408,"enrollment":2109,"conditions":2129,"interventions":2130},[58],[206,15],[2092,2112],{"trials":2132,"activeCount":67},[],{"intervention":2134,"totalTrials":285,"cells":2135},"Tafluprost 0.0015% ophthalmic solution",{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2144,"NA":2153},{"trials":2137,"activeCount":67},[],{"trials":2139,"activeCount":67},[],{"trials":2141,"activeCount":67},[],{"trials":2143,"activeCount":67},[],{"trials":2145,"activeCount":67},[2146],{"nctId":2147,"briefTitle":2148,"status":98,"phases":2149,"primaryCompletion":1271,"completion":1271,"start":611,"enrollment":2150,"conditions":2151,"interventions":2152},"NCT00966940","Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension",[58],51,[33],[228,2134],{"trials":2154,"activeCount":67},[],{"intervention":2156,"totalTrials":285,"cells":2157},"Olopatadine hydrochloride 0.6% nasal spray",{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2176},{"trials":2159,"activeCount":67},[],{"trials":2161,"activeCount":67},[],{"trials":2163,"activeCount":67},[],{"trials":2165,"activeCount":67},[],{"trials":2167,"activeCount":67},[2168],{"nctId":2169,"briefTitle":2170,"status":98,"phases":2171,"primaryCompletion":78,"completion":78,"start":177,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT00789555","Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis",[58],1260,[2174],"Perennial Allergic Rhinitis",[2156],{"trials":2177,"activeCount":67},[],{"intervention":2179,"totalTrials":285,"cells":2180},"Travoprost\u002FTimolol Maleate BAK-Free Fixed Combination",{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2198},{"trials":2182,"activeCount":67},[],{"trials":2184,"activeCount":67},[],{"trials":2186,"activeCount":67},[],{"trials":2188,"activeCount":67},[],{"trials":2190,"activeCount":67},[2191],{"nctId":2192,"briefTitle":2193,"status":479,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":497,"enrollment":1919,"conditions":2196,"interventions":2197},"NCT01514721","Efficacy of Changing to DuoTrav® (Travoprost 0.004%\u002FTimolol 0.5% BAK-Free Fixed Combination) From Prior Therapy",[58],"2013-11",[33],[2179],{"trials":2199,"activeCount":67},[],{"intervention":2201,"totalTrials":285,"cells":2202},"Brinzolamide 1% \u002F timolol 0.5% maleate fixed combination",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2221},{"trials":2204,"activeCount":67},[],{"trials":2206,"activeCount":67},[],{"trials":2208,"activeCount":67},[],{"trials":2210,"activeCount":67},[],{"trials":2212,"activeCount":67},[2213],{"nctId":2214,"briefTitle":2215,"status":98,"phases":2216,"primaryCompletion":2217,"completion":2217,"start":470,"enrollment":2218,"conditions":2219,"interventions":2220},"NCT01415401","Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada",[58],"2013-06",57,[33,15,116],[2201],{"trials":2222,"activeCount":67},[],{"intervention":2224,"totalTrials":285,"cells":2225},"Dexamethasone 0.1% ophthalmic suspension",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2244},{"trials":2227,"activeCount":67},[],{"trials":2229,"activeCount":67},[],{"trials":2231,"activeCount":67},[],{"trials":2233,"activeCount":67},[],{"trials":2235,"activeCount":67},[2236],{"nctId":2237,"briefTitle":2238,"status":98,"phases":2239,"primaryCompletion":782,"completion":782,"start":1271,"enrollment":2240,"conditions":2241,"interventions":2242},"NCT01119287","Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis",[58],180,[91],[2224,2243],"Olopatadine hydrochloride 0.1% ophthalmic solution",{"trials":2245,"activeCount":67},[],{"intervention":2243,"totalTrials":285,"cells":2247},{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2254,"PHASE4":2256,"NA":2262},{"trials":2249,"activeCount":67},[],{"trials":2251,"activeCount":67},[],{"trials":2253,"activeCount":67},[],{"trials":2255,"activeCount":67},[],{"trials":2257,"activeCount":67},[2258],{"nctId":2237,"briefTitle":2238,"status":98,"phases":2259,"primaryCompletion":782,"completion":782,"start":1271,"enrollment":2240,"conditions":2260,"interventions":2261},[58],[91],[2224,2243],{"trials":2263,"activeCount":67},[],{"intervention":2265,"totalTrials":285,"cells":2266},"Healon",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2285},{"trials":2268,"activeCount":67},[],{"trials":2270,"activeCount":67},[],{"trials":2272,"activeCount":67},[],{"trials":2274,"activeCount":67},[],{"trials":2276,"activeCount":67},[2277],{"nctId":2278,"briefTitle":2279,"status":98,"phases":2280,"primaryCompletion":782,"start":993,"enrollment":2281,"conditions":2282,"interventions":2283},"NCT00763360","To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.",[58],184,[18],[2265,2284],"Amvisc Plus",{"trials":2286,"activeCount":67},[],{"intervention":2284,"totalTrials":285,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2303},{"trials":2290,"activeCount":67},[],{"trials":2292,"activeCount":67},[],{"trials":2294,"activeCount":67},[],{"trials":2296,"activeCount":67},[],{"trials":2298,"activeCount":67},[2299],{"nctId":2278,"briefTitle":2279,"status":98,"phases":2300,"primaryCompletion":782,"start":993,"enrollment":2281,"conditions":2301,"interventions":2302},[58],[18],[2265,2284],{"trials":2304,"activeCount":67},[],{"intervention":1070,"totalTrials":285,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2321},{"trials":2308,"activeCount":67},[],{"trials":2310,"activeCount":67},[],{"trials":2312,"activeCount":67},[],{"trials":2314,"activeCount":67},[],{"trials":2316,"activeCount":67},[2317],{"nctId":1062,"briefTitle":1063,"status":98,"phases":2318,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":2319,"interventions":2320},[58],[104,15],[219,1070,209],{"trials":2322,"activeCount":67},[],{"intervention":2324,"totalTrials":285,"cells":2325},"AL-4943A",{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2342},{"trials":2327,"activeCount":67},[],{"trials":2329,"activeCount":67},[],{"trials":2331,"activeCount":67},[],{"trials":2333,"activeCount":67},[],{"trials":2335,"activeCount":67},[2336],{"nctId":2337,"briefTitle":2338,"status":98,"phases":2339,"primaryCompletion":1187,"completion":1187,"start":782,"enrollment":792,"conditions":2340,"interventions":2341},"NCT01294969","Patient Perception Study for AL-4943A",[58],[91],[2324],{"trials":2343,"activeCount":67},[],{"intervention":520,"totalTrials":285,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2360},{"trials":2347,"activeCount":67},[],{"trials":2349,"activeCount":67},[],{"trials":2351,"activeCount":67},[],{"trials":2353,"activeCount":67},[],{"trials":2355,"activeCount":67},[2356],{"nctId":513,"briefTitle":514,"status":479,"phases":2357,"primaryCompletion":516,"completion":516,"start":517,"enrollment":268,"conditions":2358,"interventions":2359},[58],[116,15],[456,520,521],{"trials":2361,"activeCount":67},[],{"intervention":521,"totalTrials":285,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2378},{"trials":2365,"activeCount":67},[],{"trials":2367,"activeCount":67},[],{"trials":2369,"activeCount":67},[],{"trials":2371,"activeCount":67},[],{"trials":2373,"activeCount":67},[2374],{"nctId":513,"briefTitle":514,"status":479,"phases":2375,"primaryCompletion":516,"completion":516,"start":517,"enrollment":268,"conditions":2376,"interventions":2377},[58],[116,15],[456,520,521],{"trials":2379,"activeCount":67},[],{"intervention":966,"totalTrials":285,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2396},{"trials":2383,"activeCount":67},[],{"trials":2385,"activeCount":67},[],{"trials":2387,"activeCount":67},[],{"trials":2389,"activeCount":67},[],{"trials":2391,"activeCount":67},[2392],{"nctId":958,"briefTitle":959,"status":98,"phases":2393,"primaryCompletion":961,"completion":961,"start":203,"enrollment":962,"conditions":2394,"interventions":2395},[58],[104,15],[965,966],{"trials":2397,"activeCount":67},[],{"intervention":1333,"totalTrials":285,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2414},{"trials":2401,"activeCount":67},[],{"trials":2403,"activeCount":67},[],{"trials":2405,"activeCount":67},[],{"trials":2407,"activeCount":67},[],{"trials":2409,"activeCount":67},[2410],{"nctId":1327,"briefTitle":1328,"status":98,"phases":2411,"primaryCompletion":89,"start":927,"enrollment":1330,"conditions":2412,"interventions":2413},[58],[181],[1314,1333],{"trials":2415,"activeCount":67},[],{"intervention":2417,"totalTrials":285,"cells":2418},"Olopatadine 0.6% \u002F Azelastine 137 mcg",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2436},{"trials":2420,"activeCount":67},[],{"trials":2422,"activeCount":67},[],{"trials":2424,"activeCount":67},[],{"trials":2426,"activeCount":67},[],{"trials":2428,"activeCount":67},[2429],{"nctId":2430,"briefTitle":2431,"status":98,"phases":2432,"primaryCompletion":177,"start":612,"enrollment":1626,"conditions":2433,"interventions":2435},"NCT00772304","Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w\u002FAllergic Rhinitis",[58],[2434],"Allergic Rhinitis",[2417],{"trials":2437,"activeCount":67},[],{"intervention":1342,"totalTrials":285,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2454},{"trials":2441,"activeCount":67},[],{"trials":2443,"activeCount":67},[],{"trials":2445,"activeCount":67},[],{"trials":2447,"activeCount":67},[],{"trials":2449,"activeCount":67},[2450],{"nctId":1335,"briefTitle":1336,"status":98,"phases":2451,"primaryCompletion":1090,"start":993,"enrollment":1338,"conditions":2452,"interventions":2453},[58],[181],[1341,1342],{"trials":2455,"activeCount":67},[],{"intervention":2457,"totalTrials":285,"cells":2458},"Travoprost\u002Ftimolol fixed combination",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2467,"NA":2475},{"trials":2460,"activeCount":67},[],{"trials":2462,"activeCount":67},[],{"trials":2464,"activeCount":67},[],{"trials":2466,"activeCount":67},[],{"trials":2468,"activeCount":67},[2469],{"nctId":2470,"briefTitle":2471,"status":75,"phases":2472,"primaryCompletion":413,"completion":413,"start":413,"enrollment":67,"conditions":2473,"interventions":2474},"NCT01510132","Travacom Post Marketing Surveillance Study",[58],[116,15],[2457],{"trials":2476,"activeCount":67},[],{"intervention":2478,"totalTrials":285,"cells":2479},"Brinzolamide 1% added to Travoprost 0.004%",{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2486,"PHASE4":2488,"NA":2499},{"trials":2481,"activeCount":67},[],{"trials":2483,"activeCount":67},[],{"trials":2485,"activeCount":67},[],{"trials":2487,"activeCount":67},[],{"trials":2489,"activeCount":67},[2490],{"nctId":2491,"briefTitle":2492,"status":98,"phases":2493,"primaryCompletion":551,"completion":551,"start":2494,"enrollment":2495,"conditions":2496,"interventions":2498},"NCT00372827","Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension",[58],"2004-02",245,[2497,15,1812],"Primary Open-angle Glaucoma",[2478],{"trials":2500,"activeCount":67},[],{"intervention":2502,"totalTrials":285,"cells":2503},"Olopatadine HCL (Patanase) Nasal Spray, 0.6%",{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2512,"NA":2523},{"trials":2505,"activeCount":67},[],{"trials":2507,"activeCount":67},[],{"trials":2509,"activeCount":67},[],{"trials":2511,"activeCount":67},[],{"trials":2513,"activeCount":67},[2514],{"nctId":2515,"briefTitle":2516,"status":98,"phases":2517,"primaryCompletion":380,"start":611,"enrollment":2518,"conditions":2519,"interventions":2521},"NCT00979615","Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis",[58],129,[2520],"Vasomotor Rhinitis",[2502,2522],"Azelastine HCl (Astelin) Nasal Spray, 137 mcg",{"trials":2524,"activeCount":67},[],{"intervention":2522,"totalTrials":285,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2541},{"trials":2528,"activeCount":67},[],{"trials":2530,"activeCount":67},[],{"trials":2532,"activeCount":67},[],{"trials":2534,"activeCount":67},[],{"trials":2536,"activeCount":67},[2537],{"nctId":2515,"briefTitle":2516,"status":98,"phases":2538,"primaryCompletion":380,"start":611,"enrollment":2518,"conditions":2539,"interventions":2540},[58],[2520],[2502,2522],{"trials":2542,"activeCount":67},[],{"intervention":2544,"totalTrials":285,"cells":2545},"Elazop",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2563},{"trials":2547,"activeCount":67},[],{"trials":2549,"activeCount":67},[],{"trials":2551,"activeCount":67},[],{"trials":2553,"activeCount":67},[],{"trials":2555,"activeCount":67},[2556],{"nctId":2557,"briefTitle":2558,"status":98,"phases":2559,"primaryCompletion":77,"completion":77,"start":1271,"enrollment":2560,"conditions":2561,"interventions":2562},"NCT01055366","ELAZOP Switching Study in Korea",[58],96,[206],[2544],{"trials":2564,"activeCount":67},[],{"intervention":2566,"totalTrials":285,"cells":2567},"Moxifloxacin 0.5% ophthalmic solution",{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2587},{"trials":2569,"activeCount":67},[],{"trials":2571,"activeCount":67},[],{"trials":2573,"activeCount":67},[],{"trials":2575,"activeCount":67},[],{"trials":2577,"activeCount":67},[2578],{"nctId":2579,"briefTitle":2580,"status":98,"phases":2581,"primaryCompletion":611,"start":1090,"enrollment":2582,"conditions":2583,"interventions":2585},"NCT00840580","Effect on Wound Healing of Vigamox Versus Cravit",[58],79,[2584],"Cataract Extraction",[2566,2586],"Levofloxacin 0.5% ophthalmic solution",{"trials":2588,"activeCount":67},[],{"intervention":2586,"totalTrials":285,"cells":2590},{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2597,"PHASE4":2599,"NA":2605},{"trials":2592,"activeCount":67},[],{"trials":2594,"activeCount":67},[],{"trials":2596,"activeCount":67},[],{"trials":2598,"activeCount":67},[],{"trials":2600,"activeCount":67},[2601],{"nctId":2579,"briefTitle":2580,"status":98,"phases":2602,"primaryCompletion":611,"start":1090,"enrollment":2582,"conditions":2603,"interventions":2604},[58],[2584],[2566,2586],{"trials":2606,"activeCount":67},[],{"intervention":2608,"totalTrials":285,"cells":2609},"Travatan® Z",{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2628},{"trials":2611,"activeCount":67},[],{"trials":2613,"activeCount":67},[],{"trials":2615,"activeCount":67},[],{"trials":2617,"activeCount":67},[],{"trials":2619,"activeCount":67},[2620],{"nctId":2621,"briefTitle":2622,"status":98,"phases":2623,"primaryCompletion":2624,"completion":2624,"start":632,"enrollment":995,"conditions":2625,"interventions":2626},"NCT00468988","Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers",[58],"2007-07",[33],[2608,2627],"Xalatan®",{"trials":2629,"activeCount":67},[],{"intervention":2627,"totalTrials":285,"cells":2631},{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2640,"NA":2646},{"trials":2633,"activeCount":67},[],{"trials":2635,"activeCount":67},[],{"trials":2637,"activeCount":67},[],{"trials":2639,"activeCount":67},[],{"trials":2641,"activeCount":67},[2642],{"nctId":2621,"briefTitle":2622,"status":98,"phases":2643,"primaryCompletion":2624,"completion":2624,"start":632,"enrollment":995,"conditions":2644,"interventions":2645},[58],[33],[2608,2627],{"trials":2647,"activeCount":67},[],{"intervention":2649,"totalTrials":285,"cells":2650},"travoprost 0.004% and brinzolamide 1%",{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2668},{"trials":2652,"activeCount":67},[],{"trials":2654,"activeCount":67},[],{"trials":2656,"activeCount":67},[],{"trials":2658,"activeCount":67},[],{"trials":2660,"activeCount":67},[2661],{"nctId":2662,"briefTitle":2663,"status":98,"phases":2664,"primaryCompletion":612,"start":847,"enrollment":28,"conditions":2665,"interventions":2666},"NCT00471380","A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension",[58],[33,15],[2649,2667],"fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle",{"trials":2669,"activeCount":67},[],{"intervention":2667,"totalTrials":285,"cells":2671},{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2678,"PHASE4":2680,"NA":2686},{"trials":2673,"activeCount":67},[],{"trials":2675,"activeCount":67},[],{"trials":2677,"activeCount":67},[],{"trials":2679,"activeCount":67},[],{"trials":2681,"activeCount":67},[2682],{"nctId":2662,"briefTitle":2663,"status":98,"phases":2683,"primaryCompletion":612,"start":847,"enrollment":28,"conditions":2684,"interventions":2685},[58],[33,15],[2649,2667],{"trials":2687,"activeCount":67},[],{"intervention":2689,"totalTrials":285,"cells":2690},"Vigamox Ophthalmic Solution",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2708},{"trials":2692,"activeCount":67},[],{"trials":2694,"activeCount":67},[],{"trials":2696,"activeCount":67},[],{"trials":2698,"activeCount":67},[],{"trials":2700,"activeCount":67},[2701],{"nctId":2702,"briefTitle":2703,"status":98,"phases":2704,"primaryCompletion":819,"completion":819,"start":612,"enrollment":2006,"conditions":2705,"interventions":2706},"NCT00798577","Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment",[58],[80],[2689,2707],"BSS placebo",{"trials":2709,"activeCount":67},[],{"intervention":2707,"totalTrials":285,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2726},{"trials":2713,"activeCount":67},[],{"trials":2715,"activeCount":67},[],{"trials":2717,"activeCount":67},[],{"trials":2719,"activeCount":67},[],{"trials":2721,"activeCount":67},[2722],{"nctId":2702,"briefTitle":2703,"status":98,"phases":2723,"primaryCompletion":819,"completion":819,"start":612,"enrollment":2006,"conditions":2724,"interventions":2725},[58],[80],[2689,2707],{"trials":2727,"activeCount":67},[],{"intervention":2729,"totalTrials":285,"cells":2730},"Brinzolamide 1% and timolol 0.5% fixed combination eye drops",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2748},{"trials":2732,"activeCount":67},[],{"trials":2734,"activeCount":67},[],{"trials":2736,"activeCount":67},[],{"trials":2738,"activeCount":67},[],{"trials":2740,"activeCount":67},[2741],{"nctId":2742,"briefTitle":2743,"status":98,"phases":2744,"primaryCompletion":412,"completion":412,"start":166,"enrollment":2745,"conditions":2746,"interventions":2747},"NCT01484951","AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure",[58],74,[33],[2729],{"trials":2749,"activeCount":67},[],{"intervention":2751,"totalTrials":285,"cells":2752},"Travoprost 0.004%\u002FTimolol 0.5% Fixed Combination",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2769},{"trials":2754,"activeCount":67},[],{"trials":2756,"activeCount":67},[],{"trials":2758,"activeCount":67},[],{"trials":2760,"activeCount":67},[],{"trials":2762,"activeCount":67},[2763],{"nctId":2764,"briefTitle":2765,"status":75,"phases":2766,"primaryCompletion":799,"completion":799,"start":799,"enrollment":67,"conditions":2767,"interventions":2768},"NCT01696383","Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia",[58],[33,15],[2751],{"trials":2770,"activeCount":67},[],{"intervention":2772,"totalTrials":11,"cells":2773},"Anecortave Acetate Sterile Suspension, 60 mg\u002FmL",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2807,"PHASE4":2841,"NA":2843},{"trials":2775,"activeCount":67},[],{"trials":2777,"activeCount":67},[],{"trials":2779,"activeCount":67},[2780,2789,2797],{"nctId":2781,"briefTitle":2782,"status":98,"phases":2783,"primaryCompletion":101,"completion":101,"start":737,"enrollment":839,"conditions":2784,"interventions":2786},"NCT00315640","Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation",[56],[2785],"Eye Diseases",[2787,2788,2772],"Anecortave Acetate Sterile Suspension, 6 mg\u002FmL","Anecortave Acetate Suspension Depot, 30 mg\u002FmL",{"nctId":2790,"briefTitle":2791,"status":98,"phases":2792,"primaryCompletion":909,"completion":909,"start":2793,"enrollment":749,"conditions":2794,"interventions":2795},"NCT00320203","Anecortave Acetate in Patients With Open-angle Glaucoma",[56],"2006-03",[116],[2787,2796,2772],"Anecortave Acetate Sterile Suspension, 30 mg\u002FmL",{"nctId":2798,"briefTitle":2799,"status":479,"phases":2800,"primaryCompletion":611,"completion":611,"start":648,"enrollment":2801,"conditions":2802,"interventions":2803},"NCT00788541","A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension",[56],197,[104,15],[2787,2804,2805,2806],"Anecortave Acetate Sterile Suspension, 3.75 mg\u002FmL","Anecortave Acetate Sterile Suspension, 96 mg\u002FmL","Anecortave Acetate Sterile Suspension, 60 mg\u002FML",{"trials":2808,"activeCount":67},[2809,2816,2826,2833],{"nctId":2810,"briefTitle":2811,"status":479,"phases":2812,"primaryCompletion":648,"completion":648,"start":892,"enrollment":1563,"conditions":2813,"interventions":2815},"NCT00332657","Anecortave Acetate Risk Reduction Trial (AART)",[57],[2814],"AMD",[2796,2772],{"nctId":2817,"briefTitle":2818,"status":98,"phases":2819,"primaryCompletion":611,"completion":611,"start":2820,"enrollment":2821,"conditions":2822,"interventions":2824},"NCT00691717","Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension",[56,57],"2008-06",201,[116,2823],"Oular Hypertension",[2796,2772,2825],"Anecortave Acetate Sterile Suspension, 75 mg\u002FmL",{"nctId":2827,"briefTitle":2828,"status":479,"phases":2829,"primaryCompletion":648,"completion":648,"start":2830,"enrollment":2006,"conditions":2831,"interventions":2832},"NCT00333216","Anecortave Acetate Risk-Reduction Trial (AART)",[57],"2005-05",[2814],[2796,2806],{"nctId":2834,"briefTitle":2835,"status":98,"phases":2836,"primaryCompletion":113,"completion":113,"start":2837,"enrollment":138,"conditions":2838,"interventions":2840},"NCT00299507","Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)",[57],"2005-03",[2839],"Macular Degeneration",[2796,2772],{"trials":2842,"activeCount":67},[],{"trials":2844,"activeCount":67},[],{"intervention":2846,"totalTrials":457,"cells":2847},"Nepafenac Ophthalmic Suspension, 0.1%",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2872,"PHASE4":2904,"NA":2906},{"trials":2849,"activeCount":67},[],{"trials":2851,"activeCount":67},[],{"trials":2853,"activeCount":67},[2854,2864],{"nctId":2855,"briefTitle":2856,"status":98,"phases":2857,"primaryCompletion":829,"completion":829,"start":177,"enrollment":2858,"conditions":2859,"interventions":2861},"NCT00782717","A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients",[56],263,[2860],"Macular Edema",[2862,2863],"Nepafenac ophthalmic suspension, 0.1%","Prednisolone acetate ophthalmic suspension",{"nctId":2865,"briefTitle":2866,"status":98,"phases":2867,"primaryCompletion":470,"completion":470,"start":498,"enrollment":2868,"conditions":2869,"interventions":2870},"NCT01318499","Nepafenac 0.3% Two Study",[56],1342,[18],[2871,2846],"Nepafenac Ophthalmic Suspension, 0.3%",{"trials":2873,"activeCount":67},[2874,2881,2890,2897],{"nctId":2875,"briefTitle":2876,"status":98,"phases":2877,"primaryCompletion":1562,"completion":1562,"start":838,"enrollment":2878,"conditions":2879,"interventions":2880},"NCT01426854","Nepafenac Compared to Placebo for Ocular Pain and Inflammation",[57],260,[18],[2846],{"nctId":2882,"briefTitle":2883,"status":479,"phases":2884,"primaryCompletion":166,"completion":1810,"start":640,"enrollment":2885,"conditions":2886,"interventions":2888},"NCT00939276","Macular Edema Incidence\u002FSeverity Reduction With Nevanac",[57],175,[2887],"Diabetic Retinopathy",[2862,2889],"Nepafenac ophthalmic suspension vehicle",{"nctId":2891,"briefTitle":2892,"status":98,"phases":2893,"primaryCompletion":166,"start":435,"enrollment":2894,"conditions":2895,"interventions":2896},"NCT01109173","Confirmatory Study Nepafenac 0.3%",[57],2120,[18],[2871,2846],{"nctId":2898,"briefTitle":2899,"status":98,"phases":2900,"primaryCompletion":2793,"start":2901,"enrollment":381,"conditions":2902,"interventions":2903},"NCT00333255","Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery",[57],"2005-09",[18],[2846],{"trials":2905,"activeCount":67},[],{"trials":2907,"activeCount":67},[],{"intervention":2796,"totalTrials":457,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2926,"PHASE4":2944,"NA":2946},{"trials":2911,"activeCount":67},[],{"trials":2913,"activeCount":67},[],{"trials":2915,"activeCount":67},[2916,2922],{"nctId":2917,"briefTitle":2918,"status":98,"phases":2919,"primaryCompletion":101,"completion":101,"start":847,"enrollment":962,"conditions":2920,"interventions":2921},"NCT00451152","Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma",[56],[116],[2796],{"nctId":2790,"briefTitle":2791,"status":98,"phases":2923,"primaryCompletion":909,"completion":909,"start":2793,"enrollment":749,"conditions":2924,"interventions":2925},[56],[116],[2787,2796,2772],{"trials":2927,"activeCount":67},[2928,2932,2936,2940],{"nctId":2810,"briefTitle":2811,"status":479,"phases":2929,"primaryCompletion":648,"completion":648,"start":892,"enrollment":1563,"conditions":2930,"interventions":2931},[57],[2814],[2796,2772],{"nctId":2817,"briefTitle":2818,"status":98,"phases":2933,"primaryCompletion":611,"completion":611,"start":2820,"enrollment":2821,"conditions":2934,"interventions":2935},[56,57],[116,2823],[2796,2772,2825],{"nctId":2827,"briefTitle":2828,"status":479,"phases":2937,"primaryCompletion":648,"completion":648,"start":2830,"enrollment":2006,"conditions":2938,"interventions":2939},[57],[2814],[2796,2806],{"nctId":2834,"briefTitle":2835,"status":98,"phases":2941,"primaryCompletion":113,"completion":113,"start":2837,"enrollment":138,"conditions":2942,"interventions":2943},[57],[2839],[2796,2772],{"trials":2945,"activeCount":67},[],{"trials":2947,"activeCount":67},[],{"intervention":119,"totalTrials":457,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2961,"PHASE3":2980,"PHASE4":3006,"NA":3008},{"trials":2951,"activeCount":67},[],{"trials":2953,"activeCount":67},[2954],{"nctId":2955,"briefTitle":2956,"status":98,"phases":2957,"primaryCompletion":392,"completion":392,"start":165,"enrollment":2958,"conditions":2959,"interventions":2960},"NCT01658839","Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients",[55],25,[33,15],[119],{"trials":2962,"activeCount":67},[2963,2976],{"nctId":2964,"briefTitle":2965,"status":98,"phases":2966,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":2969,"interventions":2970},"NCT01298687","Divided Dose of TRAVATAN®",[56],"2011-04",67,[116,15],[2971,2972,2973,2974,2975,543],"Travoprost Ophthalmic Solution, 0.00013%","Travoprost Ophthalmic Solution, 0.00033%","Travoprost Ophthalmic Solution, 0.001%","Travoprost Ophthalmic Solution, 0.00267%","Travoprost Ophthalmic Solution, 0.004%",{"nctId":109,"briefTitle":110,"status":98,"phases":2977,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":2978,"interventions":2979},[56],[15,116],[118,119,62],{"trials":2981,"activeCount":67},[2982,2990,2999],{"nctId":2983,"briefTitle":2984,"status":98,"phases":2985,"primaryCompletion":774,"completion":774,"start":469,"enrollment":2986,"conditions":2987,"interventions":2988},"NCT01453855","Travoprost 3-Month Safety and Efficacy Study",[57],1099,[104,15],[2989,119],"Travoprost ophthalmic solution, 0.003%",{"nctId":2991,"briefTitle":2992,"status":98,"phases":2993,"primaryCompletion":1090,"start":847,"enrollment":2994,"conditions":2995,"interventions":2996},"NCT00465803","A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension",[57],81,[116,15],[2997,119,2998],"Travoprost 0.004%\u002Ftimolol 0.5% ophthalmic solution","Timolol maleate ophthalmic solution, 0.5%",{"nctId":3000,"briefTitle":3001,"status":75,"phases":3002,"primaryCompletion":77,"completion":77,"start":469,"enrollment":67,"conditions":3003,"interventions":3004},"NCT01452009","Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%",[57],[206,15],[2975,3005],"TRAVATAN®",{"trials":3007,"activeCount":67},[],{"trials":3009,"activeCount":67},[],{"intervention":3011,"totalTrials":597,"cells":3012},"Moxidex otic solution",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3029,"PHASE4":3062,"NA":3064},{"trials":3014,"activeCount":67},[],{"trials":3016,"activeCount":67},[],{"trials":3018,"activeCount":67},[3019],{"nctId":3020,"briefTitle":3021,"status":98,"phases":3022,"primaryCompletion":1090,"completion":1090,"start":3023,"enrollment":3024,"conditions":3025,"interventions":3027},"NCT00578773","A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea",[56],"2007-11",303,[3026],"Acute Otitis Media",[3011,3028],"Moxifloxacin otic solution",{"trials":3030,"activeCount":67},[3031,3038,3046,3053],{"nctId":3032,"briefTitle":3033,"status":479,"phases":3034,"primaryCompletion":1187,"completion":1187,"start":404,"enrollment":3035,"conditions":3036,"interventions":3037},"NCT01071902","Safety and Efficacy of Moxidex Otic",[57],400,[3026],[3011,3028],{"nctId":3039,"briefTitle":3040,"status":98,"phases":3041,"primaryCompletion":631,"completion":631,"start":737,"enrollment":3042,"conditions":3043,"interventions":3044},"NCT00578474","A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes",[57],911,[3026],[3011,3045],"Ofloxacin otic solution",{"nctId":3047,"briefTitle":3048,"status":98,"phases":3049,"primaryCompletion":1090,"completion":1090,"start":551,"enrollment":3050,"conditions":3051,"interventions":3052},"NCT00579189","Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes",[57],776,[3026],[3011,3028],{"nctId":3054,"briefTitle":3055,"status":98,"phases":3056,"primaryCompletion":1090,"completion":1090,"start":2820,"enrollment":3057,"conditions":3058,"interventions":3060},"NCT00750633","A Phase III Study of an Otic Formulation in Acute Otitis Externa",[57],990,[3059],"Acute Otitis Externa",[3011,3028,3061],"Dexamethasone phosphate otic solution",{"trials":3063,"activeCount":67},[],{"trials":3065,"activeCount":67},[],{"intervention":1298,"totalTrials":758,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3083,"PHASE3":3106,"PHASE4":3112,"NA":3114},{"trials":3069,"activeCount":67},[],{"trials":3071,"activeCount":67},[3072],{"nctId":3073,"briefTitle":3074,"status":75,"phases":3075,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":67,"conditions":3078,"interventions":3080},"NCT02281292","A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema",[55],"2017-06","2015-12",[3079],"Diabetic Macular Edema",[3081,3082,1298],"LKA651 ophthalmic solution","Ranibizumab ophthalmic solution",{"trials":3084,"activeCount":67},[3085,3098],{"nctId":3086,"briefTitle":3087,"status":98,"phases":3088,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":3092,"conditions":3093,"interventions":3095},"NCT02515942","CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)",[56],"2017-08-14","2017-12-01","2015-09-25",114,[3094],"Geographic Atrophy",[3096,3097,1298],"CLG561","LFG316",{"nctId":3099,"briefTitle":3100,"status":479,"phases":3101,"primaryCompletion":1809,"completion":1809,"start":497,"enrollment":3102,"conditions":3103,"interventions":3104},"NCT01603043","A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)",[56],10,[3094],[3105,1298],"Al-78898A",{"trials":3107,"activeCount":67},[3108],{"nctId":1290,"briefTitle":1291,"status":98,"phases":3109,"primaryCompletion":1293,"completion":1293,"start":392,"enrollment":1294,"conditions":3110,"interventions":3111},[57],[1296],[1279,1298],{"trials":3113,"activeCount":67},[],{"trials":3115,"activeCount":67},[],{"intervention":2871,"totalTrials":758,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3128,"PHASE4":3150,"NA":3152},{"trials":3119,"activeCount":67},[],{"trials":3121,"activeCount":67},[],{"trials":3123,"activeCount":67},[3124],{"nctId":2865,"briefTitle":2866,"status":98,"phases":3125,"primaryCompletion":470,"completion":470,"start":498,"enrollment":2868,"conditions":3126,"interventions":3127},[56],[18],[2871,2846],{"trials":3129,"activeCount":67},[3130,3139,3143],{"nctId":3131,"briefTitle":3132,"status":98,"phases":3133,"primaryCompletion":2108,"completion":2108,"start":2217,"enrollment":3134,"conditions":3135,"interventions":3137},"NCT01853072","Nepafenac Once Daily for Macular Edema - Study 1",[57],881,[3136,18],"Non-Proliferative Diabetic Retinopathy",[2871,3138],"Prednisolone acetate",{"nctId":2891,"briefTitle":2892,"status":98,"phases":3140,"primaryCompletion":166,"start":435,"enrollment":2894,"conditions":3141,"interventions":3142},[57],[18],[2871,2846],{"nctId":3144,"briefTitle":3145,"status":98,"phases":3146,"primaryCompletion":2108,"completion":2108,"start":2217,"enrollment":3147,"conditions":3148,"interventions":3149},"NCT01872611","Nepafenac Once Daily for Macular Edema - Study 2",[57],819,[3136,18],[2871,3138],{"trials":3151,"activeCount":67},[],{"trials":3153,"activeCount":67},[],{"intervention":3155,"totalTrials":758,"cells":3156},"Travoprost 0.004%\u002FTimolol 0.5% ophthalmic solution",{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3188,"NA":3190},{"trials":3158,"activeCount":67},[],{"trials":3160,"activeCount":67},[],{"trials":3162,"activeCount":67},[],{"trials":3164,"activeCount":67},[3165,3173,3180,3184],{"nctId":3166,"briefTitle":3167,"status":98,"phases":3168,"primaryCompletion":648,"completion":648,"start":2820,"enrollment":3169,"conditions":3170,"interventions":3171},"NCT00760539","Safety and Efficacy of Travoprost\u002FTimolol BAC-free",[57],87,[104,15],[3172,3155],"Travoprost 0.004%\u002FTimolol 0.5% BAC-free ophthalmic solution",{"nctId":3174,"briefTitle":3175,"status":98,"phases":3176,"primaryCompletion":648,"completion":648,"start":993,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT00672997","A Phase III Study of Travoprost\u002FTimolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],301,[104,15],[3172,3155],{"nctId":2991,"briefTitle":2992,"status":98,"phases":3181,"primaryCompletion":1090,"start":847,"enrollment":2994,"conditions":3182,"interventions":3183},[57],[116,15],[2997,119,2998],{"nctId":735,"briefTitle":548,"status":98,"phases":3185,"primaryCompletion":737,"completion":737,"start":570,"enrollment":268,"conditions":3186,"interventions":3187},[57],[104,15],[740,689,741],{"trials":3189,"activeCount":67},[],{"trials":3191,"activeCount":67},[],{"intervention":3028,"totalTrials":758,"cells":3193},{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3204,"PHASE4":3218,"NA":3220},{"trials":3195,"activeCount":67},[],{"trials":3197,"activeCount":67},[],{"trials":3199,"activeCount":67},[3200],{"nctId":3020,"briefTitle":3021,"status":98,"phases":3201,"primaryCompletion":1090,"completion":1090,"start":3023,"enrollment":3024,"conditions":3202,"interventions":3203},[56],[3026],[3011,3028],{"trials":3205,"activeCount":67},[3206,3210,3214],{"nctId":3032,"briefTitle":3033,"status":479,"phases":3207,"primaryCompletion":1187,"completion":1187,"start":404,"enrollment":3035,"conditions":3208,"interventions":3209},[57],[3026],[3011,3028],{"nctId":3047,"briefTitle":3048,"status":98,"phases":3211,"primaryCompletion":1090,"completion":1090,"start":551,"enrollment":3050,"conditions":3212,"interventions":3213},[57],[3026],[3011,3028],{"nctId":3054,"briefTitle":3055,"status":98,"phases":3215,"primaryCompletion":1090,"completion":1090,"start":2820,"enrollment":3057,"conditions":3216,"interventions":3217},[57],[3059],[3011,3028,3061],{"trials":3219,"activeCount":67},[],{"trials":3221,"activeCount":67},[],{"intervention":474,"totalTrials":758,"cells":3223},{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3238,"PHASE4":3248,"NA":3250},{"trials":3225,"activeCount":67},[],{"trials":3227,"activeCount":67},[],{"trials":3229,"activeCount":67},[3230,3234],{"nctId":466,"briefTitle":467,"status":98,"phases":3231,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":3232,"interventions":3233},[56],[104,15],[456,474,475],{"nctId":477,"briefTitle":478,"status":479,"phases":3235,"primaryCompletion":404,"completion":404,"start":100,"enrollment":481,"conditions":3236,"interventions":3237},[56],[104,15],[456,474,475],{"trials":3239,"activeCount":67},[3240,3244],{"nctId":494,"briefTitle":495,"status":98,"phases":3241,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":3242,"interventions":3243},[57],[104,15],[456,474,475],{"nctId":503,"briefTitle":504,"status":98,"phases":3245,"primaryCompletion":412,"completion":412,"start":506,"enrollment":507,"conditions":3246,"interventions":3247},[57],[104,15],[456,474,475],{"trials":3249,"activeCount":67},[],{"trials":3251,"activeCount":67},[],{"intervention":475,"totalTrials":758,"cells":3253},{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3268,"PHASE4":3278,"NA":3280},{"trials":3255,"activeCount":67},[],{"trials":3257,"activeCount":67},[],{"trials":3259,"activeCount":67},[3260,3264],{"nctId":466,"briefTitle":467,"status":98,"phases":3261,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":3262,"interventions":3263},[56],[104,15],[456,474,475],{"nctId":477,"briefTitle":478,"status":479,"phases":3265,"primaryCompletion":404,"completion":404,"start":100,"enrollment":481,"conditions":3266,"interventions":3267},[56],[104,15],[456,474,475],{"trials":3269,"activeCount":67},[3270,3274],{"nctId":494,"briefTitle":495,"status":98,"phases":3271,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":3272,"interventions":3273},[57],[104,15],[456,474,475],{"nctId":503,"briefTitle":504,"status":98,"phases":3275,"primaryCompletion":412,"completion":412,"start":506,"enrollment":507,"conditions":3276,"interventions":3277},[57],[104,15],[456,474,475],{"trials":3279,"activeCount":67},[],{"trials":3281,"activeCount":67},[],{"intervention":3283,"totalTrials":941,"cells":3284},"Alcon Investigational Agent",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3312,"NA":3314},{"trials":3286,"activeCount":67},[],{"trials":3288,"activeCount":67},[],{"trials":3290,"activeCount":67},[],{"trials":3292,"activeCount":67},[3293,3300,3306],{"nctId":3294,"briefTitle":3295,"status":98,"phases":3296,"primaryCompletion":3297,"completion":3297,"start":571,"conditions":3298,"interventions":3299},"NCT00047515","Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69",[57],"2003-12",[104,15],[3283],{"nctId":3301,"briefTitle":3302,"status":98,"phases":3303,"primaryCompletion":1156,"completion":1156,"start":571,"conditions":3304,"interventions":3305},"NCT00047528","Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41",[57],[104,15],[3283],{"nctId":3307,"briefTitle":3308,"status":98,"phases":3309,"primaryCompletion":1156,"completion":1156,"start":580,"conditions":3310,"interventions":3311},"NCT00047541","Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70",[57],[104,15],[3283],{"trials":3313,"activeCount":67},[],{"trials":3315,"activeCount":67},[],{"intervention":3317,"totalTrials":941,"cells":3318},"0.003% AR-15512 ophthalmic solution",{"EARLY_PHASE1":3319,"PHASE1":3321,"PHASE2":3323,"PHASE3":3325,"PHASE4":3355,"NA":3357},{"trials":3320,"activeCount":67},[],{"trials":3322,"activeCount":67},[],{"trials":3324,"activeCount":67},[],{"trials":3326,"activeCount":67},[3327,3337,3347],{"nctId":3328,"briefTitle":3329,"status":98,"phases":3330,"primaryCompletion":3331,"completion":3331,"start":3332,"enrollment":3333,"conditions":3334,"interventions":3336},"NCT06544694","A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease",[57],"2025-03-21","2024-10-08",80,[3335],"Dry Eye Disease",[3317],{"nctId":3338,"briefTitle":3339,"status":98,"phases":3340,"primaryCompletion":3341,"completion":3341,"start":3342,"enrollment":3343,"conditions":3344,"interventions":3345},"NCT06660290","A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes",[57],"2025-02-06","2025-01-15",55,[3335],[3317,3346],"Artificial tears",{"nctId":3348,"briefTitle":3349,"status":98,"phases":3350,"primaryCompletion":3351,"completion":3351,"start":3352,"enrollment":2994,"conditions":3353,"interventions":3354},"NCT06544707","A Study Designed to Evaluate Tear Production",[57],"2025-01-30","2024-10-15",[3335],[3317],{"trials":3356,"activeCount":67},[],{"trials":3358,"activeCount":67},[],{"intervention":3360,"totalTrials":941,"cells":3361},"anecortave acetate",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3377,"PHASE4":3395,"NA":3397},{"trials":3363,"activeCount":67},[],{"trials":3365,"activeCount":67},[],{"trials":3367,"activeCount":67},[3368],{"nctId":3369,"briefTitle":3370,"status":98,"phases":3371,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":3375,"interventions":3376},"NCT00346866","Anecortave Acetate Versus Placebo in AMD Patients Following PDT",[56],"2001-12","2000-05",136,[2814],[3360],{"trials":3378,"activeCount":67},[3379,3388],{"nctId":3380,"briefTitle":3381,"status":98,"phases":3382,"primaryCompletion":3383,"completion":3383,"start":3384,"conditions":3385,"interventions":3387},"NCT00058994","An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD",[57],"2006-11","2003-03",[2839,3386],"Maculopathy, Age-Related",[3360],{"nctId":3389,"briefTitle":3390,"status":75,"phases":3391,"primaryCompletion":621,"completion":621,"start":993,"enrollment":67,"conditions":3392,"interventions":3393},"NCT00705770","A Multi-Dose Study With a Treatment for Open-Angle Glaucoma",[56,57],[104],[3394,3394,3394],"Anecortave Acetate",{"trials":3396,"activeCount":67},[],{"trials":3398,"activeCount":67},[],{"intervention":3400,"totalTrials":941,"cells":3401},"EXE844 Sterile Otic Suspension, 0.3%",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3415,"PHASE3":3417,"PHASE4":3437,"NA":3439},{"trials":3403,"activeCount":67},[],{"trials":3405,"activeCount":67},[3406],{"nctId":3407,"briefTitle":3408,"status":98,"phases":3409,"primaryCompletion":517,"completion":517,"start":3410,"enrollment":63,"conditions":3411,"interventions":3414},"NCT02539654","Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)",[55],"2015-11-17",[3412,3413],"Otitis Media With Effusion in Children","Otitis Media Recurrent",[3400],{"trials":3416,"activeCount":67},[],{"trials":3418,"activeCount":67},[3419,3428],{"nctId":3420,"briefTitle":3421,"status":98,"phases":3422,"primaryCompletion":3423,"completion":3423,"start":3424,"enrollment":3425,"conditions":3426,"interventions":3427},"NCT02432105","Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)",[57],"2016-06-15","2015-06-25",470,[3412,3413],[3400],{"nctId":3429,"briefTitle":3430,"status":98,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":3434,"conditions":3435,"interventions":3436},"NCT02436304","Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2",[57],"2016-08-04","2015-06-19",404,[3412,3413],[3400],{"trials":3438,"activeCount":67},[],{"trials":3440,"activeCount":67},[],{"intervention":3442,"totalTrials":941,"cells":3443},"Next Generation Ophthalmic Irrigating Solution",{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3450,"PHASE4":3477,"NA":3479},{"trials":3445,"activeCount":67},[],{"trials":3447,"activeCount":67},[],{"trials":3449,"activeCount":67},[],{"trials":3451,"activeCount":67},[3452,3461,3470],{"nctId":3453,"briefTitle":3454,"status":98,"phases":3455,"primaryCompletion":1768,"completion":1768,"start":3456,"enrollment":3457,"conditions":3458,"interventions":3459},"NCT00346528","Safety of NGOIS Compared to BSS Plus in Pediatric Patients",[57],"2006-07",18,[18],[3442,3460],"BSS Plus",{"nctId":3462,"briefTitle":3463,"status":98,"phases":3464,"primaryCompletion":3465,"completion":3465,"start":3466,"enrollment":3467,"conditions":3468,"interventions":3469},"NCT00333268","Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus",[57],"2005-07","2004-09",369,[18],[3442,3460],{"nctId":3471,"briefTitle":3472,"status":98,"phases":3473,"primaryCompletion":2793,"completion":2793,"start":3474,"enrollment":3467,"conditions":3475,"interventions":3476},"NCT00333203","Next Generation Ophthalmic Irrigating Solution Posterior Segment Study",[57],"2005-10",[2785],[3442],{"trials":3478,"activeCount":67},[],{"trials":3480,"activeCount":67},[],{"intervention":171,"totalTrials":941,"cells":3482},{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3489,"PHASE4":3503,"NA":3505},{"trials":3484,"activeCount":67},[],{"trials":3486,"activeCount":67},[],{"trials":3488,"activeCount":67},[],{"trials":3490,"activeCount":67},[3491,3495,3499],{"nctId":1020,"briefTitle":1021,"status":98,"phases":3492,"primaryCompletion":165,"completion":165,"start":1023,"enrollment":1024,"conditions":3493,"interventions":3494},[57],[104,15],[1027,171,1028],{"nctId":487,"briefTitle":488,"status":98,"phases":3496,"primaryCompletion":165,"completion":165,"start":166,"enrollment":490,"conditions":3497,"interventions":3498},[57],[104,15],[456,171,172],{"nctId":162,"briefTitle":163,"status":98,"phases":3500,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":3501,"interventions":3502},[57],[104,15],[170,62,171,172],{"trials":3504,"activeCount":67},[],{"trials":3506,"activeCount":67},[],{"intervention":396,"totalTrials":941,"cells":3508},{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3515,"PHASE4":3534,"NA":3536},{"trials":3510,"activeCount":67},[],{"trials":3512,"activeCount":67},[],{"trials":3514,"activeCount":67},[],{"trials":3516,"activeCount":67},[3517,3521,3525],{"nctId":389,"briefTitle":390,"status":98,"phases":3518,"primaryCompletion":392,"completion":392,"start":165,"enrollment":393,"conditions":3519,"interventions":3520},[57],[91],[396,365,397,398],{"nctId":409,"briefTitle":410,"status":98,"phases":3522,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":3523,"interventions":3524},[57],[91],[396,417,365],{"nctId":3526,"briefTitle":3527,"status":98,"phases":3528,"primaryCompletion":165,"completion":165,"start":1474,"enrollment":3529,"conditions":3530,"interventions":3531},"NCT01698814","A Six-Week Safety Study of an Investigational Ophthalmic Solution",[57],518,[91],[3532,3533],"AL-4943A Ophthalmic Solution","AL-4943A Ophthalmic Solution Vehicle",{"trials":3535,"activeCount":67},[],{"trials":3537,"activeCount":67},[],{"intervention":543,"totalTrials":941,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3544,"PHASE3":3554,"PHASE4":3567,"NA":3569},{"trials":3541,"activeCount":67},[],{"trials":3543,"activeCount":67},[],{"trials":3545,"activeCount":67},[3546,3550],{"nctId":2964,"briefTitle":2965,"status":98,"phases":3547,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":3548,"interventions":3549},[56],[116,15],[2971,2972,2973,2974,2975,543],{"nctId":534,"briefTitle":535,"status":98,"phases":3551,"primaryCompletion":403,"start":537,"enrollment":538,"conditions":3552,"interventions":3553},[56],[540,15],[542,543,525],{"trials":3555,"activeCount":67},[3556],{"nctId":3557,"briefTitle":3558,"status":98,"phases":3559,"primaryCompletion":961,"completion":961,"start":450,"enrollment":2281,"conditions":3560,"interventions":3564},"NCT01652664","Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients",[57],[3561,3562,3563],"Pediatric Glaucoma","Elevated IOP in Pediatric Patients","Ocular Hypertension in Pediatric Patients",[3565,3566,543],"Travoprost 0.004% PQ ophthalmic solution","Timolol, 0.5% or 0.25% ophthalmic solution",{"trials":3568,"activeCount":67},[],{"trials":3570,"activeCount":67},[],{"intervention":565,"totalTrials":941,"cells":3572},{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3577,"PHASE3":3579,"PHASE4":3593,"NA":3595},{"trials":3574,"activeCount":67},[],{"trials":3576,"activeCount":67},[],{"trials":3578,"activeCount":67},[],{"trials":3580,"activeCount":67},[3581,3585,3589],{"nctId":557,"briefTitle":558,"status":98,"phases":3582,"primaryCompletion":560,"completion":560,"start":561,"conditions":3583,"interventions":3584},[57],[563,15],[525,565],{"nctId":567,"briefTitle":568,"status":98,"phases":3586,"primaryCompletion":570,"completion":570,"start":571,"conditions":3587,"interventions":3588},[57],[573,15],[525,565],{"nctId":576,"briefTitle":577,"status":98,"phases":3590,"primaryCompletion":579,"completion":579,"start":580,"conditions":3591,"interventions":3592},[57],[573,15],[525,565],{"trials":3594,"activeCount":67},[],{"trials":3596,"activeCount":67},[],{"intervention":3138,"totalTrials":195,"cells":3598},{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3603,"PHASE3":3605,"PHASE4":3615,"NA":3617},{"trials":3600,"activeCount":67},[],{"trials":3602,"activeCount":67},[],{"trials":3604,"activeCount":67},[],{"trials":3606,"activeCount":67},[3607,3611],{"nctId":3131,"briefTitle":3132,"status":98,"phases":3608,"primaryCompletion":2108,"completion":2108,"start":2217,"enrollment":3134,"conditions":3609,"interventions":3610},[57],[3136,18],[2871,3138],{"nctId":3144,"briefTitle":3145,"status":98,"phases":3612,"primaryCompletion":2108,"completion":2108,"start":2217,"enrollment":3147,"conditions":3613,"interventions":3614},[57],[3136,18],[2871,3138],{"trials":3616,"activeCount":67},[],{"trials":3618,"activeCount":67},[],{"intervention":1232,"totalTrials":195,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3627,"PHASE4":3640,"NA":3642},{"trials":3622,"activeCount":67},[],{"trials":3624,"activeCount":67},[],{"trials":3626,"activeCount":67},[],{"trials":3628,"activeCount":67},[3629,3636],{"nctId":3630,"briefTitle":3631,"status":479,"phases":3632,"primaryCompletion":166,"completion":166,"start":1271,"enrollment":138,"conditions":3633,"interventions":3634},"NCT00912054","DuoTrav APS Versus XALACOM® in Ocular Surface Health",[57],[206,15],[1232,3635],"Xalacom",{"nctId":1226,"briefTitle":1227,"status":75,"phases":3637,"primaryCompletion":1229,"completion":1229,"start":927,"enrollment":67,"conditions":3638,"interventions":3639},[57],[116,15],[1232,1215],{"trials":3641,"activeCount":67},[],{"trials":3643,"activeCount":67},[],{"intervention":3645,"totalTrials":195,"cells":3646},"Difluprednate 0.05% ophthalmic emulsion",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3660,"PHASE4":3670,"NA":3672},{"trials":3648,"activeCount":67},[],{"trials":3650,"activeCount":67},[],{"trials":3652,"activeCount":67},[3653],{"nctId":3654,"briefTitle":3655,"status":98,"phases":3656,"primaryCompletion":413,"completion":413,"start":506,"enrollment":3657,"conditions":3658,"interventions":3659},"NCT01276223","Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients",[56],722,[3335],[3645],{"trials":3661,"activeCount":67},[3662],{"nctId":3663,"briefTitle":3664,"status":98,"phases":3665,"primaryCompletion":1810,"completion":1810,"start":1833,"enrollment":1039,"conditions":3666,"interventions":3668},"NCT01201798","Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis",[57],[3667],"Endogenous Anterior Uveitis",[3645,3669],"Prednisolone acetate 1.0% ophthalmic suspension",{"trials":3671,"activeCount":67},[],{"trials":3673,"activeCount":67},[],{"intervention":3172,"totalTrials":195,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3692,"NA":3694},{"trials":3677,"activeCount":67},[],{"trials":3679,"activeCount":67},[],{"trials":3681,"activeCount":67},[],{"trials":3683,"activeCount":67},[3684,3688],{"nctId":3166,"briefTitle":3167,"status":98,"phases":3685,"primaryCompletion":648,"completion":648,"start":2820,"enrollment":3169,"conditions":3686,"interventions":3687},[57],[104,15],[3172,3155],{"nctId":3174,"briefTitle":3175,"status":98,"phases":3689,"primaryCompletion":648,"completion":648,"start":993,"enrollment":3177,"conditions":3690,"interventions":3691},[57],[104,15],[3172,3155],{"trials":3693,"activeCount":67},[],{"trials":3695,"activeCount":67},[],{"intervention":822,"totalTrials":195,"cells":3697},{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3712,"PHASE4":3718,"NA":3720},{"trials":3699,"activeCount":67},[],{"trials":3701,"activeCount":67},[],{"trials":3703,"activeCount":67},[3704],{"nctId":3705,"briefTitle":3706,"status":98,"phases":3707,"primaryCompletion":3708,"completion":3708,"start":891,"enrollment":3374,"conditions":3709,"interventions":3710},"NCT00527501","IOP Lowering Efficacy of Travoprost\u002FBrinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension",[56],"2007-12",[116,15],[3711],"Travoprost\u002Fbrinzolamide",{"trials":3713,"activeCount":67},[3714],{"nctId":816,"briefTitle":817,"status":479,"phases":3715,"primaryCompletion":819,"completion":819,"start":612,"enrollment":457,"conditions":3716,"interventions":3717},[57],[33,15],[822,805],{"trials":3719,"activeCount":67},[],{"trials":3721,"activeCount":67},[],{"intervention":385,"totalTrials":195,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3740,"NA":3742},{"trials":3725,"activeCount":67},[],{"trials":3727,"activeCount":67},[],{"trials":3729,"activeCount":67},[],{"trials":3731,"activeCount":67},[3732,3736],{"nctId":377,"briefTitle":378,"status":98,"phases":3733,"primaryCompletion":380,"completion":380,"start":100,"enrollment":381,"conditions":3734,"interventions":3735},[57],[91],[384,385,386,387],{"nctId":389,"briefTitle":390,"status":98,"phases":3737,"primaryCompletion":392,"completion":392,"start":165,"enrollment":393,"conditions":3738,"interventions":3739},[57],[91],[396,365,397,398],{"trials":3741,"activeCount":67},[],{"trials":3743,"activeCount":67},[],{"intervention":386,"totalTrials":195,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3752,"PHASE4":3762,"NA":3764},{"trials":3747,"activeCount":67},[],{"trials":3749,"activeCount":67},[],{"trials":3751,"activeCount":67},[],{"trials":3753,"activeCount":67},[3754,3758],{"nctId":377,"briefTitle":378,"status":98,"phases":3755,"primaryCompletion":380,"completion":380,"start":100,"enrollment":381,"conditions":3756,"interventions":3757},[57],[91],[384,385,386,387],{"nctId":1256,"briefTitle":1257,"status":98,"phases":3759,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":3760,"interventions":3761},[57],[91],[1264,1245,386],{"trials":3763,"activeCount":67},[],{"trials":3765,"activeCount":67},[],{"intervention":3460,"totalTrials":195,"cells":3767},{"EARLY_PHASE1":3768,"PHASE1":3770,"PHASE2":3772,"PHASE3":3774,"PHASE4":3784,"NA":3786},{"trials":3769,"activeCount":67},[],{"trials":3771,"activeCount":67},[],{"trials":3773,"activeCount":67},[],{"trials":3775,"activeCount":67},[3776,3780],{"nctId":3453,"briefTitle":3454,"status":98,"phases":3777,"primaryCompletion":1768,"completion":1768,"start":3456,"enrollment":3457,"conditions":3778,"interventions":3779},[57],[18],[3442,3460],{"nctId":3462,"briefTitle":3463,"status":98,"phases":3781,"primaryCompletion":3465,"completion":3465,"start":3466,"enrollment":3467,"conditions":3782,"interventions":3783},[57],[18],[3442,3460],{"trials":3785,"activeCount":67},[],{"trials":3787,"activeCount":67},[],{"intervention":3789,"totalTrials":195,"cells":3790},"TOBRADEX",{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3797,"PHASE4":3817,"NA":3819},{"trials":3792,"activeCount":67},[],{"trials":3794,"activeCount":67},[],{"trials":3796,"activeCount":67},[],{"trials":3798,"activeCount":67},[3799,3808],{"nctId":3800,"briefTitle":3801,"status":98,"phases":3802,"primaryCompletion":1126,"completion":1918,"start":748,"enrollment":3803,"conditions":3804,"interventions":3806},"NCT00576251","TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%\u002FDexamethasone 0.05% Ophthalmic Suspension",[57],221,[3805],"Ocular Inflammation Associated With Blepharaconjunctivitis",[3807,3789],"Tobramycin 0.3%\u002FDexamethasone 0.05%",{"nctId":3809,"briefTitle":3810,"status":75,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3812,"enrollment":67,"conditions":3813,"interventions":3815},"NCT00404937","Tobradex BID Compared to TOBRADEX and TOBREX\u002FVehicle",[57],"2006-12",[3814],"Post-surgical Inflammation",[3816],"Tobradex",{"trials":3818,"activeCount":67},[],{"trials":3820,"activeCount":67},[],{"intervention":172,"totalTrials":195,"cells":3822},{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3839,"NA":3841},{"trials":3824,"activeCount":67},[],{"trials":3826,"activeCount":67},[],{"trials":3828,"activeCount":67},[],{"trials":3830,"activeCount":67},[3831,3835],{"nctId":487,"briefTitle":488,"status":98,"phases":3832,"primaryCompletion":165,"completion":165,"start":166,"enrollment":490,"conditions":3833,"interventions":3834},[57],[104,15],[456,171,172],{"nctId":162,"briefTitle":163,"status":98,"phases":3836,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":3837,"interventions":3838},[57],[104,15],[170,62,171,172],{"trials":3840,"activeCount":67},[],{"trials":3842,"activeCount":67},[],{"intervention":398,"totalTrials":195,"cells":3844},{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3849,"PHASE3":3851,"PHASE4":3861,"NA":3863},{"trials":3846,"activeCount":67},[],{"trials":3848,"activeCount":67},[],{"trials":3850,"activeCount":67},[],{"trials":3852,"activeCount":67},[3853,3857],{"nctId":389,"briefTitle":390,"status":98,"phases":3854,"primaryCompletion":392,"completion":392,"start":165,"enrollment":393,"conditions":3855,"interventions":3856},[57],[91],[396,365,397,398],{"nctId":3526,"briefTitle":3527,"status":98,"phases":3858,"primaryCompletion":165,"completion":165,"start":1474,"enrollment":3529,"conditions":3859,"interventions":3860},[57],[91],[3532,3533],{"trials":3862,"activeCount":67},[],{"trials":3864,"activeCount":67},[],{"intervention":183,"totalTrials":195,"cells":3866},{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3881,"PHASE4":3887,"NA":3889},{"trials":3868,"activeCount":67},[],{"trials":3870,"activeCount":67},[],{"trials":3872,"activeCount":67},[3873],{"nctId":3874,"briefTitle":3875,"status":98,"phases":3876,"primaryCompletion":648,"start":612,"enrollment":3877,"conditions":3878,"interventions":3879},"NCT00794144","Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to \u003C 6 Years of Age",[56],132,[2434],[183,3880],"Olopatadine Hydrochloride Nasal Spray Vehicle",{"trials":3882,"activeCount":67},[3883],{"nctId":174,"briefTitle":175,"status":98,"phases":3884,"primaryCompletion":177,"start":178,"enrollment":179,"conditions":3885,"interventions":3886},[57],[181],[183,62],{"trials":3888,"activeCount":67},[],{"trials":3890,"activeCount":67},[],{"intervention":3892,"totalTrials":195,"cells":3893},"AL-60371, 0.3% Otic Suspension",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3917,"NA":3919},{"trials":3895,"activeCount":67},[],{"trials":3897,"activeCount":67},[],{"trials":3899,"activeCount":67},[],{"trials":3901,"activeCount":67},[3902,3909],{"nctId":3903,"briefTitle":3904,"status":98,"phases":3905,"primaryCompletion":1726,"completion":1726,"start":412,"enrollment":3906,"conditions":3907,"interventions":3908},"NCT01535599","Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa",[57],768,[3059],[3892],{"nctId":3910,"briefTitle":3904,"status":98,"phases":3911,"primaryCompletion":1474,"completion":1474,"start":1562,"enrollment":3912,"conditions":3913,"interventions":3914},"NCT01535560",[57],589,[3059],[3915,3916],"AL-60371, 0.3% otic suspension","AL-60371 Vehicle",{"trials":3918,"activeCount":67},[],{"trials":3920,"activeCount":67},[],{"intervention":3922,"totalTrials":195,"cells":3923},"Olopatadine hydrochloride ophthalmic solution vehicle",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3937,"PHASE3":3939,"PHASE4":3945,"NA":3947},{"trials":3925,"activeCount":67},[],{"trials":3927,"activeCount":67},[3928],{"nctId":3929,"briefTitle":3930,"status":98,"phases":3931,"primaryCompletion":3932,"completion":3932,"start":2967,"enrollment":25,"conditions":3933,"interventions":3934},"NCT01326858","Safety and Comfort of AL-4943A Ophthalmic Solution",[55],"2011-06",[91],[3935,3922,3936],"Olopatadine hydrochloride ophthalmic solution, 0.7%","Ketotifen fumarate ophthalmic solution, 0.025%",{"trials":3938,"activeCount":67},[],{"trials":3940,"activeCount":67},[3941],{"nctId":419,"briefTitle":420,"status":98,"phases":3942,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":3943,"interventions":3944},[57],[91],[384,427],{"trials":3946,"activeCount":67},[],{"trials":3948,"activeCount":67},[],{"intervention":3950,"totalTrials":195,"cells":3951},"Brinzolamide 10 mg\u002Fml + Timolol 5 mg\u002Fml eye drops, suspension",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3978,"NA":3980},{"trials":3953,"activeCount":67},[],{"trials":3955,"activeCount":67},[],{"trials":3957,"activeCount":67},[],{"trials":3959,"activeCount":67},[3960,3968],{"nctId":3961,"briefTitle":3962,"status":98,"phases":3963,"primaryCompletion":891,"completion":891,"start":3474,"enrollment":3964,"conditions":3965,"interventions":3966},"NCT00314171","A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension",[57],437,[116,15],[3950,3967],"Dorzolamide 20 mg\u002Fml + Timolol 5 mg\u002Fml eye drops, solution",{"nctId":3969,"briefTitle":3962,"status":98,"phases":3970,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":3973,"conditions":3974,"interventions":3975},"NCT00314158",[57],"2007-01","2005-11",523,[116,15],[3950,3976,3977],"Brinzolamide 10 mg\u002Fml (AZOPT) eye drops, suspension","Timolol 5 mg\u002Fml eye drops, solution",{"trials":3979,"activeCount":67},[],{"trials":3981,"activeCount":67},[],{"intervention":3967,"totalTrials":195,"cells":3983},{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3988,"PHASE3":3990,"PHASE4":4004,"NA":4006},{"trials":3985,"activeCount":67},[],{"trials":3987,"activeCount":67},[],{"trials":3989,"activeCount":67},[],{"trials":3991,"activeCount":67},[3992,3996],{"nctId":3961,"briefTitle":3962,"status":98,"phases":3993,"primaryCompletion":891,"completion":891,"start":3474,"enrollment":3964,"conditions":3994,"interventions":3995},[57],[116,15],[3950,3967],{"nctId":3997,"briefTitle":548,"status":98,"phases":3998,"primaryCompletion":994,"completion":994,"start":3999,"enrollment":4000,"conditions":4001,"interventions":4002},"NCT00333125",[57],"2006-04",319,[33,15],[4003,3967],"Travoprost 40 mcg\u002Fml + Timolol 5 mg\u002Fml eye drops, solution",{"trials":4005,"activeCount":67},[],{"trials":4007,"activeCount":67},[],{"intervention":4009,"totalTrials":195,"cells":4010},"Brolucizumab ophthalmic solution",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4042,"NA":4044},{"trials":4012,"activeCount":67},[],{"trials":4014,"activeCount":67},[],{"trials":4016,"activeCount":67},[],{"trials":4018,"activeCount":67},[4019,4032],{"nctId":4020,"briefTitle":4021,"status":98,"phases":4022,"primaryCompletion":4023,"completion":4024,"start":4025,"enrollment":4026,"conditions":4027,"interventions":4030},"NCT02434328","Efficacy and Safety of RTH258 Versus Aflibercept - Study 2",[57],"2017-04-05","2018-03-08","2015-07-28",1048,[4028,4029],"Neovascular Age-Related Macular Degeneration","Choroidal Neovascularization",[4009,4031],"Aflibercept ophthalmic solution",{"nctId":4033,"briefTitle":4034,"status":98,"phases":4035,"primaryCompletion":4036,"completion":4037,"start":4038,"enrollment":4039,"conditions":4040,"interventions":4041},"NCT02307682","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",[57],"2017-04-22","2018-03-28","2014-12-08",1775,[4028,4029],[4009,4031],{"trials":4043,"activeCount":67},[],{"trials":4045,"activeCount":67},[],{"intervention":4031,"totalTrials":195,"cells":4047},{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4064,"NA":4066},{"trials":4049,"activeCount":67},[],{"trials":4051,"activeCount":67},[],{"trials":4053,"activeCount":67},[],{"trials":4055,"activeCount":67},[4056,4060],{"nctId":4020,"briefTitle":4021,"status":98,"phases":4057,"primaryCompletion":4023,"completion":4024,"start":4025,"enrollment":4026,"conditions":4058,"interventions":4059},[57],[4028,4029],[4009,4031],{"nctId":4033,"briefTitle":4034,"status":98,"phases":4061,"primaryCompletion":4036,"completion":4037,"start":4038,"enrollment":4039,"conditions":4062,"interventions":4063},[57],[4028,4029],[4009,4031],{"trials":4065,"activeCount":67},[],{"trials":4067,"activeCount":67},[],{"intervention":4069,"totalTrials":195,"cells":4070},"Anecortave Acetate 15 mg sterile suspension",{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4075,"PHASE3":4077,"PHASE4":4097,"NA":4099},{"trials":4072,"activeCount":67},[],{"trials":4074,"activeCount":67},[],{"trials":4076,"activeCount":67},[],{"trials":4078,"activeCount":67},[4079,4087],{"nctId":4080,"briefTitle":4081,"status":98,"phases":4082,"primaryCompletion":728,"completion":728,"start":4083,"enrollment":4084,"conditions":4085,"interventions":4086},"NCT00041483","Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD",[57],"2002-06",530,[2839],[4069],{"nctId":4088,"briefTitle":4089,"status":98,"phases":4090,"primaryCompletion":993,"completion":993,"start":3971,"enrollment":4091,"conditions":4092,"interventions":4096},"NCT00051129","Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)",[57],291,[2839,3386,4093,4094,4095],"Age-Related Maculopathies","Age-Related Maculopathy","Maculopathies, Age-Related",[4069],{"trials":4098,"activeCount":67},[],{"trials":4100,"activeCount":67},[],{"intervention":721,"totalTrials":195,"cells":4102},{"EARLY_PHASE1":4103,"PHASE1":4105,"PHASE2":4107,"PHASE3":4113,"PHASE4":4126,"NA":4128},{"trials":4104,"activeCount":67},[],{"trials":4106,"activeCount":67},[],{"trials":4108,"activeCount":67},[4109],{"nctId":710,"briefTitle":711,"status":98,"phases":4110,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":4111,"interventions":4112},[56],[206,15],[718,719,689,720,721,722],{"trials":4114,"activeCount":67},[4115],{"nctId":4116,"briefTitle":4117,"status":98,"phases":4118,"primaryCompletion":4119,"completion":4119,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4123},"NCT07082816","Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction",[57],"2026-04-06","2025-09-02",489,[15,206],[4124,4125],"Netarsudil 0.01%\u002Flatanoprost 0.005% ophthalmic solution","Netarsudil 0.02%\u002Flatanoprost 0.005% ophthalmic solution",{"trials":4127,"activeCount":67},[],{"trials":4129,"activeCount":67},[],{"intervention":4131,"totalTrials":285,"cells":4132},"Moxifloxacin ophthalmic solution, 0.5%",{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4139,"PHASE4":4150,"NA":4152},{"trials":4134,"activeCount":67},[],{"trials":4136,"activeCount":67},[],{"trials":4138,"activeCount":67},[],{"trials":4140,"activeCount":67},[4141],{"nctId":4142,"briefTitle":4143,"status":98,"phases":4144,"primaryCompletion":224,"completion":224,"start":4145,"enrollment":4146,"conditions":4147,"interventions":4148},"NCT01573910","An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients",[57],"2012-05",985,[80],[4131,4149],"Ofloxacin ophthalmic solution, 0.3%",{"trials":4151,"activeCount":67},[],{"trials":4153,"activeCount":67},[],{"intervention":4149,"totalTrials":285,"cells":4155},{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4168,"NA":4170},{"trials":4157,"activeCount":67},[],{"trials":4159,"activeCount":67},[],{"trials":4161,"activeCount":67},[],{"trials":4163,"activeCount":67},[4164],{"nctId":4142,"briefTitle":4143,"status":98,"phases":4165,"primaryCompletion":224,"completion":224,"start":4145,"enrollment":4146,"conditions":4166,"interventions":4167},[57],[80],[4131,4149],{"trials":4169,"activeCount":67},[],{"trials":4171,"activeCount":67},[],{"intervention":4173,"totalTrials":285,"cells":4174},"Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4190,"NA":4192},{"trials":4176,"activeCount":67},[],{"trials":4178,"activeCount":67},[],{"trials":4180,"activeCount":67},[],{"trials":4182,"activeCount":67},[4183],{"nctId":4184,"briefTitle":2828,"status":479,"phases":4185,"primaryCompletion":1090,"completion":1090,"start":589,"enrollment":4186,"conditions":4187,"interventions":4189},"NCT00307398",[57],2596,[4188],"Dry AMD",[4173],{"trials":4191,"activeCount":67},[],{"trials":4193,"activeCount":67},[],{"intervention":4195,"totalTrials":285,"cells":4196},"Tobradex ST",{"EARLY_PHASE1":4197,"PHASE1":4199,"PHASE2":4201,"PHASE3":4203,"PHASE4":4214,"NA":4216},{"trials":4198,"activeCount":67},[],{"trials":4200,"activeCount":67},[],{"trials":4202,"activeCount":67},[],{"trials":4204,"activeCount":67},[4205],{"nctId":4206,"briefTitle":4207,"status":98,"phases":4208,"primaryCompletion":435,"start":537,"enrollment":4209,"conditions":4210,"interventions":4212},"NCT01102244","A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis",[57],122,[4211],"Blepharitis",[4195,4213],"Azasite",{"trials":4215,"activeCount":67},[],{"trials":4217,"activeCount":67},[],{"intervention":4213,"totalTrials":285,"cells":4219},{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4224,"PHASE3":4226,"PHASE4":4232,"NA":4234},{"trials":4221,"activeCount":67},[],{"trials":4223,"activeCount":67},[],{"trials":4225,"activeCount":67},[],{"trials":4227,"activeCount":67},[4228],{"nctId":4206,"briefTitle":4207,"status":98,"phases":4229,"primaryCompletion":435,"start":537,"enrollment":4209,"conditions":4230,"interventions":4231},[57],[4211],[4195,4213],{"trials":4233,"activeCount":67},[],{"trials":4235,"activeCount":67},[],{"intervention":3635,"totalTrials":285,"cells":4237},{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4242,"PHASE3":4244,"PHASE4":4250,"NA":4252},{"trials":4239,"activeCount":67},[],{"trials":4241,"activeCount":67},[],{"trials":4243,"activeCount":67},[],{"trials":4245,"activeCount":67},[4246],{"nctId":3630,"briefTitle":3631,"status":479,"phases":4247,"primaryCompletion":166,"completion":166,"start":1271,"enrollment":138,"conditions":4248,"interventions":4249},[57],[206,15],[1232,3635],{"trials":4251,"activeCount":67},[],{"trials":4253,"activeCount":67},[],{"intervention":4255,"totalTrials":285,"cells":4256},"Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4273,"NA":4275},{"trials":4258,"activeCount":67},[],{"trials":4260,"activeCount":67},[],{"trials":4262,"activeCount":67},[],{"trials":4264,"activeCount":67},[4265],{"nctId":4266,"briefTitle":4267,"status":98,"phases":4268,"primaryCompletion":3812,"completion":3812,"start":550,"enrollment":4269,"conditions":4270,"interventions":4271},"NCT00332293","AL-15469A for the Treatment of Bacterial Conjunctivitis",[57],695,[80],[4255,4272],"Moxifloxacin hydrochloride ophthalmic solution 0.5% as base",{"trials":4274,"activeCount":67},[],{"trials":4276,"activeCount":67},[],{"intervention":4272,"totalTrials":285,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4291,"NA":4293},{"trials":4280,"activeCount":67},[],{"trials":4282,"activeCount":67},[],{"trials":4284,"activeCount":67},[],{"trials":4286,"activeCount":67},[4287],{"nctId":4266,"briefTitle":4267,"status":98,"phases":4288,"primaryCompletion":3812,"completion":3812,"start":550,"enrollment":4269,"conditions":4289,"interventions":4290},[57],[80],[4255,4272],{"trials":4292,"activeCount":67},[],{"trials":4294,"activeCount":67},[],{"intervention":3669,"totalTrials":285,"cells":4296},{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4309,"NA":4311},{"trials":4298,"activeCount":67},[],{"trials":4300,"activeCount":67},[],{"trials":4302,"activeCount":67},[],{"trials":4304,"activeCount":67},[4305],{"nctId":3663,"briefTitle":3664,"status":98,"phases":4306,"primaryCompletion":1810,"completion":1810,"start":1833,"enrollment":1039,"conditions":4307,"interventions":4308},[57],[3667],[3645,3669],{"trials":4310,"activeCount":67},[],{"trials":4312,"activeCount":67},[],{"intervention":4314,"totalTrials":285,"cells":4315},"Travoprost 0.004% with and without BAK",{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4322,"PHASE4":4333,"NA":4335},{"trials":4317,"activeCount":67},[],{"trials":4319,"activeCount":67},[],{"trials":4321,"activeCount":67},[],{"trials":4323,"activeCount":67},[4324],{"nctId":4325,"briefTitle":4326,"status":98,"phases":4327,"primaryCompletion":4328,"completion":4328,"start":4329,"enrollment":4330,"conditions":4331,"interventions":4332},"NCT00288951","Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients",[57],"2005-06","2004-10",690,[116,15],[4314],{"trials":4334,"activeCount":67},[],{"trials":4336,"activeCount":67},[],{"intervention":4338,"totalTrials":285,"cells":4339},"Travoprost APS 40 micrograms\u002Fml eye drop solution",{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4346,"PHASE4":4356,"NA":4358},{"trials":4341,"activeCount":67},[],{"trials":4343,"activeCount":67},[],{"trials":4345,"activeCount":67},[],{"trials":4347,"activeCount":67},[4348],{"nctId":4349,"briefTitle":4350,"status":98,"phases":4351,"primaryCompletion":166,"completion":166,"start":1229,"enrollment":4352,"conditions":4353,"interventions":4354},"NCT00892762","Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health",[57],434,[206,15],[4338,4355],"Latanoprost 50 micrograms\u002Fml eye drop solution",{"trials":4357,"activeCount":67},[],{"trials":4359,"activeCount":67},[],{"intervention":4355,"totalTrials":285,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4368,"PHASE4":4374,"NA":4376},{"trials":4363,"activeCount":67},[],{"trials":4365,"activeCount":67},[],{"trials":4367,"activeCount":67},[],{"trials":4369,"activeCount":67},[4370],{"nctId":4349,"briefTitle":4350,"status":98,"phases":4371,"primaryCompletion":166,"completion":166,"start":1229,"enrollment":4352,"conditions":4372,"interventions":4373},[57],[206,15],[4338,4355],{"trials":4375,"activeCount":67},[],{"trials":4377,"activeCount":67},[],{"intervention":4379,"totalTrials":285,"cells":4380},"Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4387,"PHASE4":4396,"NA":4398},{"trials":4382,"activeCount":67},[],{"trials":4384,"activeCount":67},[],{"trials":4386,"activeCount":67},[],{"trials":4388,"activeCount":67},[4389],{"nctId":4390,"briefTitle":4391,"status":98,"phases":4392,"primaryCompletion":1271,"completion":1271,"start":612,"enrollment":4393,"conditions":4394,"interventions":4395},"NCT00759148","Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis",[57],1179,[80],[4379],{"trials":4397,"activeCount":67},[],{"trials":4399,"activeCount":67},[],{"intervention":4401,"totalTrials":285,"cells":4402},"Olopatadine 0.6% nasal spray",{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4407,"PHASE3":4409,"PHASE4":4418,"NA":4420},{"trials":4404,"activeCount":67},[],{"trials":4406,"activeCount":67},[],{"trials":4408,"activeCount":67},[],{"trials":4410,"activeCount":67},[4411],{"nctId":4412,"briefTitle":4413,"status":98,"phases":4414,"primaryCompletion":909,"completion":909,"start":3812,"enrollment":4415,"conditions":4416,"interventions":4417},"NCT00578331","Safety Study of Olopatadine Nasal Spray",[57],890,[2174],[4401],{"trials":4419,"activeCount":67},[],{"trials":4421,"activeCount":67},[],{"intervention":131,"totalTrials":285,"cells":4423},{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4430,"PHASE4":4436,"NA":4438},{"trials":4425,"activeCount":67},[],{"trials":4427,"activeCount":67},[],{"trials":4429,"activeCount":67},[],{"trials":4431,"activeCount":67},[4432],{"nctId":123,"briefTitle":124,"status":98,"phases":4433,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":4434,"interventions":4435},[57],[104,15],[131,132,133,62],{"trials":4437,"activeCount":67},[],{"trials":4439,"activeCount":67},[],{"intervention":132,"totalTrials":285,"cells":4441},{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4448,"PHASE4":4454,"NA":4456},{"trials":4443,"activeCount":67},[],{"trials":4445,"activeCount":67},[],{"trials":4447,"activeCount":67},[],{"trials":4449,"activeCount":67},[4450],{"nctId":123,"briefTitle":124,"status":98,"phases":4451,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":4452,"interventions":4453},[57],[104,15],[131,132,133,62],{"trials":4455,"activeCount":67},[],{"trials":4457,"activeCount":67},[],{"intervention":133,"totalTrials":285,"cells":4459},{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4464,"PHASE3":4466,"PHASE4":4472,"NA":4474},{"trials":4461,"activeCount":67},[],{"trials":4463,"activeCount":67},[],{"trials":4465,"activeCount":67},[],{"trials":4467,"activeCount":67},[4468],{"nctId":123,"briefTitle":124,"status":98,"phases":4469,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":4470,"interventions":4471},[57],[104,15],[131,132,133,62],{"trials":4473,"activeCount":67},[],{"trials":4475,"activeCount":67},[],{"intervention":2889,"totalTrials":285,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4484,"PHASE4":4490,"NA":4492},{"trials":4479,"activeCount":67},[],{"trials":4481,"activeCount":67},[],{"trials":4483,"activeCount":67},[],{"trials":4485,"activeCount":67},[4486],{"nctId":2882,"briefTitle":2883,"status":479,"phases":4487,"primaryCompletion":166,"completion":1810,"start":640,"enrollment":2885,"conditions":4488,"interventions":4489},[57],[2887],[2862,2889],{"trials":4491,"activeCount":67},[],{"trials":4493,"activeCount":67},[],{"intervention":4495,"totalTrials":285,"cells":4496},"Travoprost 0.004%\u002FTimolol maleate 0.5% ophthalmic solution",{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4503,"PHASE4":4513,"NA":4515},{"trials":4498,"activeCount":67},[],{"trials":4500,"activeCount":67},[],{"trials":4502,"activeCount":67},[],{"trials":4504,"activeCount":67},[4505],{"nctId":4506,"briefTitle":4507,"status":98,"phases":4508,"primaryCompletion":3466,"completion":3466,"start":875,"enrollment":4509,"conditions":4510,"interventions":4511},"NCT00311389","A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],408,[930,15],[4495,4512],"Latanoprost 0.005%\u002FTimolol 0.005% ophthalmic solution",{"trials":4514,"activeCount":67},[],{"trials":4516,"activeCount":67},[],{"intervention":4512,"totalTrials":285,"cells":4518},{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4523,"PHASE3":4525,"PHASE4":4531,"NA":4533},{"trials":4520,"activeCount":67},[],{"trials":4522,"activeCount":67},[],{"trials":4524,"activeCount":67},[],{"trials":4526,"activeCount":67},[4527],{"nctId":4506,"briefTitle":4507,"status":98,"phases":4528,"primaryCompletion":3466,"completion":3466,"start":875,"enrollment":4509,"conditions":4529,"interventions":4530},[57],[930,15],[4495,4512],{"trials":4532,"activeCount":67},[],{"trials":4534,"activeCount":67},[],{"intervention":387,"totalTrials":285,"cells":4536},{"EARLY_PHASE1":4537,"PHASE1":4539,"PHASE2":4541,"PHASE3":4543,"PHASE4":4549,"NA":4551},{"trials":4538,"activeCount":67},[],{"trials":4540,"activeCount":67},[],{"trials":4542,"activeCount":67},[],{"trials":4544,"activeCount":67},[4545],{"nctId":377,"briefTitle":378,"status":98,"phases":4546,"primaryCompletion":380,"completion":380,"start":100,"enrollment":381,"conditions":4547,"interventions":4548},[57],[91],[384,385,386,387],{"trials":4550,"activeCount":67},[],{"trials":4552,"activeCount":67},[],{"intervention":869,"totalTrials":285,"cells":4554},{"EARLY_PHASE1":4555,"PHASE1":4557,"PHASE2":4559,"PHASE3":4561,"PHASE4":4567,"NA":4569},{"trials":4556,"activeCount":67},[],{"trials":4558,"activeCount":67},[],{"trials":4560,"activeCount":67},[],{"trials":4562,"activeCount":67},[4563],{"nctId":864,"briefTitle":865,"status":479,"phases":4564,"primaryCompletion":819,"completion":819,"start":612,"enrollment":8,"conditions":4565,"interventions":4566},[57],[33,15],[869,833,850],{"trials":4568,"activeCount":67},[],{"trials":4570,"activeCount":67},[],{"intervention":4572,"totalTrials":285,"cells":4573},"Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg\u002FmL",{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4580,"PHASE4":4588,"NA":4590},{"trials":4575,"activeCount":67},[],{"trials":4577,"activeCount":67},[],{"trials":4579,"activeCount":67},[],{"trials":4581,"activeCount":67},[4582],{"nctId":4583,"briefTitle":4584,"status":479,"phases":4585,"primaryCompletion":612,"completion":612,"start":560,"enrollment":1039,"conditions":4586,"interventions":4587},"NCT00065728","Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD",[57],[2839],[4572],{"trials":4589,"activeCount":67},[],{"trials":4591,"activeCount":67},[],{"intervention":4593,"totalTrials":285,"cells":4594},"Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution",{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4601,"PHASE4":4611,"NA":4613},{"trials":4596,"activeCount":67},[],{"trials":4598,"activeCount":67},[],{"trials":4600,"activeCount":67},[],{"trials":4602,"activeCount":67},[4603],{"nctId":4604,"briefTitle":4605,"status":98,"phases":4606,"primaryCompletion":1625,"completion":1625,"start":927,"enrollment":4607,"conditions":4608,"interventions":4609},"NCT00848536","Efficacy Study of Travoprost APS Versus TRAVATAN",[57],371,[206,15],[4593,4610],"Travoprost 0.004% (BAK-preserved) Eye Drops, Solution",{"trials":4612,"activeCount":67},[],{"trials":4614,"activeCount":67},[],{"intervention":4610,"totalTrials":285,"cells":4616},{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4621,"PHASE3":4623,"PHASE4":4629,"NA":4631},{"trials":4618,"activeCount":67},[],{"trials":4620,"activeCount":67},[],{"trials":4622,"activeCount":67},[],{"trials":4624,"activeCount":67},[4625],{"nctId":4604,"briefTitle":4605,"status":98,"phases":4626,"primaryCompletion":1625,"completion":1625,"start":927,"enrollment":4607,"conditions":4627,"interventions":4628},[57],[206,15],[4593,4610],{"trials":4630,"activeCount":67},[],{"trials":4632,"activeCount":67},[],{"intervention":4634,"totalTrials":285,"cells":4635},"Triamcinolone Acetonide Injectable Suspension",{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4642,"PHASE4":4651,"NA":4653},{"trials":4637,"activeCount":67},[],{"trials":4639,"activeCount":67},[],{"trials":4641,"activeCount":67},[],{"trials":4643,"activeCount":67},[4644],{"nctId":4645,"briefTitle":4646,"status":98,"phases":4647,"primaryCompletion":178,"completion":178,"start":178,"enrollment":538,"conditions":4648,"interventions":4650},"NCT00532415","Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy",[57],[4649],"Vitrectomy",[4634],{"trials":4652,"activeCount":67},[],{"trials":4654,"activeCount":67},[],{"intervention":3807,"totalTrials":285,"cells":4656},{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4661,"PHASE3":4663,"PHASE4":4669,"NA":4671},{"trials":4658,"activeCount":67},[],{"trials":4660,"activeCount":67},[],{"trials":4662,"activeCount":67},[],{"trials":4664,"activeCount":67},[4665],{"nctId":3800,"briefTitle":3801,"status":98,"phases":4666,"primaryCompletion":1126,"completion":1918,"start":748,"enrollment":3803,"conditions":4667,"interventions":4668},[57],[3805],[3807,3789],{"trials":4670,"activeCount":67},[],{"trials":4672,"activeCount":67},[],{"intervention":1027,"totalTrials":285,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4687,"NA":4689},{"trials":4676,"activeCount":67},[],{"trials":4678,"activeCount":67},[],{"trials":4680,"activeCount":67},[],{"trials":4682,"activeCount":67},[4683],{"nctId":1020,"briefTitle":1021,"status":98,"phases":4684,"primaryCompletion":165,"completion":165,"start":1023,"enrollment":1024,"conditions":4685,"interventions":4686},[57],[104,15],[1027,171,1028],{"trials":4688,"activeCount":67},[],{"trials":4690,"activeCount":67},[],{"intervention":2989,"totalTrials":285,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4699,"PHASE4":4705,"NA":4707},{"trials":4694,"activeCount":67},[],{"trials":4696,"activeCount":67},[],{"trials":4698,"activeCount":67},[],{"trials":4700,"activeCount":67},[4701],{"nctId":2983,"briefTitle":2984,"status":98,"phases":4702,"primaryCompletion":774,"completion":774,"start":469,"enrollment":2986,"conditions":4703,"interventions":4704},[57],[104,15],[2989,119],{"trials":4706,"activeCount":67},[],{"trials":4708,"activeCount":67},[],{"intervention":2825,"totalTrials":285,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4717,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":67},[],{"trials":4714,"activeCount":67},[],{"trials":4716,"activeCount":67},[],{"trials":4718,"activeCount":67},[4719],{"nctId":2817,"briefTitle":2818,"status":98,"phases":4720,"primaryCompletion":611,"completion":611,"start":2820,"enrollment":2821,"conditions":4721,"interventions":4722},[56,57],[116,2823],[2796,2772,2825],{"trials":4724,"activeCount":67},[],{"trials":4726,"activeCount":67},[],{"intervention":4728,"totalTrials":285,"cells":4729},"AL-8309B Ophthalmic Solution",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4736,"PHASE4":4748,"NA":4750},{"trials":4731,"activeCount":67},[],{"trials":4733,"activeCount":67},[],{"trials":4735,"activeCount":67},[],{"trials":4737,"activeCount":67},[4738],{"nctId":4739,"briefTitle":4740,"status":479,"phases":4741,"primaryCompletion":4145,"completion":4145,"start":4742,"enrollment":4743,"conditions":4744,"interventions":4746},"NCT00890097","Geographic Atrophy Treatment Evaluation",[57],"2009-04",772,[3094,4745],"Age-Related Macular Degeneration",[4728,4747],"AL-8309B Vehicle",{"trials":4749,"activeCount":67},[],{"trials":4751,"activeCount":67},[],{"intervention":4747,"totalTrials":285,"cells":4753},{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4760,"PHASE4":4766,"NA":4768},{"trials":4755,"activeCount":67},[],{"trials":4757,"activeCount":67},[],{"trials":4759,"activeCount":67},[],{"trials":4761,"activeCount":67},[4762],{"nctId":4739,"briefTitle":4740,"status":479,"phases":4763,"primaryCompletion":4145,"completion":4145,"start":4742,"enrollment":4743,"conditions":4764,"interventions":4765},[57],[3094,4745],[4728,4747],{"trials":4767,"activeCount":67},[],{"trials":4769,"activeCount":67},[],{"intervention":4771,"totalTrials":285,"cells":4772},"Sodium Hyaluronate Ophthalmic Solution, 0.18%",{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4789,"NA":4791},{"trials":4774,"activeCount":67},[],{"trials":4776,"activeCount":67},[],{"trials":4778,"activeCount":67},[],{"trials":4780,"activeCount":67},[4781],{"nctId":4782,"briefTitle":4783,"status":98,"phases":4784,"primaryCompletion":4145,"completion":4145,"start":838,"enrollment":4785,"conditions":4786,"interventions":4788},"NCT01382225","Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome",[57],1936,[4787],"Dry Eye Syndrome",[4771],{"trials":4790,"activeCount":67},[],{"trials":4792,"activeCount":67},[],{"intervention":3565,"totalTrials":285,"cells":4794},{"EARLY_PHASE1":4795,"PHASE1":4797,"PHASE2":4799,"PHASE3":4801,"PHASE4":4807,"NA":4809},{"trials":4796,"activeCount":67},[],{"trials":4798,"activeCount":67},[],{"trials":4800,"activeCount":67},[],{"trials":4802,"activeCount":67},[4803],{"nctId":3557,"briefTitle":3558,"status":98,"phases":4804,"primaryCompletion":961,"completion":961,"start":450,"enrollment":2281,"conditions":4805,"interventions":4806},[57],[3561,3562,3563],[3565,3566,543],{"trials":4808,"activeCount":67},[],{"trials":4810,"activeCount":67},[],{"intervention":3566,"totalTrials":285,"cells":4812},{"EARLY_PHASE1":4813,"PHASE1":4815,"PHASE2":4817,"PHASE3":4819,"PHASE4":4825,"NA":4827},{"trials":4814,"activeCount":67},[],{"trials":4816,"activeCount":67},[],{"trials":4818,"activeCount":67},[],{"trials":4820,"activeCount":67},[4821],{"nctId":3557,"briefTitle":3558,"status":98,"phases":4822,"primaryCompletion":961,"completion":961,"start":450,"enrollment":2281,"conditions":4823,"interventions":4824},[57],[3561,3562,3563],[3565,3566,543],{"trials":4826,"activeCount":67},[],{"trials":4828,"activeCount":67},[],{"intervention":4830,"totalTrials":285,"cells":4831},"Brimonidine Tartrate Ophthalmic Solution",{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4836,"PHASE3":4838,"PHASE4":4846,"NA":4848},{"trials":4833,"activeCount":67},[],{"trials":4835,"activeCount":67},[],{"trials":4837,"activeCount":67},[],{"trials":4839,"activeCount":67},[4840],{"nctId":4841,"briefTitle":4842,"status":98,"phases":4843,"primaryCompletion":570,"completion":570,"start":875,"conditions":4844,"interventions":4845},"NCT00061529","A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],[104,15],[4830],{"trials":4847,"activeCount":67},[],{"trials":4849,"activeCount":67},[],{"intervention":4851,"totalTrials":285,"cells":4852},"Nepafenac ophthalmic solution 0.1%",{"EARLY_PHASE1":4853,"PHASE1":4855,"PHASE2":4857,"PHASE3":4859,"PHASE4":4869,"NA":4871},{"trials":4854,"activeCount":67},[],{"trials":4856,"activeCount":67},[],{"trials":4858,"activeCount":67},[],{"trials":4860,"activeCount":67},[4861],{"nctId":4862,"briefTitle":4863,"status":98,"phases":4864,"primaryCompletion":3812,"completion":3812,"start":874,"enrollment":4865,"conditions":4866,"interventions":4867},"NCT00332774","Nevanac 3-Month Safety Study With QID Dosing",[57],149,[18],[4851,4868],"Ketorolac Tromethamine ophthalmic solution 0.4%",{"trials":4870,"activeCount":67},[],{"trials":4872,"activeCount":67},[],{"intervention":4868,"totalTrials":285,"cells":4874},{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4879,"PHASE3":4881,"PHASE4":4887,"NA":4889},{"trials":4876,"activeCount":67},[],{"trials":4878,"activeCount":67},[],{"trials":4880,"activeCount":67},[],{"trials":4882,"activeCount":67},[4883],{"nctId":4862,"briefTitle":4863,"status":98,"phases":4884,"primaryCompletion":3812,"completion":3812,"start":874,"enrollment":4865,"conditions":4885,"interventions":4886},[57],[18],[4851,4868],{"trials":4888,"activeCount":67},[],{"trials":4890,"activeCount":67},[],{"intervention":4892,"totalTrials":285,"cells":4893},"BETOPTIC S",{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4898,"PHASE3":4900,"PHASE4":4909,"NA":4911},{"trials":4895,"activeCount":67},[],{"trials":4897,"activeCount":67},[],{"trials":4899,"activeCount":67},[],{"trials":4901,"activeCount":67},[4902],{"nctId":4903,"briefTitle":4904,"status":98,"phases":4905,"primaryCompletion":3383,"completion":3383,"start":875,"enrollment":1834,"conditions":4906,"interventions":4907},"NCT00061542","Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension",[57],[33,15],[4892,4908],"Timolol Gel-forming Solution",{"trials":4910,"activeCount":67},[],{"trials":4912,"activeCount":67},[],{"intervention":4908,"totalTrials":285,"cells":4914},{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4919,"PHASE3":4921,"PHASE4":4927,"NA":4929},{"trials":4916,"activeCount":67},[],{"trials":4918,"activeCount":67},[],{"trials":4920,"activeCount":67},[],{"trials":4922,"activeCount":67},[4923],{"nctId":4903,"briefTitle":4904,"status":98,"phases":4924,"primaryCompletion":3383,"completion":3383,"start":875,"enrollment":1834,"conditions":4925,"interventions":4926},[57],[33,15],[4892,4908],{"trials":4928,"activeCount":67},[],{"trials":4930,"activeCount":67},[],{"intervention":732,"totalTrials":285,"cells":4932},{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4937,"PHASE3":4939,"PHASE4":4945,"NA":4947},{"trials":4934,"activeCount":67},[],{"trials":4936,"activeCount":67},[],{"trials":4938,"activeCount":67},[],{"trials":4940,"activeCount":67},[4941],{"nctId":726,"briefTitle":548,"status":98,"phases":4942,"primaryCompletion":728,"completion":728,"start":579,"enrollment":729,"conditions":4943,"interventions":4944},[57],[116,15],[732,689,733],{"trials":4946,"activeCount":67},[],{"trials":4948,"activeCount":67},[],{"intervention":733,"totalTrials":285,"cells":4950},{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4963,"NA":4965},{"trials":4952,"activeCount":67},[],{"trials":4954,"activeCount":67},[],{"trials":4956,"activeCount":67},[],{"trials":4958,"activeCount":67},[4959],{"nctId":726,"briefTitle":548,"status":98,"phases":4960,"primaryCompletion":728,"completion":728,"start":579,"enrollment":729,"conditions":4961,"interventions":4962},[57],[116,15],[732,689,733],{"trials":4964,"activeCount":67},[],{"trials":4966,"activeCount":67},[],{"intervention":1264,"totalTrials":285,"cells":4968},{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":4973,"PHASE3":4975,"PHASE4":4981,"NA":4983},{"trials":4970,"activeCount":67},[],{"trials":4972,"activeCount":67},[],{"trials":4974,"activeCount":67},[],{"trials":4976,"activeCount":67},[4977],{"nctId":1256,"briefTitle":1257,"status":98,"phases":4978,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":4979,"interventions":4980},[57],[91],[1264,1245,386],{"trials":4982,"activeCount":67},[],{"trials":4984,"activeCount":67},[],{"intervention":417,"totalTrials":285,"cells":4986},{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":4993,"PHASE4":4999,"NA":5001},{"trials":4988,"activeCount":67},[],{"trials":4990,"activeCount":67},[],{"trials":4992,"activeCount":67},[],{"trials":4994,"activeCount":67},[4995],{"nctId":409,"briefTitle":410,"status":98,"phases":4996,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":4997,"interventions":4998},[57],[91],[396,417,365],{"trials":5000,"activeCount":67},[],{"trials":5002,"activeCount":67},[],{"intervention":5004,"totalTrials":285,"cells":5005},"Difluprednate ophthalmic emulsion, 0.05%",{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5012,"PHASE4":5023,"NA":5025},{"trials":5007,"activeCount":67},[],{"trials":5009,"activeCount":67},[],{"trials":5011,"activeCount":67},[],{"trials":5013,"activeCount":67},[5014],{"nctId":5015,"briefTitle":5016,"status":98,"phases":5017,"primaryCompletion":1562,"completion":1562,"start":434,"enrollment":3333,"conditions":5018,"interventions":5021},"NCT01124045","Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery",[57],[5019,5020],"Cataracts","Inflammation",[5004,5022],"Prednisolone acetate ophthalmic suspension, 1.0%",{"trials":5024,"activeCount":67},[],{"trials":5026,"activeCount":67},[],{"intervention":5022,"totalTrials":285,"cells":5028},{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5041,"NA":5043},{"trials":5030,"activeCount":67},[],{"trials":5032,"activeCount":67},[],{"trials":5034,"activeCount":67},[],{"trials":5036,"activeCount":67},[5037],{"nctId":5015,"briefTitle":5016,"status":98,"phases":5038,"primaryCompletion":1562,"completion":1562,"start":434,"enrollment":3333,"conditions":5039,"interventions":5040},[57],[5019,5020],[5004,5022],{"trials":5042,"activeCount":67},[],{"trials":5044,"activeCount":67},[],{"intervention":5046,"totalTrials":285,"cells":5047},"Travoprost 0.004%\u002FTimolol 0.5%",{"EARLY_PHASE1":5048,"PHASE1":5050,"PHASE2":5052,"PHASE3":5054,"PHASE4":5064,"NA":5066},{"trials":5049,"activeCount":67},[],{"trials":5051,"activeCount":67},[],{"trials":5053,"activeCount":67},[],{"trials":5055,"activeCount":67},[5056],{"nctId":5057,"briefTitle":5058,"status":98,"phases":5059,"primaryCompletion":469,"completion":469,"start":1625,"enrollment":5060,"conditions":5061,"interventions":5062},"NCT00872651","Travoprost 0.004%\u002FTimolol 0.5% Versus Latanoprost 0.005%\u002FTimolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],242,[116,15],[5046,5063],"Latanoprost 0.005% \u002F Timolol 0.5%",{"trials":5065,"activeCount":67},[],{"trials":5067,"activeCount":67},[],{"intervention":5063,"totalTrials":285,"cells":5069},{"EARLY_PHASE1":5070,"PHASE1":5072,"PHASE2":5074,"PHASE3":5076,"PHASE4":5082,"NA":5084},{"trials":5071,"activeCount":67},[],{"trials":5073,"activeCount":67},[],{"trials":5075,"activeCount":67},[],{"trials":5077,"activeCount":67},[5078],{"nctId":5057,"briefTitle":5058,"status":98,"phases":5079,"primaryCompletion":469,"completion":469,"start":1625,"enrollment":5060,"conditions":5080,"interventions":5081},[57],[116,15],[5046,5063],{"trials":5083,"activeCount":67},[],{"trials":5085,"activeCount":67},[],{"intervention":5087,"totalTrials":285,"cells":5088},"quinolone",{"EARLY_PHASE1":5089,"PHASE1":5091,"PHASE2":5093,"PHASE3":5095,"PHASE4":5103,"NA":5105},{"trials":5090,"activeCount":67},[],{"trials":5092,"activeCount":67},[],{"trials":5094,"activeCount":67},[],{"trials":5096,"activeCount":67},[5097],{"nctId":5098,"briefTitle":4267,"status":98,"phases":5099,"primaryCompletion":632,"start":3972,"enrollment":5100,"conditions":5101,"interventions":5102},"NCT00331916",[57],600,[80],[5087],{"trials":5104,"activeCount":67},[],{"trials":5106,"activeCount":67},[],{"intervention":555,"totalTrials":285,"cells":5108},{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5113,"PHASE3":5115,"PHASE4":5121,"NA":5123},{"trials":5110,"activeCount":67},[],{"trials":5112,"activeCount":67},[],{"trials":5114,"activeCount":67},[],{"trials":5116,"activeCount":67},[5117],{"nctId":547,"briefTitle":548,"status":98,"phases":5118,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":5119,"interventions":5120},[57],[116,15],[555,525],{"trials":5122,"activeCount":67},[],{"trials":5124,"activeCount":67},[],{"intervention":3045,"totalTrials":285,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":67},[],{"trials":5130,"activeCount":67},[],{"trials":5132,"activeCount":67},[],{"trials":5134,"activeCount":67},[5135],{"nctId":3039,"briefTitle":3040,"status":98,"phases":5136,"primaryCompletion":631,"completion":631,"start":737,"enrollment":3042,"conditions":5137,"interventions":5138},[57],[3026],[3011,3045],{"trials":5140,"activeCount":67},[],{"trials":5142,"activeCount":67},[],{"intervention":2998,"totalTrials":285,"cells":5144},{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5157,"NA":5159},{"trials":5146,"activeCount":67},[],{"trials":5148,"activeCount":67},[],{"trials":5150,"activeCount":67},[],{"trials":5152,"activeCount":67},[5153],{"nctId":2991,"briefTitle":2992,"status":98,"phases":5154,"primaryCompletion":1090,"start":847,"enrollment":2994,"conditions":5155,"interventions":5156},[57],[116,15],[2997,119,2998],{"trials":5158,"activeCount":67},[],{"trials":5160,"activeCount":67},[],{"intervention":3916,"totalTrials":285,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5167,"PHASE3":5169,"PHASE4":5175,"NA":5177},{"trials":5164,"activeCount":67},[],{"trials":5166,"activeCount":67},[],{"trials":5168,"activeCount":67},[],{"trials":5170,"activeCount":67},[5171],{"nctId":3910,"briefTitle":3904,"status":98,"phases":5172,"primaryCompletion":1474,"completion":1474,"start":1562,"enrollment":3912,"conditions":5173,"interventions":5174},[57],[3059],[3915,3916],{"trials":5176,"activeCount":67},[],{"trials":5178,"activeCount":67},[],{"intervention":3061,"totalTrials":285,"cells":5180},{"EARLY_PHASE1":5181,"PHASE1":5183,"PHASE2":5185,"PHASE3":5187,"PHASE4":5193,"NA":5195},{"trials":5182,"activeCount":67},[],{"trials":5184,"activeCount":67},[],{"trials":5186,"activeCount":67},[],{"trials":5188,"activeCount":67},[5189],{"nctId":3054,"briefTitle":3055,"status":98,"phases":5190,"primaryCompletion":1090,"completion":1090,"start":2820,"enrollment":3057,"conditions":5191,"interventions":5192},[57],[3059],[3011,3028,3061],{"trials":5194,"activeCount":67},[],{"trials":5196,"activeCount":67},[],{"intervention":160,"totalTrials":285,"cells":5198},{"EARLY_PHASE1":5199,"PHASE1":5201,"PHASE2":5203,"PHASE3":5205,"PHASE4":5211,"NA":5213},{"trials":5200,"activeCount":67},[],{"trials":5202,"activeCount":67},[],{"trials":5204,"activeCount":67},[],{"trials":5206,"activeCount":67},[5207],{"nctId":149,"briefTitle":150,"status":98,"phases":5208,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":5209,"interventions":5210},[57],[157,158],[160,62],{"trials":5212,"activeCount":67},[],{"trials":5214,"activeCount":67},[],{"intervention":879,"totalTrials":285,"cells":5216},{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5223,"PHASE4":5229,"NA":5231},{"trials":5218,"activeCount":67},[],{"trials":5220,"activeCount":67},[],{"trials":5222,"activeCount":67},[],{"trials":5224,"activeCount":67},[5225],{"nctId":871,"briefTitle":872,"status":98,"phases":5226,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":5227,"interventions":5228},[57],[33,15],[879,880],{"trials":5230,"activeCount":67},[],{"trials":5232,"activeCount":67},[],{"intervention":3005,"totalTrials":285,"cells":5234},{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5247,"NA":5249},{"trials":5236,"activeCount":67},[],{"trials":5238,"activeCount":67},[],{"trials":5240,"activeCount":67},[],{"trials":5242,"activeCount":67},[5243],{"nctId":3000,"briefTitle":3001,"status":75,"phases":5244,"primaryCompletion":77,"completion":77,"start":469,"enrollment":67,"conditions":5245,"interventions":5246},[57],[206,15],[2975,3005],{"trials":5248,"activeCount":67},[],{"trials":5250,"activeCount":67},[],{"intervention":4003,"totalTrials":285,"cells":5252},{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5257,"PHASE3":5259,"PHASE4":5265,"NA":5267},{"trials":5254,"activeCount":67},[],{"trials":5256,"activeCount":67},[],{"trials":5258,"activeCount":67},[],{"trials":5260,"activeCount":67},[5261],{"nctId":3997,"briefTitle":548,"status":98,"phases":5262,"primaryCompletion":994,"completion":994,"start":3999,"enrollment":4000,"conditions":5263,"interventions":5264},[57],[33,15],[4003,3967],{"trials":5266,"activeCount":67},[],{"trials":5268,"activeCount":67},[],{"intervention":5270,"totalTrials":285,"cells":5271},"Rimexolone",{"EARLY_PHASE1":5272,"PHASE1":5274,"PHASE2":5276,"PHASE3":5278,"PHASE4":5286,"NA":5288},{"trials":5273,"activeCount":67},[],{"trials":5275,"activeCount":67},[],{"trials":5277,"activeCount":67},[],{"trials":5279,"activeCount":67},[5280],{"nctId":5281,"briefTitle":5282,"status":98,"phases":5283,"primaryCompletion":891,"completion":891,"start":3456,"enrollment":1540,"conditions":5284,"interventions":5285},"NCT00471419","Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye",[57],[24],[5270],{"trials":5287,"activeCount":67},[],{"trials":5289,"activeCount":67},[],{"intervention":5291,"totalTrials":285,"cells":5292},"AL-3862+timolol ophthalmic suspension",{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5299,"PHASE4":5308,"NA":5310},{"trials":5294,"activeCount":67},[],{"trials":5296,"activeCount":67},[],{"trials":5298,"activeCount":67},[],{"trials":5300,"activeCount":67},[5301],{"nctId":5302,"briefTitle":5303,"status":98,"phases":5304,"primaryCompletion":909,"completion":909,"start":3708,"enrollment":2518,"conditions":5305,"interventions":5306},"NCT00576342","Patient Preference Study",[57],[33,15],[5291,5307],"Dorzolamide+timolol ophthalmic solution",{"trials":5309,"activeCount":67},[],{"trials":5311,"activeCount":67},[],{"intervention":5307,"totalTrials":285,"cells":5313},{"EARLY_PHASE1":5314,"PHASE1":5316,"PHASE2":5318,"PHASE3":5320,"PHASE4":5326,"NA":5328},{"trials":5315,"activeCount":67},[],{"trials":5317,"activeCount":67},[],{"trials":5319,"activeCount":67},[],{"trials":5321,"activeCount":67},[5322],{"nctId":5302,"briefTitle":5303,"status":98,"phases":5323,"primaryCompletion":909,"completion":909,"start":3708,"enrollment":2518,"conditions":5324,"interventions":5325},[57],[33,15],[5291,5307],{"trials":5327,"activeCount":67},[],{"trials":5329,"activeCount":67},[],{"intervention":5331,"totalTrials":285,"cells":5332},"Nepafenac 1mg\u002Fml eye drops, suspension",{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5339,"PHASE4":5349,"NA":5351},{"trials":5334,"activeCount":67},[],{"trials":5336,"activeCount":67},[],{"trials":5338,"activeCount":67},[],{"trials":5340,"activeCount":67},[5341],{"nctId":5342,"briefTitle":5343,"status":98,"phases":5344,"primaryCompletion":3456,"completion":3456,"start":3972,"enrollment":5345,"conditions":5346,"interventions":5347},"NCT00405730","Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo",[57],227,[5019],[5331,5348],"Ketorolac Trometamol 5 mg\u002Fml eye drops, solution",{"trials":5350,"activeCount":67},[],{"trials":5352,"activeCount":67},[],{"intervention":5348,"totalTrials":285,"cells":5354},{"EARLY_PHASE1":5355,"PHASE1":5357,"PHASE2":5359,"PHASE3":5361,"PHASE4":5367,"NA":5369},{"trials":5356,"activeCount":67},[],{"trials":5358,"activeCount":67},[],{"trials":5360,"activeCount":67},[],{"trials":5362,"activeCount":67},[5363],{"nctId":5342,"briefTitle":5343,"status":98,"phases":5364,"primaryCompletion":3456,"completion":3456,"start":3972,"enrollment":5345,"conditions":5365,"interventions":5366},[57],[5019],[5331,5348],{"trials":5368,"activeCount":67},[],{"trials":5370,"activeCount":67},[],{"intervention":170,"totalTrials":285,"cells":5372},{"EARLY_PHASE1":5373,"PHASE1":5375,"PHASE2":5377,"PHASE3":5379,"PHASE4":5385,"NA":5387},{"trials":5374,"activeCount":67},[],{"trials":5376,"activeCount":67},[],{"trials":5378,"activeCount":67},[],{"trials":5380,"activeCount":67},[5381],{"nctId":162,"briefTitle":163,"status":98,"phases":5382,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":5383,"interventions":5384},[57],[104,15],[170,62,171,172],{"trials":5386,"activeCount":67},[],{"trials":5388,"activeCount":67},[],{"intervention":4124,"totalTrials":285,"cells":5390},{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5395,"PHASE3":5397,"PHASE4":5403,"NA":5405},{"trials":5392,"activeCount":67},[],{"trials":5394,"activeCount":67},[],{"trials":5396,"activeCount":67},[],{"trials":5398,"activeCount":67},[5399],{"nctId":4116,"briefTitle":4117,"status":98,"phases":5400,"primaryCompletion":4119,"completion":4119,"start":4120,"enrollment":4121,"conditions":5401,"interventions":5402},[57],[15,206],[4124,4125],{"trials":5404,"activeCount":67},[],{"trials":5406,"activeCount":67},[],{"intervention":5408,"totalTrials":285,"cells":5409},"Tobramycin 0.3% \u002F Dexamethasone 0.033% ophthalmic suspension",{"EARLY_PHASE1":5410,"PHASE1":5412,"PHASE2":5414,"PHASE3":5416,"PHASE4":5427,"NA":5429},{"trials":5411,"activeCount":67},[],{"trials":5413,"activeCount":67},[],{"trials":5415,"activeCount":67},[],{"trials":5417,"activeCount":67},[5418],{"nctId":5419,"briefTitle":5420,"status":98,"phases":5421,"primaryCompletion":5422,"completion":5422,"start":3999,"enrollment":5423,"conditions":5424,"interventions":5425},"NCT00362895","A Bioequivalence Study of Tobradex AF",[57],"2006-08",995,[18],[5408,5426],"Tobramycin 0.3% \u002F Dexamethasone 0.1% ophthalmic suspension",{"trials":5428,"activeCount":67},[],{"trials":5430,"activeCount":67},[],{"intervention":5426,"totalTrials":285,"cells":5432},{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5439,"PHASE4":5445,"NA":5447},{"trials":5434,"activeCount":67},[],{"trials":5436,"activeCount":67},[],{"trials":5438,"activeCount":67},[],{"trials":5440,"activeCount":67},[5441],{"nctId":5419,"briefTitle":5420,"status":98,"phases":5442,"primaryCompletion":5422,"completion":5422,"start":3999,"enrollment":5423,"conditions":5443,"interventions":5444},[57],[18],[5408,5426],{"trials":5446,"activeCount":67},[],{"trials":5448,"activeCount":67},[],{"intervention":3346,"totalTrials":285,"cells":5450},{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5455,"PHASE3":5457,"PHASE4":5463,"NA":5465},{"trials":5452,"activeCount":67},[],{"trials":5454,"activeCount":67},[],{"trials":5456,"activeCount":67},[],{"trials":5458,"activeCount":67},[5459],{"nctId":3338,"briefTitle":3339,"status":98,"phases":5460,"primaryCompletion":3341,"completion":3341,"start":3342,"enrollment":3343,"conditions":5461,"interventions":5462},[57],[3335],[3317,3346],{"trials":5464,"activeCount":67},[],{"trials":5466,"activeCount":67},[],{"intervention":5468,"totalTrials":285,"cells":5469},"Travoprost\u002FTimolol Maleate Fixed Combination solution",{"EARLY_PHASE1":5470,"PHASE1":5472,"PHASE2":5474,"PHASE3":5476,"PHASE4":5485,"NA":5487},{"trials":5471,"activeCount":67},[],{"trials":5473,"activeCount":67},[],{"trials":5475,"activeCount":67},[],{"trials":5477,"activeCount":67},[5478],{"nctId":5479,"briefTitle":5480,"status":98,"phases":5481,"primaryCompletion":1023,"completion":1023,"start":101,"enrollment":5482,"conditions":5483,"interventions":5484},"NCT00928590","Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension",[57],155,[116,15],[5468],{"trials":5486,"activeCount":67},[],{"trials":5488,"activeCount":67},[],{"intervention":5490,"totalTrials":285,"cells":5491},"Tobradex AF",{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5496,"PHASE3":5498,"PHASE4":5507,"NA":5509},{"trials":5493,"activeCount":67},[],{"trials":5495,"activeCount":67},[],{"trials":5497,"activeCount":67},[],{"trials":5499,"activeCount":67},[5500],{"nctId":5501,"briefTitle":5502,"status":98,"phases":5503,"primaryCompletion":994,"start":3383,"enrollment":5504,"conditions":5505,"interventions":5506},"NCT00473070","A Clinical Study of Tobradex AF",[57],900,[18],[5490],{"trials":5508,"activeCount":67},[],{"trials":5510,"activeCount":67},[],{"intervention":5512,"totalTrials":285,"cells":5513},"Moxifloxacin 0.5%\u002FDexamethasone Phosphate 0.075% Ophthalmic Gel",{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5520,"PHASE4":5530,"NA":5532},{"trials":5515,"activeCount":67},[],{"trials":5517,"activeCount":67},[],{"trials":5519,"activeCount":67},[],{"trials":5521,"activeCount":67},[5522],{"nctId":5523,"briefTitle":5524,"status":75,"phases":5525,"primaryCompletion":5526,"completion":5526,"start":961,"enrollment":67,"conditions":5527,"interventions":5528},"NCT01515826","VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery",[57],"2014-10",[5019],[5512,5529],"Moxifloxacin 0.5%\u002FDexamethasone Phosphate 0.1% Ophthalmic Solution",{"trials":5531,"activeCount":67},[],{"trials":5533,"activeCount":67},[],{"intervention":5529,"totalTrials":285,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5542,"PHASE4":5548,"NA":5550},{"trials":5537,"activeCount":67},[],{"trials":5539,"activeCount":67},[],{"trials":5541,"activeCount":67},[],{"trials":5543,"activeCount":67},[5544],{"nctId":5523,"briefTitle":5524,"status":75,"phases":5545,"primaryCompletion":5526,"completion":5526,"start":961,"enrollment":67,"conditions":5546,"interventions":5547},[57],[5019],[5512,5529],{"trials":5549,"activeCount":67},[],{"trials":5551,"activeCount":67},[],{"intervention":3976,"totalTrials":285,"cells":5553},{"EARLY_PHASE1":5554,"PHASE1":5556,"PHASE2":5558,"PHASE3":5560,"PHASE4":5566,"NA":5568},{"trials":5555,"activeCount":67},[],{"trials":5557,"activeCount":67},[],{"trials":5559,"activeCount":67},[],{"trials":5561,"activeCount":67},[5562],{"nctId":3969,"briefTitle":3962,"status":98,"phases":5563,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":3973,"conditions":5564,"interventions":5565},[57],[116,15],[3950,3976,3977],{"trials":5567,"activeCount":67},[],{"trials":5569,"activeCount":67},[],{"intervention":3977,"totalTrials":285,"cells":5571},{"EARLY_PHASE1":5572,"PHASE1":5574,"PHASE2":5576,"PHASE3":5578,"PHASE4":5584,"NA":5586},{"trials":5573,"activeCount":67},[],{"trials":5575,"activeCount":67},[],{"trials":5577,"activeCount":67},[],{"trials":5579,"activeCount":67},[5580],{"nctId":3969,"briefTitle":3962,"status":98,"phases":5581,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":3973,"conditions":5582,"interventions":5583},[57],[116,15],[3950,3976,3977],{"trials":5585,"activeCount":67},[],{"trials":5587,"activeCount":67},[],{"intervention":194,"totalTrials":285,"cells":5589},{"EARLY_PHASE1":5590,"PHASE1":5592,"PHASE2":5594,"PHASE3":5596,"PHASE4":5602,"NA":5604},{"trials":5591,"activeCount":67},[],{"trials":5593,"activeCount":67},[],{"trials":5595,"activeCount":67},[],{"trials":5597,"activeCount":67},[5598],{"nctId":185,"briefTitle":186,"status":98,"phases":5599,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":5600,"interventions":5601},[57],[157],[194,62],{"trials":5603,"activeCount":67},[],{"trials":5605,"activeCount":67},[],{"intervention":272,"totalTrials":941,"cells":5607},{"EARLY_PHASE1":5608,"PHASE1":5610,"PHASE2":5612,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5609,"activeCount":67},[],{"trials":5611,"activeCount":67},[],{"trials":5613,"activeCount":67},[5614,5623,5627],{"nctId":5615,"briefTitle":5616,"status":98,"phases":5617,"primaryCompletion":5618,"completion":5618,"start":2217,"enrollment":5619,"conditions":5620,"interventions":5621},"NCT01849692","ESBA1008 Microvolume Study",[56],"2015-01",107,[270],[272,5622],"Ranibizumab",{"nctId":263,"briefTitle":264,"status":98,"phases":5624,"primaryCompletion":203,"completion":266,"start":267,"enrollment":268,"conditions":5625,"interventions":5626},[56],[270],[272,254],{"nctId":5628,"briefTitle":5629,"status":98,"phases":5630,"primaryCompletion":267,"completion":267,"start":1833,"enrollment":5631,"conditions":5632,"interventions":5633},"NCT01304693","ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients",[55,56],376,[270],[272,5634],"Ranibizumab 0.5 mg",{"trials":5636,"activeCount":67},[],{"trials":5638,"activeCount":67},[],{"trials":5640,"activeCount":67},[],{"intervention":2787,"totalTrials":941,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5661,"PHASE4":5663,"NA":5665},{"trials":5644,"activeCount":67},[],{"trials":5646,"activeCount":67},[],{"trials":5648,"activeCount":67},[5649,5653,5657],{"nctId":2781,"briefTitle":2782,"status":98,"phases":5650,"primaryCompletion":101,"completion":101,"start":737,"enrollment":839,"conditions":5651,"interventions":5652},[56],[2785],[2787,2788,2772],{"nctId":2790,"briefTitle":2791,"status":98,"phases":5654,"primaryCompletion":909,"completion":909,"start":2793,"enrollment":749,"conditions":5655,"interventions":5656},[56],[116],[2787,2796,2772],{"nctId":2798,"briefTitle":2799,"status":479,"phases":5658,"primaryCompletion":611,"completion":611,"start":648,"enrollment":2801,"conditions":5659,"interventions":5660},[56],[104,15],[2787,2804,2805,2806],{"trials":5662,"activeCount":67},[],{"trials":5664,"activeCount":67},[],{"trials":5666,"activeCount":67},[],{"intervention":5622,"totalTrials":195,"cells":5668},{"EARLY_PHASE1":5669,"PHASE1":5671,"PHASE2":5673,"PHASE3":5687,"PHASE4":5689,"NA":5691},{"trials":5670,"activeCount":67},[],{"trials":5672,"activeCount":67},[],{"trials":5674,"activeCount":67},[5675,5679],{"nctId":5615,"briefTitle":5616,"status":98,"phases":5676,"primaryCompletion":5618,"completion":5618,"start":2217,"enrollment":5619,"conditions":5677,"interventions":5678},[56],[270],[272,5622],{"nctId":5680,"briefTitle":5681,"status":98,"phases":5682,"primaryCompletion":1562,"completion":1562,"start":3932,"enrollment":5683,"conditions":5684,"interventions":5685},"NCT01157065","Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration",[56],99,[270],[5686,5622],"AL-78898A",{"trials":5688,"activeCount":67},[],{"trials":5690,"activeCount":67},[],{"trials":5692,"activeCount":67},[],{"intervention":3096,"totalTrials":195,"cells":5694},{"EARLY_PHASE1":5695,"PHASE1":5697,"PHASE2":5707,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5696,"activeCount":67},[],{"trials":5698,"activeCount":67},[5699],{"nctId":5700,"briefTitle":5701,"status":98,"phases":5702,"primaryCompletion":5703,"completion":5703,"start":1726,"enrollment":25,"conditions":5704,"interventions":5706},"NCT01835015","Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration",[55],"2014-11",[5705],"Age-related Macular Degeneration",[3096],{"trials":5708,"activeCount":67},[5709],{"nctId":3086,"briefTitle":3087,"status":98,"phases":5710,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":3092,"conditions":5711,"interventions":5712},[56],[3094],[3096,3097,1298],{"trials":5714,"activeCount":67},[],{"trials":5716,"activeCount":67},[],{"trials":5718,"activeCount":67},[],{"intervention":3105,"totalTrials":195,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5725,"PHASE3":5735,"PHASE4":5737,"NA":5739},{"trials":5722,"activeCount":67},[],{"trials":5724,"activeCount":67},[],{"trials":5726,"activeCount":67},[5727,5731],{"nctId":3099,"briefTitle":3100,"status":479,"phases":5728,"primaryCompletion":1809,"completion":1809,"start":497,"enrollment":3102,"conditions":5729,"interventions":5730},[56],[3094],[3105,1298],{"nctId":5680,"briefTitle":5681,"status":98,"phases":5732,"primaryCompletion":1562,"completion":1562,"start":3932,"enrollment":5683,"conditions":5733,"interventions":5734},[56],[270],[5686,5622],{"trials":5736,"activeCount":67},[],{"trials":5738,"activeCount":67},[],{"trials":5740,"activeCount":67},[],{"intervention":914,"totalTrials":195,"cells":5742},{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5747,"PHASE3":5757,"PHASE4":5759,"NA":5761},{"trials":5744,"activeCount":67},[],{"trials":5746,"activeCount":67},[],{"trials":5748,"activeCount":67},[5749,5753],{"nctId":906,"briefTitle":907,"status":98,"phases":5750,"primaryCompletion":909,"start":748,"enrollment":910,"conditions":5751,"interventions":5752},[56],[116,15],[913,914,915,916],{"nctId":2964,"briefTitle":2965,"status":98,"phases":5754,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":5755,"interventions":5756},[56],[116,15],[2971,2972,2973,2974,2975,543],{"trials":5758,"activeCount":67},[],{"trials":5760,"activeCount":67},[],{"trials":5762,"activeCount":67},[],{"intervention":5634,"totalTrials":195,"cells":5764},{"EARLY_PHASE1":5765,"PHASE1":5767,"PHASE2":5769,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5766,"activeCount":67},[],{"trials":5768,"activeCount":67},[],{"trials":5770,"activeCount":67},[5771,5782],{"nctId":5772,"briefTitle":5773,"status":479,"phases":5774,"primaryCompletion":5775,"completion":5776,"start":5777,"enrollment":2958,"conditions":5778,"interventions":5780},"NCT02398500","Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration",[55,56],"2016-02-29","2016-05-20","2015-07-22",[5779],"Age-related Macular Degeneration (AMD)",[5781,5634],"LMG324",{"nctId":5628,"briefTitle":5629,"status":98,"phases":5783,"primaryCompletion":267,"completion":267,"start":1833,"enrollment":5631,"conditions":5784,"interventions":5785},[55,56],[270],[272,5634],{"trials":5787,"activeCount":67},[],{"trials":5789,"activeCount":67},[],{"trials":5791,"activeCount":67},[],{"intervention":5793,"totalTrials":195,"cells":5794},"Dexamethasone ophthalmic suspension, 0.1%",{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5799,"PHASE3":5823,"PHASE4":5825,"NA":5827},{"trials":5796,"activeCount":67},[],{"trials":5798,"activeCount":67},[],{"trials":5800,"activeCount":67},[5801,5811],{"nctId":5802,"briefTitle":5803,"status":98,"phases":5804,"primaryCompletion":537,"completion":537,"start":5805,"enrollment":5806,"conditions":5807,"interventions":5808},"NCT01001091","AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation",[56],"2009-12",312,[91],[5809,5810,5793],"AL-38583 ophthalmic solution","AL-38583 ophthalmic solution vehicle",{"nctId":5812,"briefTitle":5813,"status":98,"phases":5814,"primaryCompletion":5815,"completion":5815,"start":224,"enrollment":5816,"conditions":5817,"interventions":5818},"NCT02079649","Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis",[56],"2014-07",224,[91],[5819,5820,5821,5822],"AL-53817 Ophthalmic Solution, 0.1%","AL-78843 Ophthalmic Solution, 0.03%","Dexamethasone Ophthalmic Suspension, 0.1%","AL-53817 Vehicle",{"trials":5824,"activeCount":67},[],{"trials":5826,"activeCount":67},[],{"trials":5828,"activeCount":67},[],{"intervention":3097,"totalTrials":285,"cells":5830},{"EARLY_PHASE1":5831,"PHASE1":5833,"PHASE2":5835,"PHASE3":5841,"PHASE4":5843,"NA":5845},{"trials":5832,"activeCount":67},[],{"trials":5834,"activeCount":67},[],{"trials":5836,"activeCount":67},[5837],{"nctId":3086,"briefTitle":3087,"status":98,"phases":5838,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":3092,"conditions":5839,"interventions":5840},[56],[3094],[3096,3097,1298],{"trials":5842,"activeCount":67},[],{"trials":5844,"activeCount":67},[],{"trials":5846,"activeCount":67},[],{"intervention":5848,"totalTrials":285,"cells":5849},"AL-3789 Sterile Suspension",{"EARLY_PHASE1":5850,"PHASE1":5852,"PHASE2":5854,"PHASE3":5862,"PHASE4":5864,"NA":5866},{"trials":5851,"activeCount":67},[],{"trials":5853,"activeCount":67},[],{"trials":5855,"activeCount":67},[5856],{"nctId":5857,"briefTitle":5858,"status":98,"phases":5859,"primaryCompletion":113,"start":1126,"enrollment":2958,"conditions":5860,"interventions":5861},"NCT00643669","24 Hour IOP Lowering Efficacy of AL-3789",[56],[116],[5848],{"trials":5863,"activeCount":67},[],{"trials":5865,"activeCount":67},[],{"trials":5867,"activeCount":67},[],{"intervention":5869,"totalTrials":285,"cells":5870},"Combination IOP Lowering Therapy",{"EARLY_PHASE1":5871,"PHASE1":5873,"PHASE2":5875,"PHASE3":5884,"PHASE4":5886,"NA":5888},{"trials":5872,"activeCount":67},[],{"trials":5874,"activeCount":67},[],{"trials":5876,"activeCount":67},[5877],{"nctId":5878,"briefTitle":5879,"status":98,"phases":5880,"primaryCompletion":702,"completion":702,"start":5881,"conditions":5882,"interventions":5883},"NCT00051194","A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension",[56],"2002-09",[930,15],[5869],{"trials":5885,"activeCount":67},[],{"trials":5887,"activeCount":67},[],{"trials":5889,"activeCount":67},[],{"intervention":82,"totalTrials":285,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5893,"activeCount":67},[],{"trials":5895,"activeCount":67},[],{"trials":5897,"activeCount":67},[5898],{"nctId":73,"briefTitle":74,"status":75,"phases":5899,"primaryCompletion":77,"start":78,"enrollment":67,"conditions":5900,"interventions":5901},[56],[80],[82,83,84,62],{"trials":5903,"activeCount":67},[],{"trials":5905,"activeCount":67},[],{"trials":5907,"activeCount":67},[],{"intervention":83,"totalTrials":285,"cells":5909},{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5914,"PHASE3":5920,"PHASE4":5922,"NA":5924},{"trials":5911,"activeCount":67},[],{"trials":5913,"activeCount":67},[],{"trials":5915,"activeCount":67},[5916],{"nctId":73,"briefTitle":74,"status":75,"phases":5917,"primaryCompletion":77,"start":78,"enrollment":67,"conditions":5918,"interventions":5919},[56],[80],[82,83,84,62],{"trials":5921,"activeCount":67},[],{"trials":5923,"activeCount":67},[],{"trials":5925,"activeCount":67},[],{"intervention":84,"totalTrials":285,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5929,"activeCount":67},[],{"trials":5931,"activeCount":67},[],{"trials":5933,"activeCount":67},[5934],{"nctId":73,"briefTitle":74,"status":75,"phases":5935,"primaryCompletion":77,"start":78,"enrollment":67,"conditions":5936,"interventions":5937},[56],[80],[82,83,84,62],{"trials":5939,"activeCount":67},[],{"trials":5941,"activeCount":67},[],{"trials":5943,"activeCount":67},[],{"intervention":5945,"totalTrials":285,"cells":5946},"Hydroxypropyl Guar Galactomannan",{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5951,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5948,"activeCount":67},[],{"trials":5950,"activeCount":67},[],{"trials":5952,"activeCount":67},[5953],{"nctId":5954,"briefTitle":5955,"status":98,"phases":5956,"primaryCompletion":612,"start":631,"enrollment":1091,"conditions":5957,"interventions":5958},"NCT00760045","Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time",[56],[3335],[5945,5959],"0.1% sodium hyaluronate ophthalmic solution",{"trials":5961,"activeCount":67},[],{"trials":5963,"activeCount":67},[],{"trials":5965,"activeCount":67},[],{"intervention":5959,"totalTrials":285,"cells":5967},{"EARLY_PHASE1":5968,"PHASE1":5970,"PHASE2":5972,"PHASE3":5978,"PHASE4":5980,"NA":5982},{"trials":5969,"activeCount":67},[],{"trials":5971,"activeCount":67},[],{"trials":5973,"activeCount":67},[5974],{"nctId":5954,"briefTitle":5955,"status":98,"phases":5975,"primaryCompletion":612,"start":631,"enrollment":1091,"conditions":5976,"interventions":5977},[56],[3335],[5945,5959],{"trials":5979,"activeCount":67},[],{"trials":5981,"activeCount":67},[],{"trials":5983,"activeCount":67},[],{"intervention":5985,"totalTrials":285,"cells":5986},"Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel",{"EARLY_PHASE1":5987,"PHASE1":5989,"PHASE2":5991,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5988,"activeCount":67},[],{"trials":5990,"activeCount":67},[],{"trials":5992,"activeCount":67},[5993],{"nctId":5994,"briefTitle":5995,"status":98,"phases":5996,"primaryCompletion":101,"completion":101,"start":819,"enrollment":5997,"conditions":5998,"interventions":5999},"NCT00840268","A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients",[56],427,[24],[5985,6000],"Hydroxypropyl Guar Galactomannan Vehicle",{"trials":6002,"activeCount":67},[],{"trials":6004,"activeCount":67},[],{"trials":6006,"activeCount":67},[],{"intervention":6000,"totalTrials":285,"cells":6008},{"EARLY_PHASE1":6009,"PHASE1":6011,"PHASE2":6013,"PHASE3":6019,"PHASE4":6021,"NA":6023},{"trials":6010,"activeCount":67},[],{"trials":6012,"activeCount":67},[],{"trials":6014,"activeCount":67},[6015],{"nctId":5994,"briefTitle":5995,"status":98,"phases":6016,"primaryCompletion":101,"completion":101,"start":819,"enrollment":5997,"conditions":6017,"interventions":6018},[56],[24],[5985,6000],{"trials":6020,"activeCount":67},[],{"trials":6022,"activeCount":67},[],{"trials":6024,"activeCount":67},[],{"intervention":6026,"totalTrials":285,"cells":6027},"AL-54478 0.005%",{"EARLY_PHASE1":6028,"PHASE1":6030,"PHASE2":6032,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6029,"activeCount":67},[],{"trials":6031,"activeCount":67},[],{"trials":6033,"activeCount":67},[6034],{"nctId":6035,"briefTitle":6036,"status":98,"phases":6037,"primaryCompletion":1187,"completion":1187,"start":3932,"enrollment":1961,"conditions":6038,"interventions":6040},"NCT01318252","AL-54478 Proof of Concept Study",[56],[540,6039],"Ocular Hypertension (OHT)",[6026,6041,6042],"Latanoprost 0.005%","AL-54478 Vehicle",{"trials":6044,"activeCount":67},[],{"trials":6046,"activeCount":67},[],{"trials":6048,"activeCount":67},[],{"intervention":6041,"totalTrials":285,"cells":6050},{"EARLY_PHASE1":6051,"PHASE1":6053,"PHASE2":6055,"PHASE3":6061,"PHASE4":6063,"NA":6065},{"trials":6052,"activeCount":67},[],{"trials":6054,"activeCount":67},[],{"trials":6056,"activeCount":67},[6057],{"nctId":6035,"briefTitle":6036,"status":98,"phases":6058,"primaryCompletion":1187,"completion":1187,"start":3932,"enrollment":1961,"conditions":6059,"interventions":6060},[56],[540,6039],[6026,6041,6042],{"trials":6062,"activeCount":67},[],{"trials":6064,"activeCount":67},[],{"trials":6066,"activeCount":67},[],{"intervention":6042,"totalTrials":285,"cells":6068},{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6073,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6070,"activeCount":67},[],{"trials":6072,"activeCount":67},[],{"trials":6074,"activeCount":67},[6075],{"nctId":6035,"briefTitle":6036,"status":98,"phases":6076,"primaryCompletion":1187,"completion":1187,"start":3932,"enrollment":1961,"conditions":6077,"interventions":6078},[56],[540,6039],[6026,6041,6042],{"trials":6080,"activeCount":67},[],{"trials":6082,"activeCount":67},[],{"trials":6084,"activeCount":67},[],{"intervention":913,"totalTrials":285,"cells":6086},{"EARLY_PHASE1":6087,"PHASE1":6089,"PHASE2":6091,"PHASE3":6097,"PHASE4":6099,"NA":6101},{"trials":6088,"activeCount":67},[],{"trials":6090,"activeCount":67},[],{"trials":6092,"activeCount":67},[6093],{"nctId":906,"briefTitle":907,"status":98,"phases":6094,"primaryCompletion":909,"start":748,"enrollment":910,"conditions":6095,"interventions":6096},[56],[116,15],[913,914,915,916],{"trials":6098,"activeCount":67},[],{"trials":6100,"activeCount":67},[],{"trials":6102,"activeCount":67},[],{"intervention":915,"totalTrials":285,"cells":6104},{"EARLY_PHASE1":6105,"PHASE1":6107,"PHASE2":6109,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6106,"activeCount":67},[],{"trials":6108,"activeCount":67},[],{"trials":6110,"activeCount":67},[6111],{"nctId":906,"briefTitle":907,"status":98,"phases":6112,"primaryCompletion":909,"start":748,"enrollment":910,"conditions":6113,"interventions":6114},[56],[116,15],[913,914,915,916],{"trials":6116,"activeCount":67},[],{"trials":6118,"activeCount":67},[],{"trials":6120,"activeCount":67},[],{"intervention":5781,"totalTrials":285,"cells":6122},{"EARLY_PHASE1":6123,"PHASE1":6125,"PHASE2":6127,"PHASE3":6133,"PHASE4":6135,"NA":6137},{"trials":6124,"activeCount":67},[],{"trials":6126,"activeCount":67},[],{"trials":6128,"activeCount":67},[6129],{"nctId":5772,"briefTitle":5773,"status":479,"phases":6130,"primaryCompletion":5775,"completion":5776,"start":5777,"enrollment":2958,"conditions":6131,"interventions":6132},[55,56],[5779],[5781,5634],{"trials":6134,"activeCount":67},[],{"trials":6136,"activeCount":67},[],{"trials":6138,"activeCount":67},[],{"intervention":6140,"totalTrials":285,"cells":6141},"AL-46383A Ophthalmic Solution",{"EARLY_PHASE1":6142,"PHASE1":6144,"PHASE2":6146,"PHASE3":6157,"PHASE4":6159,"NA":6161},{"trials":6143,"activeCount":67},[],{"trials":6145,"activeCount":67},[],{"trials":6147,"activeCount":67},[6148],{"nctId":6149,"briefTitle":6150,"status":479,"phases":6151,"primaryCompletion":829,"completion":829,"start":1229,"enrollment":6152,"conditions":6153,"interventions":6155},"NCT00901693","An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis",[56],452,[6154],"Adenoviral Conjunctivitis",[6140,6156],"AL-46383A Ophthalmic Solution Vehicle",{"trials":6158,"activeCount":67},[],{"trials":6160,"activeCount":67},[],{"trials":6162,"activeCount":67},[],{"intervention":6156,"totalTrials":285,"cells":6164},{"EARLY_PHASE1":6165,"PHASE1":6167,"PHASE2":6169,"PHASE3":6175,"PHASE4":6177,"NA":6179},{"trials":6166,"activeCount":67},[],{"trials":6168,"activeCount":67},[],{"trials":6170,"activeCount":67},[6171],{"nctId":6149,"briefTitle":6150,"status":479,"phases":6172,"primaryCompletion":829,"completion":829,"start":1229,"enrollment":6152,"conditions":6173,"interventions":6174},[56],[6154],[6140,6156],{"trials":6176,"activeCount":67},[],{"trials":6178,"activeCount":67},[],{"trials":6180,"activeCount":67},[],{"intervention":6182,"totalTrials":285,"cells":6183},"Brolucizumab 3 mg\u002F50 μL",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6199,"PHASE4":6201,"NA":6203},{"trials":6185,"activeCount":67},[],{"trials":6187,"activeCount":67},[],{"trials":6189,"activeCount":67},[6190],{"nctId":6191,"briefTitle":6192,"status":98,"phases":6193,"primaryCompletion":6194,"completion":6194,"start":6195,"enrollment":2150,"conditions":6196,"interventions":6197},"NCT02507388","Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration",[56],"2016-09-06","2015-08-24",[4028],[6182,6198],"Brolucizumab 6 mg\u002F50 μL",{"trials":6200,"activeCount":67},[],{"trials":6202,"activeCount":67},[],{"trials":6204,"activeCount":67},[],{"intervention":6198,"totalTrials":285,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6208,"activeCount":67},[],{"trials":6210,"activeCount":67},[],{"trials":6212,"activeCount":67},[6213],{"nctId":6191,"briefTitle":6192,"status":98,"phases":6214,"primaryCompletion":6194,"completion":6194,"start":6195,"enrollment":2150,"conditions":6215,"interventions":6216},[56],[4028],[6182,6198],{"trials":6218,"activeCount":67},[],{"trials":6220,"activeCount":67},[],{"trials":6222,"activeCount":67},[],{"intervention":6224,"totalTrials":285,"cells":6225},"AL-60371\u002FAL-817 otic suspension",{"EARLY_PHASE1":6226,"PHASE1":6228,"PHASE2":6230,"PHASE3":6239,"PHASE4":6241,"NA":6243},{"trials":6227,"activeCount":67},[],{"trials":6229,"activeCount":67},[],{"trials":6231,"activeCount":67},[6232],{"nctId":6233,"briefTitle":6234,"status":479,"phases":6235,"primaryCompletion":266,"completion":266,"start":1408,"enrollment":1158,"conditions":6236,"interventions":6237},"NCT01908803","Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes",[56],[3026],[6224,6238],"Ciprofloxacin 0.3%\u002Fdexamethasone 0.1% otic suspension",{"trials":6240,"activeCount":67},[],{"trials":6242,"activeCount":67},[],{"trials":6244,"activeCount":67},[],{"intervention":6238,"totalTrials":285,"cells":6246},{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6251,"PHASE3":6257,"PHASE4":6259,"NA":6261},{"trials":6248,"activeCount":67},[],{"trials":6250,"activeCount":67},[],{"trials":6252,"activeCount":67},[6253],{"nctId":6233,"briefTitle":6234,"status":479,"phases":6254,"primaryCompletion":266,"completion":266,"start":1408,"enrollment":1158,"conditions":6255,"interventions":6256},[56],[3026],[6224,6238],{"trials":6258,"activeCount":67},[],{"trials":6260,"activeCount":67},[],{"trials":6262,"activeCount":67},[],{"intervention":6264,"totalTrials":285,"cells":6265},"ESBA105 ophthalmic solution",{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6280,"PHASE4":6282,"NA":6284},{"trials":6267,"activeCount":67},[],{"trials":6269,"activeCount":67},[],{"trials":6271,"activeCount":67},[6272],{"nctId":6273,"briefTitle":6274,"status":98,"phases":6275,"primaryCompletion":1727,"completion":1727,"start":3932,"enrollment":6276,"conditions":6277,"interventions":6279},"NCT01338610","ESBA105 in Patients With Severe Dry Eye",[56],334,[6278],"Eyes Dry Chronic",[6264],{"trials":6281,"activeCount":67},[],{"trials":6283,"activeCount":67},[],{"trials":6285,"activeCount":67},[],{"intervention":2863,"totalTrials":285,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6289,"activeCount":67},[],{"trials":6291,"activeCount":67},[],{"trials":6293,"activeCount":67},[6294],{"nctId":2855,"briefTitle":2856,"status":98,"phases":6295,"primaryCompletion":829,"completion":829,"start":177,"enrollment":2858,"conditions":6296,"interventions":6297},[56],[2860],[2862,2863],{"trials":6299,"activeCount":67},[],{"trials":6301,"activeCount":67},[],{"trials":6303,"activeCount":67},[],{"intervention":6305,"totalTrials":285,"cells":6306},"Moxifloxacin\u002Fdexamethasone phosphate ophthalmic solution",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6323,"PHASE4":6325,"NA":6327},{"trials":6308,"activeCount":67},[],{"trials":6310,"activeCount":67},[],{"trials":6312,"activeCount":67},[6313],{"nctId":6314,"briefTitle":6315,"status":479,"phases":6316,"primaryCompletion":819,"completion":819,"start":3708,"enrollment":6317,"conditions":6318,"interventions":6320},"NCT00579020","A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates",[56],144,[6319],"Corneal Infiltrates",[6305,6321,6322],"Moxifloxacin ophthalmic solution 0.5%","Dexamethasone phosphate solution, 0.1%",{"trials":6324,"activeCount":67},[],{"trials":6326,"activeCount":67},[],{"trials":6328,"activeCount":67},[],{"intervention":6321,"totalTrials":285,"cells":6330},{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6335,"PHASE3":6341,"PHASE4":6343,"NA":6345},{"trials":6332,"activeCount":67},[],{"trials":6334,"activeCount":67},[],{"trials":6336,"activeCount":67},[6337],{"nctId":6314,"briefTitle":6315,"status":479,"phases":6338,"primaryCompletion":819,"completion":819,"start":3708,"enrollment":6317,"conditions":6339,"interventions":6340},[56],[6319],[6305,6321,6322],{"trials":6342,"activeCount":67},[],{"trials":6344,"activeCount":67},[],{"trials":6346,"activeCount":67},[],{"intervention":6322,"totalTrials":285,"cells":6348},{"EARLY_PHASE1":6349,"PHASE1":6351,"PHASE2":6353,"PHASE3":6359,"PHASE4":6361,"NA":6363},{"trials":6350,"activeCount":67},[],{"trials":6352,"activeCount":67},[],{"trials":6354,"activeCount":67},[6355],{"nctId":6314,"briefTitle":6315,"status":479,"phases":6356,"primaryCompletion":819,"completion":819,"start":3708,"enrollment":6317,"conditions":6357,"interventions":6358},[56],[6319],[6305,6321,6322],{"trials":6360,"activeCount":67},[],{"trials":6362,"activeCount":67},[],{"trials":6364,"activeCount":67},[],{"intervention":6366,"totalTrials":285,"cells":6367},"AL-37807 ophthalmic suspension, 0.1%",{"EARLY_PHASE1":6368,"PHASE1":6370,"PHASE2":6372,"PHASE3":6382,"PHASE4":6384,"NA":6386},{"trials":6369,"activeCount":67},[],{"trials":6371,"activeCount":67},[],{"trials":6373,"activeCount":67},[6374],{"nctId":6375,"briefTitle":6376,"status":98,"phases":6377,"primaryCompletion":621,"completion":621,"start":3023,"enrollment":2518,"conditions":6378,"interventions":6379},"NCT00620256","Adjunctive Study of AL-37807 Ophthalmic Suspension",[56],[104,15],[6366,6380,6381],"Timolol gel forming solution, 0.5%","Latanoprost ophthalmic solution",{"trials":6383,"activeCount":67},[],{"trials":6385,"activeCount":67},[],{"trials":6387,"activeCount":67},[],{"intervention":6380,"totalTrials":285,"cells":6389},{"EARLY_PHASE1":6390,"PHASE1":6392,"PHASE2":6394,"PHASE3":6400,"PHASE4":6402,"NA":6404},{"trials":6391,"activeCount":67},[],{"trials":6393,"activeCount":67},[],{"trials":6395,"activeCount":67},[6396],{"nctId":6375,"briefTitle":6376,"status":98,"phases":6397,"primaryCompletion":621,"completion":621,"start":3023,"enrollment":2518,"conditions":6398,"interventions":6399},[56],[104,15],[6366,6380,6381],{"trials":6401,"activeCount":67},[],{"trials":6403,"activeCount":67},[],{"trials":6405,"activeCount":67},[],{"intervention":6381,"totalTrials":285,"cells":6407},{"EARLY_PHASE1":6408,"PHASE1":6410,"PHASE2":6412,"PHASE3":6418,"PHASE4":6420,"NA":6422},{"trials":6409,"activeCount":67},[],{"trials":6411,"activeCount":67},[],{"trials":6413,"activeCount":67},[6414],{"nctId":6375,"briefTitle":6376,"status":98,"phases":6415,"primaryCompletion":621,"completion":621,"start":3023,"enrollment":2518,"conditions":6416,"interventions":6417},[56],[104,15],[6366,6380,6381],{"trials":6419,"activeCount":67},[],{"trials":6421,"activeCount":67},[],{"trials":6423,"activeCount":67},[],{"intervention":6425,"totalTrials":285,"cells":6426},"AL-37807 Ophthalmic Suspension, 1.0%",{"EARLY_PHASE1":6427,"PHASE1":6429,"PHASE2":6431,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6428,"activeCount":67},[],{"trials":6430,"activeCount":67},[],{"trials":6432,"activeCount":67},[6433],{"nctId":6434,"briefTitle":548,"status":98,"phases":6435,"primaryCompletion":874,"completion":874,"start":3972,"enrollment":3169,"conditions":6436,"interventions":6437},"NCT00287521",[56],[116,15],[6425,6438,6439],"Latanoprost, 0.005%","Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%",{"trials":6441,"activeCount":67},[],{"trials":6443,"activeCount":67},[],{"trials":6445,"activeCount":67},[],{"intervention":6438,"totalTrials":285,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":67},[],{"trials":6451,"activeCount":67},[],{"trials":6453,"activeCount":67},[6454],{"nctId":6434,"briefTitle":548,"status":98,"phases":6455,"primaryCompletion":874,"completion":874,"start":3972,"enrollment":3169,"conditions":6456,"interventions":6457},[56],[116,15],[6425,6438,6439],{"trials":6459,"activeCount":67},[],{"trials":6461,"activeCount":67},[],{"trials":6463,"activeCount":67},[],{"intervention":6439,"totalTrials":285,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6470,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":67},[],{"trials":6469,"activeCount":67},[],{"trials":6471,"activeCount":67},[6472],{"nctId":6434,"briefTitle":548,"status":98,"phases":6473,"primaryCompletion":874,"completion":874,"start":3972,"enrollment":3169,"conditions":6474,"interventions":6475},[56],[116,15],[6425,6438,6439],{"trials":6477,"activeCount":67},[],{"trials":6479,"activeCount":67},[],{"trials":6481,"activeCount":67},[],{"intervention":3880,"totalTrials":285,"cells":6483},{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6485,"activeCount":67},[],{"trials":6487,"activeCount":67},[],{"trials":6489,"activeCount":67},[6490],{"nctId":3874,"briefTitle":3875,"status":98,"phases":6491,"primaryCompletion":648,"start":612,"enrollment":3877,"conditions":6492,"interventions":6493},[56],[2434],[183,3880],{"trials":6495,"activeCount":67},[],{"trials":6497,"activeCount":67},[],{"trials":6499,"activeCount":67},[],{"intervention":6501,"totalTrials":285,"cells":6502},"AL-38583 ophthalmic solution 0.05%",{"EARLY_PHASE1":6503,"PHASE1":6505,"PHASE2":6507,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6504,"activeCount":67},[],{"trials":6506,"activeCount":67},[],{"trials":6508,"activeCount":67},[6509],{"nctId":6510,"briefTitle":6511,"status":98,"phases":6512,"primaryCompletion":1625,"completion":1625,"start":1229,"enrollment":6513,"conditions":6514,"interventions":6515},"NCT00893139","A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye",[56],765,[24],[6501,6516,6517],"AL-38583 ophthalmic solution 0.10%","AL-38583 vehicle",{"trials":6519,"activeCount":67},[],{"trials":6521,"activeCount":67},[],{"trials":6523,"activeCount":67},[],{"intervention":6516,"totalTrials":285,"cells":6525},{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6536,"PHASE4":6538,"NA":6540},{"trials":6527,"activeCount":67},[],{"trials":6529,"activeCount":67},[],{"trials":6531,"activeCount":67},[6532],{"nctId":6510,"briefTitle":6511,"status":98,"phases":6533,"primaryCompletion":1625,"completion":1625,"start":1229,"enrollment":6513,"conditions":6534,"interventions":6535},[56],[24],[6501,6516,6517],{"trials":6537,"activeCount":67},[],{"trials":6539,"activeCount":67},[],{"trials":6541,"activeCount":67},[],{"intervention":6517,"totalTrials":285,"cells":6543},{"EARLY_PHASE1":6544,"PHASE1":6546,"PHASE2":6548,"PHASE3":6554,"PHASE4":6556,"NA":6558},{"trials":6545,"activeCount":67},[],{"trials":6547,"activeCount":67},[],{"trials":6549,"activeCount":67},[6550],{"nctId":6510,"briefTitle":6511,"status":98,"phases":6551,"primaryCompletion":1625,"completion":1625,"start":1229,"enrollment":6513,"conditions":6552,"interventions":6553},[56],[24],[6501,6516,6517],{"trials":6555,"activeCount":67},[],{"trials":6557,"activeCount":67},[],{"trials":6559,"activeCount":67},[],{"intervention":6561,"totalTrials":285,"cells":6562},"LME636 60 mg\u002FmL ophthalmic solution",{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6567,"PHASE3":6581,"PHASE4":6583,"NA":6585},{"trials":6564,"activeCount":67},[],{"trials":6566,"activeCount":67},[],{"trials":6568,"activeCount":67},[6569],{"nctId":6570,"briefTitle":6571,"status":98,"phases":6572,"primaryCompletion":6573,"completion":6573,"start":6574,"enrollment":6575,"conditions":6576,"interventions":6578},"NCT02482129","Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis",[56],"2016-03-21","2015-07-17",45,[6577],"Acute Anterior Uveitis",[6561,6579,6580],"Dexamethasone 0.1% ophthalmic solution","LME636 Vehicle",{"trials":6582,"activeCount":67},[],{"trials":6584,"activeCount":67},[],{"trials":6586,"activeCount":67},[],{"intervention":6579,"totalTrials":285,"cells":6588},{"EARLY_PHASE1":6589,"PHASE1":6591,"PHASE2":6593,"PHASE3":6599,"PHASE4":6601,"NA":6603},{"trials":6590,"activeCount":67},[],{"trials":6592,"activeCount":67},[],{"trials":6594,"activeCount":67},[6595],{"nctId":6570,"briefTitle":6571,"status":98,"phases":6596,"primaryCompletion":6573,"completion":6573,"start":6574,"enrollment":6575,"conditions":6597,"interventions":6598},[56],[6577],[6561,6579,6580],{"trials":6600,"activeCount":67},[],{"trials":6602,"activeCount":67},[],{"trials":6604,"activeCount":67},[],{"intervention":6580,"totalTrials":285,"cells":6606},{"EARLY_PHASE1":6607,"PHASE1":6609,"PHASE2":6611,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6608,"activeCount":67},[],{"trials":6610,"activeCount":67},[],{"trials":6612,"activeCount":67},[6613],{"nctId":6570,"briefTitle":6571,"status":98,"phases":6614,"primaryCompletion":6573,"completion":6573,"start":6574,"enrollment":6575,"conditions":6615,"interventions":6616},[56],[6577],[6561,6579,6580],{"trials":6618,"activeCount":67},[],{"trials":6620,"activeCount":67},[],{"trials":6622,"activeCount":67},[],{"intervention":6624,"totalTrials":285,"cells":6625},"MGV354 ophthalmic suspension",{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6630,"PHASE3":6641,"PHASE4":6643,"NA":6645},{"trials":6627,"activeCount":67},[],{"trials":6629,"activeCount":67},[],{"trials":6631,"activeCount":67},[6632],{"nctId":6633,"briefTitle":6634,"status":98,"phases":6635,"primaryCompletion":6636,"completion":6636,"start":6637,"enrollment":1728,"conditions":6638,"interventions":6639},"NCT02743780","A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma",[55,56],"2016-09-20","2016-03-02",[15,104],[6624,6640],"MGV354 placebo",{"trials":6642,"activeCount":67},[],{"trials":6644,"activeCount":67},[],{"trials":6646,"activeCount":67},[],{"intervention":6640,"totalTrials":285,"cells":6648},{"EARLY_PHASE1":6649,"PHASE1":6651,"PHASE2":6653,"PHASE3":6659,"PHASE4":6661,"NA":6663},{"trials":6650,"activeCount":67},[],{"trials":6652,"activeCount":67},[],{"trials":6654,"activeCount":67},[6655],{"nctId":6633,"briefTitle":6634,"status":98,"phases":6656,"primaryCompletion":6636,"completion":6636,"start":6637,"enrollment":1728,"conditions":6657,"interventions":6658},[55,56],[15,104],[6624,6640],{"trials":6660,"activeCount":67},[],{"trials":6662,"activeCount":67},[],{"trials":6664,"activeCount":67},[],{"intervention":2788,"totalTrials":285,"cells":6666},{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6668,"activeCount":67},[],{"trials":6670,"activeCount":67},[],{"trials":6672,"activeCount":67},[6673],{"nctId":2781,"briefTitle":2782,"status":98,"phases":6674,"primaryCompletion":101,"completion":101,"start":737,"enrollment":839,"conditions":6675,"interventions":6676},[56],[2785],[2787,2788,2772],{"trials":6678,"activeCount":67},[],{"trials":6680,"activeCount":67},[],{"trials":6682,"activeCount":67},[],{"intervention":6684,"totalTrials":285,"cells":6685},"Anecortave acetate 30 mg",{"EARLY_PHASE1":6686,"PHASE1":6688,"PHASE2":6690,"PHASE3":6701,"PHASE4":6703,"NA":6705},{"trials":6687,"activeCount":67},[],{"trials":6689,"activeCount":67},[],{"trials":6691,"activeCount":67},[6692],{"nctId":6693,"briefTitle":6694,"status":98,"phases":6695,"primaryCompletion":590,"completion":590,"start":6696,"enrollment":1239,"conditions":6697,"interventions":6698},"NCT00346957","A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration",[56],"1999-04",[2814],[6684,6699,6700],"Anecortave Acetate 15 mg","Anecortave Acetate 3 mg",{"trials":6702,"activeCount":67},[],{"trials":6704,"activeCount":67},[],{"trials":6706,"activeCount":67},[],{"intervention":6699,"totalTrials":285,"cells":6708},{"EARLY_PHASE1":6709,"PHASE1":6711,"PHASE2":6713,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6710,"activeCount":67},[],{"trials":6712,"activeCount":67},[],{"trials":6714,"activeCount":67},[6715],{"nctId":6693,"briefTitle":6694,"status":98,"phases":6716,"primaryCompletion":590,"completion":590,"start":6696,"enrollment":1239,"conditions":6717,"interventions":6718},[56],[2814],[6684,6699,6700],{"trials":6720,"activeCount":67},[],{"trials":6722,"activeCount":67},[],{"trials":6724,"activeCount":67},[],{"intervention":6700,"totalTrials":285,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6728,"activeCount":67},[],{"trials":6730,"activeCount":67},[],{"trials":6732,"activeCount":67},[6733],{"nctId":6693,"briefTitle":6694,"status":98,"phases":6734,"primaryCompletion":590,"completion":590,"start":6696,"enrollment":1239,"conditions":6735,"interventions":6736},[56],[2814],[6684,6699,6700],{"trials":6738,"activeCount":67},[],{"trials":6740,"activeCount":67},[],{"trials":6742,"activeCount":67},[],{"intervention":6744,"totalTrials":285,"cells":6745},"Dose Level A \u002F Brinzolamide 1% ophthalmic suspension",{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6750,"PHASE3":6765,"PHASE4":6767,"NA":6769},{"trials":6747,"activeCount":67},[],{"trials":6749,"activeCount":67},[],{"trials":6751,"activeCount":67},[6752],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6755,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6757,"interventions":6758},"NCT02140060","6-Week Proof-of-Concept Study of Travoprost\u002FBrinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension",[56],327,[33,15],[6744,6759,6760,6761,6762,6763,6764],"Dose Level B \u002F Brinzolamide 1% ophthalmic suspension","Dose Level C \u002F Brinzolamide 1% ophthalmic suspension","Brinzolamide 1% ophthalmic suspension AZOPT®","Travoprost 0.004% ophthalmic solution TRAVATAN Z®","Travoprost solution vehicle","Brinzolamide suspension vehicle",{"trials":6766,"activeCount":67},[],{"trials":6768,"activeCount":67},[],{"trials":6770,"activeCount":67},[],{"intervention":6759,"totalTrials":285,"cells":6772},{"EARLY_PHASE1":6773,"PHASE1":6775,"PHASE2":6777,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6774,"activeCount":67},[],{"trials":6776,"activeCount":67},[],{"trials":6778,"activeCount":67},[6779],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6780,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6781,"interventions":6782},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6784,"activeCount":67},[],{"trials":6786,"activeCount":67},[],{"trials":6788,"activeCount":67},[],{"intervention":6760,"totalTrials":285,"cells":6790},{"EARLY_PHASE1":6791,"PHASE1":6793,"PHASE2":6795,"PHASE3":6801,"PHASE4":6803,"NA":6805},{"trials":6792,"activeCount":67},[],{"trials":6794,"activeCount":67},[],{"trials":6796,"activeCount":67},[6797],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6798,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6799,"interventions":6800},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6802,"activeCount":67},[],{"trials":6804,"activeCount":67},[],{"trials":6806,"activeCount":67},[],{"intervention":6761,"totalTrials":285,"cells":6808},{"EARLY_PHASE1":6809,"PHASE1":6811,"PHASE2":6813,"PHASE3":6819,"PHASE4":6821,"NA":6823},{"trials":6810,"activeCount":67},[],{"trials":6812,"activeCount":67},[],{"trials":6814,"activeCount":67},[6815],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6816,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6817,"interventions":6818},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6820,"activeCount":67},[],{"trials":6822,"activeCount":67},[],{"trials":6824,"activeCount":67},[],{"intervention":6762,"totalTrials":285,"cells":6826},{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6828,"activeCount":67},[],{"trials":6830,"activeCount":67},[],{"trials":6832,"activeCount":67},[6833],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6834,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6835,"interventions":6836},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6838,"activeCount":67},[],{"trials":6840,"activeCount":67},[],{"trials":6842,"activeCount":67},[],{"intervention":6763,"totalTrials":285,"cells":6844},{"EARLY_PHASE1":6845,"PHASE1":6847,"PHASE2":6849,"PHASE3":6855,"PHASE4":6857,"NA":6859},{"trials":6846,"activeCount":67},[],{"trials":6848,"activeCount":67},[],{"trials":6850,"activeCount":67},[6851],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6852,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6853,"interventions":6854},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6856,"activeCount":67},[],{"trials":6858,"activeCount":67},[],{"trials":6860,"activeCount":67},[],{"intervention":6764,"totalTrials":285,"cells":6862},{"EARLY_PHASE1":6863,"PHASE1":6865,"PHASE2":6867,"PHASE3":6873,"PHASE4":6875,"NA":6877},{"trials":6864,"activeCount":67},[],{"trials":6866,"activeCount":67},[],{"trials":6868,"activeCount":67},[6869],{"nctId":6753,"briefTitle":6754,"status":98,"phases":6870,"primaryCompletion":5703,"completion":5703,"start":1180,"enrollment":6756,"conditions":6871,"interventions":6872},[56],[33,15],[6744,6759,6760,6761,6762,6763,6764],{"trials":6874,"activeCount":67},[],{"trials":6876,"activeCount":67},[],{"trials":6878,"activeCount":67},[],{"intervention":5809,"totalTrials":285,"cells":6880},{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6882,"activeCount":67},[],{"trials":6884,"activeCount":67},[],{"trials":6886,"activeCount":67},[6887],{"nctId":5802,"briefTitle":5803,"status":98,"phases":6888,"primaryCompletion":537,"completion":537,"start":5805,"enrollment":5806,"conditions":6889,"interventions":6890},[56],[91],[5809,5810,5793],{"trials":6892,"activeCount":67},[],{"trials":6894,"activeCount":67},[],{"trials":6896,"activeCount":67},[],{"intervention":5810,"totalTrials":285,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6903,"PHASE3":6909,"PHASE4":6911,"NA":6913},{"trials":6900,"activeCount":67},[],{"trials":6902,"activeCount":67},[],{"trials":6904,"activeCount":67},[6905],{"nctId":5802,"briefTitle":5803,"status":98,"phases":6906,"primaryCompletion":537,"completion":537,"start":5805,"enrollment":5806,"conditions":6907,"interventions":6908},[56],[91],[5809,5810,5793],{"trials":6910,"activeCount":67},[],{"trials":6912,"activeCount":67},[],{"trials":6914,"activeCount":67},[],{"intervention":2971,"totalTrials":285,"cells":6916},{"EARLY_PHASE1":6917,"PHASE1":6919,"PHASE2":6921,"PHASE3":6927,"PHASE4":6929,"NA":6931},{"trials":6918,"activeCount":67},[],{"trials":6920,"activeCount":67},[],{"trials":6922,"activeCount":67},[6923],{"nctId":2964,"briefTitle":2965,"status":98,"phases":6924,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":6925,"interventions":6926},[56],[116,15],[2971,2972,2973,2974,2975,543],{"trials":6928,"activeCount":67},[],{"trials":6930,"activeCount":67},[],{"trials":6932,"activeCount":67},[],{"intervention":2972,"totalTrials":285,"cells":6934},{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6939,"PHASE3":6945,"PHASE4":6947,"NA":6949},{"trials":6936,"activeCount":67},[],{"trials":6938,"activeCount":67},[],{"trials":6940,"activeCount":67},[6941],{"nctId":2964,"briefTitle":2965,"status":98,"phases":6942,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":6943,"interventions":6944},[56],[116,15],[2971,2972,2973,2974,2975,543],{"trials":6946,"activeCount":67},[],{"trials":6948,"activeCount":67},[],{"trials":6950,"activeCount":67},[],{"intervention":2974,"totalTrials":285,"cells":6952},{"EARLY_PHASE1":6953,"PHASE1":6955,"PHASE2":6957,"PHASE3":6963,"PHASE4":6965,"NA":6967},{"trials":6954,"activeCount":67},[],{"trials":6956,"activeCount":67},[],{"trials":6958,"activeCount":67},[6959],{"nctId":2964,"briefTitle":2965,"status":98,"phases":6960,"primaryCompletion":2967,"completion":2967,"start":506,"enrollment":2968,"conditions":6961,"interventions":6962},[56],[116,15],[2971,2972,2973,2974,2975,543],{"trials":6964,"activeCount":67},[],{"trials":6966,"activeCount":67},[],{"trials":6968,"activeCount":67},[],{"intervention":6970,"totalTrials":285,"cells":6971},"Xalatan",{"EARLY_PHASE1":6972,"PHASE1":6974,"PHASE2":6976,"PHASE3":6984,"PHASE4":6986,"NA":6988},{"trials":6973,"activeCount":67},[],{"trials":6975,"activeCount":67},[],{"trials":6977,"activeCount":67},[6978],{"nctId":6979,"briefTitle":6980,"status":98,"phases":6981,"primaryCompletion":2624,"start":847,"enrollment":1330,"conditions":6982,"interventions":6983},"NCT00465621","Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",[56],[104,15],[6970],{"trials":6985,"activeCount":67},[],{"trials":6987,"activeCount":67},[],{"trials":6989,"activeCount":67},[],{"intervention":93,"totalTrials":285,"cells":6991},{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":6996,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6993,"activeCount":67},[],{"trials":6995,"activeCount":67},[],{"trials":6997,"activeCount":67},[6998],{"nctId":86,"briefTitle":87,"status":75,"phases":6999,"primaryCompletion":89,"completion":89,"start":89,"enrollment":67,"conditions":7000,"interventions":7001},[56],[91],[93,94,62],{"trials":7003,"activeCount":67},[],{"trials":7005,"activeCount":67},[],{"trials":7007,"activeCount":67},[],{"intervention":7009,"totalTrials":285,"cells":7010},"AL-39324 ophthalmic suspension",{"EARLY_PHASE1":7011,"PHASE1":7013,"PHASE2":7015,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7012,"activeCount":67},[],{"trials":7014,"activeCount":67},[],{"trials":7016,"activeCount":67},[7017],{"nctId":7018,"briefTitle":7019,"status":98,"phases":7020,"primaryCompletion":166,"completion":166,"start":435,"enrollment":37,"conditions":7021,"interventions":7023},"NCT00992563","WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination",[56],[7022],"Age Related Macular Degeneration",[7009,7024],"Ranibizumab 10 mg\u002FmL",{"trials":7026,"activeCount":67},[],{"trials":7028,"activeCount":67},[],{"trials":7030,"activeCount":67},[],{"intervention":7024,"totalTrials":285,"cells":7032},{"EARLY_PHASE1":7033,"PHASE1":7035,"PHASE2":7037,"PHASE3":7043,"PHASE4":7045,"NA":7047},{"trials":7034,"activeCount":67},[],{"trials":7036,"activeCount":67},[],{"trials":7038,"activeCount":67},[7039],{"nctId":7018,"briefTitle":7019,"status":98,"phases":7040,"primaryCompletion":166,"completion":166,"start":435,"enrollment":37,"conditions":7041,"interventions":7042},[56],[7022],[7009,7024],{"trials":7044,"activeCount":67},[],{"trials":7046,"activeCount":67},[],{"trials":7048,"activeCount":67},[],{"intervention":106,"totalTrials":285,"cells":7050},{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7052,"activeCount":67},[],{"trials":7054,"activeCount":67},[],{"trials":7056,"activeCount":67},[7057],{"nctId":96,"briefTitle":97,"status":98,"phases":7058,"primaryCompletion":100,"completion":100,"start":101,"enrollment":102,"conditions":7059,"interventions":7060},[56],[104,15],[106,107,62],{"trials":7062,"activeCount":67},[],{"trials":7064,"activeCount":67},[],{"trials":7066,"activeCount":67},[],{"intervention":107,"totalTrials":285,"cells":7068},{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7079,"PHASE4":7081,"NA":7083},{"trials":7070,"activeCount":67},[],{"trials":7072,"activeCount":67},[],{"trials":7074,"activeCount":67},[7075],{"nctId":96,"briefTitle":97,"status":98,"phases":7076,"primaryCompletion":100,"completion":100,"start":101,"enrollment":102,"conditions":7077,"interventions":7078},[56],[104,15],[106,107,62],{"trials":7080,"activeCount":67},[],{"trials":7082,"activeCount":67},[],{"trials":7084,"activeCount":67},[],{"intervention":7086,"totalTrials":285,"cells":7087},"Glaucoma therapy",{"EARLY_PHASE1":7088,"PHASE1":7090,"PHASE2":7092,"PHASE3":7102,"PHASE4":7104,"NA":7106},{"trials":7089,"activeCount":67},[],{"trials":7091,"activeCount":67},[],{"trials":7093,"activeCount":67},[7094],{"nctId":7095,"briefTitle":7096,"status":98,"phases":7097,"primaryCompletion":7098,"completion":7098,"start":7099,"conditions":7100,"interventions":7101},"NCT00069719","Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients",[56],"2003-08","1999-02",[104,15],[7086],{"trials":7103,"activeCount":67},[],{"trials":7105,"activeCount":67},[],{"trials":7107,"activeCount":67},[],{"intervention":7109,"totalTrials":285,"cells":7110},"AL-37807",{"EARLY_PHASE1":7111,"PHASE1":7113,"PHASE2":7115,"PHASE3":7123,"PHASE4":7125,"NA":7127},{"trials":7112,"activeCount":67},[],{"trials":7114,"activeCount":67},[],{"trials":7116,"activeCount":67},[7117],{"nctId":7118,"briefTitle":7119,"status":98,"phases":7120,"primaryCompletion":891,"start":550,"enrollment":783,"conditions":7121,"interventions":7122},"NCT00372931","A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension",[56],[104,15],[7109],{"trials":7124,"activeCount":67},[],{"trials":7126,"activeCount":67},[],{"trials":7128,"activeCount":67},[],{"intervention":7130,"totalTrials":285,"cells":7131},"Brinzolamide\u002FTimolol",{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7136,"PHASE3":7144,"PHASE4":7146,"NA":7148},{"trials":7133,"activeCount":67},[],{"trials":7135,"activeCount":67},[],{"trials":7137,"activeCount":67},[7138],{"nctId":7139,"briefTitle":3962,"status":98,"phases":7140,"primaryCompletion":5422,"completion":5422,"start":550,"enrollment":7141,"conditions":7142,"interventions":7143},"NCT00326092",[56],88,[116,15],[7130],{"trials":7145,"activeCount":67},[],{"trials":7147,"activeCount":67},[],{"trials":7149,"activeCount":67},[],{"intervention":706,"totalTrials":285,"cells":7151},{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7156,"PHASE3":7162,"PHASE4":7164,"NA":7166},{"trials":7153,"activeCount":67},[],{"trials":7155,"activeCount":67},[],{"trials":7157,"activeCount":67},[7158],{"nctId":698,"briefTitle":699,"status":98,"phases":7159,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":7160,"interventions":7161},[56],[116,15],[706,689,707,708],{"trials":7163,"activeCount":67},[],{"trials":7165,"activeCount":67},[],{"trials":7167,"activeCount":67},[],{"intervention":707,"totalTrials":285,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7180,"PHASE4":7182,"NA":7184},{"trials":7171,"activeCount":67},[],{"trials":7173,"activeCount":67},[],{"trials":7175,"activeCount":67},[7176],{"nctId":698,"briefTitle":699,"status":98,"phases":7177,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":7178,"interventions":7179},[56],[116,15],[706,689,707,708],{"trials":7181,"activeCount":67},[],{"trials":7183,"activeCount":67},[],{"trials":7185,"activeCount":67},[],{"intervention":708,"totalTrials":285,"cells":7187},{"EARLY_PHASE1":7188,"PHASE1":7190,"PHASE2":7192,"PHASE3":7198,"PHASE4":7200,"NA":7202},{"trials":7189,"activeCount":67},[],{"trials":7191,"activeCount":67},[],{"trials":7193,"activeCount":67},[7194],{"nctId":698,"briefTitle":699,"status":98,"phases":7195,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":7196,"interventions":7197},[56],[116,15],[706,689,707,708],{"trials":7199,"activeCount":67},[],{"trials":7201,"activeCount":67},[],{"trials":7203,"activeCount":67},[],{"intervention":718,"totalTrials":285,"cells":7205},{"EARLY_PHASE1":7206,"PHASE1":7208,"PHASE2":7210,"PHASE3":7216,"PHASE4":7218,"NA":7220},{"trials":7207,"activeCount":67},[],{"trials":7209,"activeCount":67},[],{"trials":7211,"activeCount":67},[7212],{"nctId":710,"briefTitle":711,"status":98,"phases":7213,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":7214,"interventions":7215},[56],[206,15],[718,719,689,720,721,722],{"trials":7217,"activeCount":67},[],{"trials":7219,"activeCount":67},[],{"trials":7221,"activeCount":67},[],{"intervention":719,"totalTrials":285,"cells":7223},{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7234,"PHASE4":7236,"NA":7238},{"trials":7225,"activeCount":67},[],{"trials":7227,"activeCount":67},[],{"trials":7229,"activeCount":67},[7230],{"nctId":710,"briefTitle":711,"status":98,"phases":7231,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":7232,"interventions":7233},[56],[206,15],[718,719,689,720,721,722],{"trials":7235,"activeCount":67},[],{"trials":7237,"activeCount":67},[],{"trials":7239,"activeCount":67},[],{"intervention":720,"totalTrials":285,"cells":7241},{"EARLY_PHASE1":7242,"PHASE1":7244,"PHASE2":7246,"PHASE3":7252,"PHASE4":7254,"NA":7256},{"trials":7243,"activeCount":67},[],{"trials":7245,"activeCount":67},[],{"trials":7247,"activeCount":67},[7248],{"nctId":710,"briefTitle":711,"status":98,"phases":7249,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":7250,"interventions":7251},[56],[206,15],[718,719,689,720,721,722],{"trials":7253,"activeCount":67},[],{"trials":7255,"activeCount":67},[],{"trials":7257,"activeCount":67},[],{"intervention":722,"totalTrials":285,"cells":7259},{"EARLY_PHASE1":7260,"PHASE1":7262,"PHASE2":7264,"PHASE3":7270,"PHASE4":7272,"NA":7274},{"trials":7261,"activeCount":67},[],{"trials":7263,"activeCount":67},[],{"trials":7265,"activeCount":67},[7266],{"nctId":710,"briefTitle":711,"status":98,"phases":7267,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":7268,"interventions":7269},[56],[206,15],[718,719,689,720,721,722],{"trials":7271,"activeCount":67},[],{"trials":7273,"activeCount":67},[],{"trials":7275,"activeCount":67},[],{"intervention":118,"totalTrials":285,"cells":7277},{"EARLY_PHASE1":7278,"PHASE1":7280,"PHASE2":7282,"PHASE3":7288,"PHASE4":7290,"NA":7292},{"trials":7279,"activeCount":67},[],{"trials":7281,"activeCount":67},[],{"trials":7283,"activeCount":67},[7284],{"nctId":109,"briefTitle":110,"status":98,"phases":7285,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":7286,"interventions":7287},[56],[15,116],[118,119,62],{"trials":7289,"activeCount":67},[],{"trials":7291,"activeCount":67},[],{"trials":7293,"activeCount":67},[],{"intervention":5819,"totalTrials":285,"cells":7295},{"EARLY_PHASE1":7296,"PHASE1":7298,"PHASE2":7300,"PHASE3":7306,"PHASE4":7308,"NA":7310},{"trials":7297,"activeCount":67},[],{"trials":7299,"activeCount":67},[],{"trials":7301,"activeCount":67},[7302],{"nctId":5812,"briefTitle":5813,"status":98,"phases":7303,"primaryCompletion":5815,"completion":5815,"start":224,"enrollment":5816,"conditions":7304,"interventions":7305},[56],[91],[5819,5820,5821,5822],{"trials":7307,"activeCount":67},[],{"trials":7309,"activeCount":67},[],{"trials":7311,"activeCount":67},[],{"intervention":5820,"totalTrials":285,"cells":7313},{"EARLY_PHASE1":7314,"PHASE1":7316,"PHASE2":7318,"PHASE3":7324,"PHASE4":7326,"NA":7328},{"trials":7315,"activeCount":67},[],{"trials":7317,"activeCount":67},[],{"trials":7319,"activeCount":67},[7320],{"nctId":5812,"briefTitle":5813,"status":98,"phases":7321,"primaryCompletion":5815,"completion":5815,"start":224,"enrollment":5816,"conditions":7322,"interventions":7323},[56],[91],[5819,5820,5821,5822],{"trials":7325,"activeCount":67},[],{"trials":7327,"activeCount":67},[],{"trials":7329,"activeCount":67},[],{"intervention":5822,"totalTrials":285,"cells":7331},{"EARLY_PHASE1":7332,"PHASE1":7334,"PHASE2":7336,"PHASE3":7342,"PHASE4":7344,"NA":7346},{"trials":7333,"activeCount":67},[],{"trials":7335,"activeCount":67},[],{"trials":7337,"activeCount":67},[7338],{"nctId":5812,"briefTitle":5813,"status":98,"phases":7339,"primaryCompletion":5815,"completion":5815,"start":224,"enrollment":5816,"conditions":7340,"interventions":7341},[56],[91],[5819,5820,5821,5822],{"trials":7343,"activeCount":67},[],{"trials":7345,"activeCount":67},[],{"trials":7347,"activeCount":67},[],{"intervention":7349,"totalTrials":285,"cells":7350},"AL-59412C injectable solution",{"EARLY_PHASE1":7351,"PHASE1":7353,"PHASE2":7355,"PHASE3":7365,"PHASE4":7367,"NA":7369},{"trials":7352,"activeCount":67},[],{"trials":7354,"activeCount":67},[],{"trials":7356,"activeCount":67},[7357],{"nctId":7358,"briefTitle":7359,"status":479,"phases":7360,"primaryCompletion":413,"completion":413,"start":3932,"enrollment":758,"conditions":7361,"interventions":7362},"NCT01312454","Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C",[56],[116,15],[7349,7363,7364],"Travoprost injectable solution","AL-59412C Vehicle",{"trials":7366,"activeCount":67},[],{"trials":7368,"activeCount":67},[],{"trials":7370,"activeCount":67},[],{"intervention":7363,"totalTrials":285,"cells":7372},{"EARLY_PHASE1":7373,"PHASE1":7375,"PHASE2":7377,"PHASE3":7383,"PHASE4":7385,"NA":7387},{"trials":7374,"activeCount":67},[],{"trials":7376,"activeCount":67},[],{"trials":7378,"activeCount":67},[7379],{"nctId":7358,"briefTitle":7359,"status":479,"phases":7380,"primaryCompletion":413,"completion":413,"start":3932,"enrollment":758,"conditions":7381,"interventions":7382},[56],[116,15],[7349,7363,7364],{"trials":7384,"activeCount":67},[],{"trials":7386,"activeCount":67},[],{"trials":7388,"activeCount":67},[],{"intervention":7364,"totalTrials":285,"cells":7390},{"EARLY_PHASE1":7391,"PHASE1":7393,"PHASE2":7395,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7392,"activeCount":67},[],{"trials":7394,"activeCount":67},[],{"trials":7396,"activeCount":67},[7397],{"nctId":7358,"briefTitle":7359,"status":479,"phases":7398,"primaryCompletion":413,"completion":413,"start":3932,"enrollment":758,"conditions":7399,"interventions":7400},[56],[116,15],[7349,7363,7364],{"trials":7402,"activeCount":67},[],{"trials":7404,"activeCount":67},[],{"trials":7406,"activeCount":67},[],{"intervention":2804,"totalTrials":285,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7413,"PHASE3":7419,"PHASE4":7421,"NA":7423},{"trials":7410,"activeCount":67},[],{"trials":7412,"activeCount":67},[],{"trials":7414,"activeCount":67},[7415],{"nctId":2798,"briefTitle":2799,"status":479,"phases":7416,"primaryCompletion":611,"completion":611,"start":648,"enrollment":2801,"conditions":7417,"interventions":7418},[56],[104,15],[2787,2804,2805,2806],{"trials":7420,"activeCount":67},[],{"trials":7422,"activeCount":67},[],{"trials":7424,"activeCount":67},[],{"intervention":2805,"totalTrials":285,"cells":7426},{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7431,"PHASE3":7437,"PHASE4":7439,"NA":7441},{"trials":7428,"activeCount":67},[],{"trials":7430,"activeCount":67},[],{"trials":7432,"activeCount":67},[7433],{"nctId":2798,"briefTitle":2799,"status":479,"phases":7434,"primaryCompletion":611,"completion":611,"start":648,"enrollment":2801,"conditions":7435,"interventions":7436},[56],[104,15],[2787,2804,2805,2806],{"trials":7438,"activeCount":67},[],{"trials":7440,"activeCount":67},[],{"trials":7442,"activeCount":67},[],{"intervention":7444,"totalTrials":285,"cells":7445},"TOBRADEX Ophthalmic Suspension",{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7459,"PHASE3":7461,"PHASE4":7463,"NA":7465},{"trials":7447,"activeCount":67},[],{"trials":7449,"activeCount":67},[7450],{"nctId":7451,"briefTitle":7452,"status":98,"phases":7453,"primaryCompletion":2820,"start":2820,"enrollment":7454,"conditions":7455,"interventions":7456},"NCT00695435","Tobramycin Tear Concentrations",[55],21,[24],[7444,7457,7458],"Tobramycin 0.3% \u002F Dexamethasone 0.05% Ophthalmic Suspension","TOBREX Ophthalmic Solution",{"trials":7460,"activeCount":67},[],{"trials":7462,"activeCount":67},[],{"trials":7464,"activeCount":67},[],{"trials":7466,"activeCount":67},[],{"intervention":7457,"totalTrials":285,"cells":7468},{"EARLY_PHASE1":7469,"PHASE1":7471,"PHASE2":7477,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7470,"activeCount":67},[],{"trials":7472,"activeCount":67},[7473],{"nctId":7451,"briefTitle":7452,"status":98,"phases":7474,"primaryCompletion":2820,"start":2820,"enrollment":7454,"conditions":7475,"interventions":7476},[55],[24],[7444,7457,7458],{"trials":7478,"activeCount":67},[],{"trials":7480,"activeCount":67},[],{"trials":7482,"activeCount":67},[],{"trials":7484,"activeCount":67},[],{"intervention":7458,"totalTrials":285,"cells":7486},{"EARLY_PHASE1":7487,"PHASE1":7489,"PHASE2":7495,"PHASE3":7497,"PHASE4":7499,"NA":7501},{"trials":7488,"activeCount":67},[],{"trials":7490,"activeCount":67},[7491],{"nctId":7451,"briefTitle":7452,"status":98,"phases":7492,"primaryCompletion":2820,"start":2820,"enrollment":7454,"conditions":7493,"interventions":7494},[55],[24],[7444,7457,7458],{"trials":7496,"activeCount":67},[],{"trials":7498,"activeCount":67},[],{"trials":7500,"activeCount":67},[],{"trials":7502,"activeCount":67},[],{"intervention":7504,"totalTrials":285,"cells":7505},"LHA510 Ophthalmic Suspension",{"EARLY_PHASE1":7506,"PHASE1":7508,"PHASE2":7518,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7507,"activeCount":67},[],{"trials":7509,"activeCount":67},[7510],{"nctId":7511,"briefTitle":7512,"status":98,"phases":7513,"primaryCompletion":1180,"completion":1180,"start":7514,"enrollment":405,"conditions":7515,"interventions":7516},"NCT02076919","First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration",[55],"2014-02",[4745],[7504,7517],"LHA510 Vehicle",{"trials":7519,"activeCount":67},[],{"trials":7521,"activeCount":67},[],{"trials":7523,"activeCount":67},[],{"trials":7525,"activeCount":67},[],{"intervention":7517,"totalTrials":285,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7536,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7529,"activeCount":67},[],{"trials":7531,"activeCount":67},[7532],{"nctId":7511,"briefTitle":7512,"status":98,"phases":7533,"primaryCompletion":1180,"completion":1180,"start":7514,"enrollment":405,"conditions":7534,"interventions":7535},[55],[4745],[7504,7517],{"trials":7537,"activeCount":67},[],{"trials":7539,"activeCount":67},[],{"trials":7541,"activeCount":67},[],{"trials":7543,"activeCount":67},[],{"intervention":3081,"totalTrials":285,"cells":7545},{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7554,"PHASE3":7556,"PHASE4":7558,"NA":7560},{"trials":7547,"activeCount":67},[],{"trials":7549,"activeCount":67},[7550],{"nctId":3073,"briefTitle":3074,"status":75,"phases":7551,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":67,"conditions":7552,"interventions":7553},[55],[3079],[3081,3082,1298],{"trials":7555,"activeCount":67},[],{"trials":7557,"activeCount":67},[],{"trials":7559,"activeCount":67},[],{"trials":7561,"activeCount":67},[],{"intervention":3082,"totalTrials":285,"cells":7563},{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7572,"PHASE3":7574,"PHASE4":7576,"NA":7578},{"trials":7565,"activeCount":67},[],{"trials":7567,"activeCount":67},[7568],{"nctId":3073,"briefTitle":3074,"status":75,"phases":7569,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":67,"conditions":7570,"interventions":7571},[55],[3079],[3081,3082,1298],{"trials":7573,"activeCount":67},[],{"trials":7575,"activeCount":67},[],{"trials":7577,"activeCount":67},[],{"trials":7579,"activeCount":67},[],{"intervention":7581,"totalTrials":285,"cells":7582},"AL-53817 nasal spray solution",{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7595,"PHASE3":7597,"PHASE4":7599,"NA":7601},{"trials":7584,"activeCount":67},[],{"trials":7586,"activeCount":67},[7587],{"nctId":7588,"briefTitle":7589,"status":98,"phases":7590,"primaryCompletion":412,"completion":412,"start":1187,"enrollment":405,"conditions":7591,"interventions":7594},"NCT01454505","Safety and Efficacy of AL-53817 Nasal Spray Solution",[55],[7592,7593],"Nasal Allergies","Allergies",[7581],{"trials":7596,"activeCount":67},[],{"trials":7598,"activeCount":67},[],{"trials":7600,"activeCount":67},[],{"trials":7602,"activeCount":67},[],{"intervention":7604,"totalTrials":285,"cells":7605},"AL-60371 otic suspension",{"EARLY_PHASE1":7606,"PHASE1":7608,"PHASE2":7617,"PHASE3":7619,"PHASE4":7621,"NA":7623},{"trials":7607,"activeCount":67},[],{"trials":7609,"activeCount":67},[7610],{"nctId":7611,"briefTitle":7612,"status":75,"phases":7613,"primaryCompletion":5618,"completion":5618,"start":5703,"enrollment":67,"conditions":7614,"interventions":7616},"NCT01908764","Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery",[55],[7615],"Otitis Media",[7604],{"trials":7618,"activeCount":67},[],{"trials":7620,"activeCount":67},[],{"trials":7622,"activeCount":67},[],{"trials":7624,"activeCount":67},[],{"intervention":3935,"totalTrials":285,"cells":7626},{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7635,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7628,"activeCount":67},[],{"trials":7630,"activeCount":67},[7631],{"nctId":3929,"briefTitle":3930,"status":98,"phases":7632,"primaryCompletion":3932,"completion":3932,"start":2967,"enrollment":25,"conditions":7633,"interventions":7634},[55],[91],[3935,3922,3936],{"trials":7636,"activeCount":67},[],{"trials":7638,"activeCount":67},[],{"trials":7640,"activeCount":67},[],{"trials":7642,"activeCount":67},[],{"intervention":3936,"totalTrials":285,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7653,"PHASE3":7655,"PHASE4":7657,"NA":7659},{"trials":7646,"activeCount":67},[],{"trials":7648,"activeCount":67},[7649],{"nctId":3929,"briefTitle":3930,"status":98,"phases":7650,"primaryCompletion":3932,"completion":3932,"start":2967,"enrollment":25,"conditions":7651,"interventions":7652},[55],[91],[3935,3922,3936],{"trials":7654,"activeCount":67},[],{"trials":7656,"activeCount":67},[],{"trials":7658,"activeCount":67},[],{"trials":7660,"activeCount":67},[],{"intervention":228,"totalTrials":457,"cells":7662},{"EARLY_PHASE1":7663,"PHASE1":7665,"PHASE2":7667,"PHASE3":7669,"PHASE4":7671,"NA":7693},{"trials":7664,"activeCount":67},[],{"trials":7666,"activeCount":67},[],{"trials":7668,"activeCount":67},[],{"trials":7670,"activeCount":67},[],{"trials":7672,"activeCount":67},[7673,7677,7681,7685,7689],{"nctId":1177,"briefTitle":1178,"status":98,"phases":7674,"primaryCompletion":1180,"completion":1180,"start":450,"enrollment":102,"conditions":7675,"interventions":7676},[58],[33,15],[228,1164],{"nctId":1184,"briefTitle":1185,"status":98,"phases":7678,"primaryCompletion":497,"completion":497,"start":1187,"enrollment":1158,"conditions":7679,"interventions":7680},[58],[33,15,104],[228,1164],{"nctId":2147,"briefTitle":2148,"status":98,"phases":7682,"primaryCompletion":1271,"completion":1271,"start":611,"enrollment":2150,"conditions":7683,"interventions":7684},[58],[33],[228,2134],{"nctId":1036,"briefTitle":1037,"status":98,"phases":7686,"primaryCompletion":113,"completion":113,"start":550,"enrollment":1039,"conditions":7687,"interventions":7688},[58],[33],[1042,741],{"nctId":221,"briefTitle":222,"status":98,"phases":7690,"primaryCompletion":224,"completion":224,"start":203,"enrollment":225,"conditions":7691,"interventions":7692},[58],[15,206],[208,62,228],{"trials":7694,"activeCount":67},[7695],{"nctId":7696,"briefTitle":7697,"status":479,"phases":7698,"primaryCompletion":1727,"completion":1727,"start":570,"enrollment":7141,"conditions":7699,"interventions":7700},"NCT01485822","A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution",[],[116],[228],{"intervention":7702,"totalTrials":195,"cells":7703},"Travoprost 0.004%\u002Ftimolol 0.05% fixed combination eye drops",{"EARLY_PHASE1":7704,"PHASE1":7706,"PHASE2":7708,"PHASE3":7710,"PHASE4":7712,"NA":7714},{"trials":7705,"activeCount":67},[],{"trials":7707,"activeCount":67},[],{"trials":7709,"activeCount":67},[],{"trials":7711,"activeCount":67},[],{"trials":7713,"activeCount":67},[],{"trials":7715,"activeCount":67},[7716,7722],{"nctId":7717,"briefTitle":7718,"status":98,"phases":7719,"primaryCompletion":404,"completion":404,"start":993,"enrollment":3343,"conditions":7720,"interventions":7721},"NCT00676637","Glaucoma Adherence Study",[],[15,1386],[7702],{"nctId":7723,"briefTitle":7724,"status":98,"phases":7725,"primaryCompletion":101,"completion":101,"start":993,"enrollment":3343,"conditions":7726,"interventions":7727},"NCT00680329","Glaucoma Adherence Study, Spain",[],[15,1386],[7702],{"intervention":7729,"totalTrials":285,"cells":7730},"0.9% saline eye drops",{"EARLY_PHASE1":7731,"PHASE1":7733,"PHASE2":7735,"PHASE3":7737,"PHASE4":7739,"NA":7741},{"trials":7732,"activeCount":67},[],{"trials":7734,"activeCount":67},[],{"trials":7736,"activeCount":67},[],{"trials":7738,"activeCount":67},[],{"trials":7740,"activeCount":67},[],{"trials":7742,"activeCount":67},[7743],{"nctId":7744,"briefTitle":7745,"status":98,"phases":7746,"primaryCompletion":7747,"completion":7747,"start":6574,"enrollment":3092,"conditions":7748,"interventions":7749},"NCT02470429","Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION",[59],"2016-05-26",[24],[7729],{"intervention":7751,"totalTrials":285,"cells":7752},"FID 114657 eye drops",{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7757,"PHASE3":7759,"PHASE4":7761,"NA":7763},{"trials":7754,"activeCount":67},[],{"trials":7756,"activeCount":67},[],{"trials":7758,"activeCount":67},[],{"trials":7760,"activeCount":67},[],{"trials":7762,"activeCount":67},[],{"trials":7764,"activeCount":67},[7765],{"nctId":7766,"briefTitle":7767,"status":98,"phases":7768,"primaryCompletion":7769,"completion":7769,"start":5703,"enrollment":7770,"conditions":7771,"interventions":7772},"NCT02293538","Formula Identification (FID) 114657 in Contact Lens Wearers",[59],"2015-07",234,[30],[7751,7773],"Saline control eye drops",{"intervention":7773,"totalTrials":285,"cells":7775},{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7782,"PHASE4":7784,"NA":7786},{"trials":7777,"activeCount":67},[],{"trials":7779,"activeCount":67},[],{"trials":7781,"activeCount":67},[],{"trials":7783,"activeCount":67},[],{"trials":7785,"activeCount":67},[],{"trials":7787,"activeCount":67},[7788],{"nctId":7766,"briefTitle":7767,"status":98,"phases":7789,"primaryCompletion":7769,"completion":7769,"start":5703,"enrollment":7770,"conditions":7790,"interventions":7791},[59],[30],[7751,7773],{"intervention":7793,"totalTrials":285,"cells":7794},"Propylene Glycol, 0.6% eye drops",{"EARLY_PHASE1":7795,"PHASE1":7797,"PHASE2":7799,"PHASE3":7801,"PHASE4":7803,"NA":7805},{"trials":7796,"activeCount":67},[],{"trials":7798,"activeCount":67},[],{"trials":7800,"activeCount":67},[],{"trials":7802,"activeCount":67},[],{"trials":7804,"activeCount":67},[],{"trials":7806,"activeCount":67},[7807],{"nctId":7808,"briefTitle":7809,"status":98,"phases":7810,"primaryCompletion":5618,"completion":5618,"start":7514,"enrollment":7811,"conditions":7812,"interventions":7813},"NCT01967147","Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects",[59],279,[24],[7793,7814],"Preservative-free 0.9% Saline solution",{"intervention":7814,"totalTrials":285,"cells":7816},{"EARLY_PHASE1":7817,"PHASE1":7819,"PHASE2":7821,"PHASE3":7823,"PHASE4":7825,"NA":7827},{"trials":7818,"activeCount":67},[],{"trials":7820,"activeCount":67},[],{"trials":7822,"activeCount":67},[],{"trials":7824,"activeCount":67},[],{"trials":7826,"activeCount":67},[],{"trials":7828,"activeCount":67},[7829],{"nctId":7808,"briefTitle":7809,"status":98,"phases":7830,"primaryCompletion":5618,"completion":5618,"start":7514,"enrollment":7811,"conditions":7831,"interventions":7832},[59],[24],[7793,7814],{"intervention":7834,"totalTrials":285,"cells":7835},"Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension",{"EARLY_PHASE1":7836,"PHASE1":7838,"PHASE2":7840,"PHASE3":7842,"PHASE4":7844,"NA":7846},{"trials":7837,"activeCount":67},[],{"trials":7839,"activeCount":67},[],{"trials":7841,"activeCount":67},[],{"trials":7843,"activeCount":67},[],{"trials":7845,"activeCount":67},[],{"trials":7847,"activeCount":67},[7848],{"nctId":7849,"briefTitle":7850,"status":98,"phases":7851,"primaryCompletion":1809,"completion":1809,"start":5805,"enrollment":7852,"conditions":7853,"interventions":7854},"NCT01027494","Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora",[],318,[3026],[7834],{"intervention":7856,"totalTrials":285,"cells":7857},"Travoprost, 0.004% ophthalmic solution",{"EARLY_PHASE1":7858,"PHASE1":7860,"PHASE2":7862,"PHASE3":7864,"PHASE4":7866,"NA":7868},{"trials":7859,"activeCount":67},[],{"trials":7861,"activeCount":67},[],{"trials":7863,"activeCount":67},[],{"trials":7865,"activeCount":67},[],{"trials":7867,"activeCount":67},[],{"trials":7869,"activeCount":67},[7870],{"nctId":7871,"briefTitle":7872,"status":479,"phases":7873,"primaryCompletion":497,"completion":497,"start":7874,"enrollment":7875,"conditions":7876,"interventions":7877},"NCT00047554","Study of TRAVATAN in Subjects With Iris Pigmentation Changes",[],"2003-05",336,[104,15],[7856],{"intervention":7879,"totalTrials":285,"cells":7880},"SYSTANE® ULTRA Lubricant Eye Drops",{"EARLY_PHASE1":7881,"PHASE1":7883,"PHASE2":7885,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7882,"activeCount":67},[],{"trials":7884,"activeCount":67},[],{"trials":7886,"activeCount":67},[],{"trials":7888,"activeCount":67},[],{"trials":7890,"activeCount":67},[],{"trials":7892,"activeCount":67},[7893],{"nctId":7894,"briefTitle":7895,"status":98,"phases":7896,"primaryCompletion":7897,"completion":7897,"start":3433,"enrollment":191,"conditions":7898,"interventions":7899},"NCT02446015","Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye",[59],"2016-06-21",[4787],[7879],{"intervention":7901,"totalTrials":285,"cells":7902},"Systane Free Lubricant Eye Drops",{"EARLY_PHASE1":7903,"PHASE1":7905,"PHASE2":7907,"PHASE3":7909,"PHASE4":7911,"NA":7913},{"trials":7904,"activeCount":67},[],{"trials":7906,"activeCount":67},[],{"trials":7908,"activeCount":67},[],{"trials":7910,"activeCount":67},[],{"trials":7912,"activeCount":67},[],{"trials":7914,"activeCount":67},[7915],{"nctId":7916,"briefTitle":7917,"status":98,"phases":7918,"primaryCompletion":3383,"completion":3383,"start":3456,"enrollment":7919,"conditions":7920,"interventions":7921},"NCT00348322","Safety\u002FEfficacy of Systane Free vs Refresh Tears",[59],100,[24],[7901]]